MINISTERE DE L'ENSEIGNEMENT SUPERIEUR
ET DE LA RECHERCHE SCIENTIFIQUE

REPUBLIQUE DU MALI
UN PEUPLE – UN BUT – UNE FOI

UNIVERSITE DES SCIENCES, DES TECHNIQUES ET
DES TECHNOLOGIES DE BAMAKO (USTTB)

U.S.T.T.B

FACULTE DE PHARMACIE

ANNEE UNIVERSITAIRE 2020-2021 N°_____/

THEME

ETATS DE LIEUX DES UTILISATIONS DE *ARTEMISIA AFRA* JACQ EX. WILLD. (ASTERACEAE).

THESE

Présentée et soutenue publiquement le 19/11/2021 devant le jury de la Faculté de Pharmacie

Par :

M. Diakalia Koulou SANOGO

Pour obtenir le grade de Docteur en Pharmacie
(Diplôme d'Etat)

JURY

Président : Pr Amagana DOLO (Faculté de Pharmacie)

Membres : Dr Mahamane HAIDARA (Faculté de Pharmacie)

Dr Karim DAGNO (Invité)

Directrice : Pr Rokia SANOGO (Faculté de Pharmacie)

DEDICACES ET REMERCIEMENTS

DEDICACES

Je dédie ce travail :

- **Au Tout Puissant Allah Soubhana wata Allah ;**

Le Clément, le Miséricordieux, Seigneur des cieux, des terres et de leur contenu.

Ce travail vient de toi car la réussite de tout projet n'est que ta volonté. Paix et salut sur le Prophète Mohammed, sa noble Famille et ses compagnons.

- **A mon père Koulou SANOGO**

Ton soutien moral, affectif et matériel ne m'a jamais fait défaut malgré la distance ;

Ta modestie, ta patience et ton concept de la vie m'ont servi de repères dans les moments difficiles et m'ont conduit à cette réussite. Merci papa car, si je suis arrivé à ce niveau aujourd'hui, c'est grâce à toi. Puisse Allah te donner longue vie.

- **A ma mère feu Konimba SANOGO**

J'aurai voulu partager avec vous les joies de ce moment solennel de ma vie. Mais le destin en a décidé autrement. Mais saches que tu es tout pour moi dans cette vie, car sans toi, je ne serais pas là où j'en suis actuellement. Je ne peux jamais te remercier pour les efforts que tu as consentis pour m'accompagner durant mon enfance. Vous avez toujours été soucieuses de notre avenir, que la terre vous soit légère. Amen !

REMERCIEMENTS

- **A tout le personnel de la DMT** ce modeste travail est le vôtre. Vous m'avez tous bien accueilli à bras ouvert ; malgré vos obligations professionnelles, vous n'avez ménagé aucun effort pour m'apporter votre soutien sans faille dans les moments où le besoin se faisait sentir.
- **A tout le personnel de la FMOS/FAPH** qui ont donné le meilleur d'eux- mêmes pour mettre à notre disposition cette formation de qualité.
- **A ma famille** pour votre soutien et votre affection depuis toutes ces années. Vous avez rendu possible la réalisation de ces longues années d'études de pharmacie et de cette thèse.
- **A mes frères et sœurs** je déplore le manque de mots adéquats pour témoigner l'amour et l'admiration que j'ai pour vous.
- **A tous mes tontons et tantes v**ous m'avez constamment soutenu, aussi bien moralement que matériellement. Sachez que je vous appartiens et je suis le produit de l'éducation que vous m'avez donnée.
- **A mon papa Fassoun TRAORE** pour m'avoir adopté sans distinction aucune avec le plus grand amour, tout le respect d'un père et d'une mère. Je ne saurais vous remercier pour tout.
- **A la famille BENGALY** les mots me manquent pour vous exprimer ma profonde gratitude. Vous m'avez accueilli depuis le premier jour à Bamako en me mettant dans toutes les conditions d'apprentissage.
- **A mes camarades thésards du DMT**: MATILEBOU SANOGO, SEYDOU DEMBELE, DIENEBA TRAORE, MOUSSA FOFANA ; NEISSA COULIBALY ; ABDOULAYE M DABO ; FANTA DANAYA KONE ; IDRISSA BOUARE ; AWA COULIBALY ; BINTOU FOUNE THIERO ; SEKOU DIABY ; LASSINA DIAKITE ; ABDROUHAM POUDIOUGOU
- **A tous mes camarades de la 12ème promotion du numérus clausus FAPH** pour tous les moments de joie et de peine que nous avons partagée ensemble. Bonne carrière professionnelle à tous.

MENTION SPECIALE

A ma Directrice de thèse Pr Rokia SANOGO :

Par reconnaissance pour les suggestions et conseils que vous m'avez prodigué du début à la fin de ce travail, Merci infiniment.

Au Docteur Mahamane HAIDARA :

Pour votre encadrement de qualité.

Au corps professoral de la FAPH :

Merci pour les efforts consentis en notre formation malgré les moyens limités.

A la promotion Pr Elimane MARIKO, 12ème promotion du Numérus Clausus en Pharmacie.

A mes collègues thésards du DMT :

Pour les moments inoubliables passés en votre compagnie.

HOMMAGES AUX MEMBRES DU JURY

A NOTRE MAITE ET PRESIDENT DU JURY : Pr Amagana DOLO

- Professeur de Parasitologie-Mycologie à la Faculté de Pharmacie (FAPH)
- Directeur de l'Ecole Doctorale des Sciences et Technologiques du Mali (EDSTM/USTTB)
- Coordinateur du DES de biologie clinique à la Faculté de Pharmacie (FAPH)
- Chercheur au Malaria Research and Training Center (MRTC)

Cher maître,

Nous sommes très sensibles à l'honneur que vous nous faites en acceptant de présider ce jury. Auprès de vous nous avons pu bénéficier d'un enseignement de qualité. Nous avons admiré vos qualités scientifiques et pédagogiques. C'est un immense honneur que vous nous faites en acceptant de présider ce jury. Recevez ici cher maître l'expression de notre profonde reconnaissance.

A NOTRE MAITRE ET JUGE : Dr Mahamane HAIDARA

- ✓ Ph D en Pharmacognosie
- ✓ Maître - Assistant en Pharmacognosie à la Faculté de Pharmacie (FAPH)
- ✓ Enseignant-chercheur à la FAPH
- ✓ $2^{èmes}$ meilleurs communicateurs lors des $16^{èmes}$ et $18^{èmes}$ journées Scientifiques annuelles de la Société Ouest Africaine de Chimie (SOACHIM) respectivement à Abidjan (Côte d'Ivoire) du 03 – 06 Août 2015 et à Dakar (Sénégal) du 08 – 11 Août 2017.
- ✓ Lauréat du prix PASRES de la SOACHIM dans la thématique Chimie des substances biologiquement actives (1^{er} Prix de la meilleure communication Post - Doctorale) lors des $20^{èmes}$ Journées Scientifiques Annuelles de la SOACHIM ; du 06 – 09 Août 2019 à Bamako, Mali.

Cher maître,

Vous nous faites un immense honneur en acceptant de juger ce travail malgré vos multiples et importantes occupations. Votre disponibilité, vos critiques et suggestions nous a été d'un grand apport pendant toute la réalisation de ce document.

Veuillez recevoir ici, cher maître notre profonde gratitude.

A NOTRE MAITRE ET JUGE : Dr Karim DAGNO

- Maitre de recherche, CRRA Sotuba/IER.
- Certificat en Gestion de Cycle de Projet et Approche Gestion Axée Résultat (GCP-GAR).
- PhD en Sciences Agronomiques et Ingénierie biologique – Option : Phytopathologie.
- Master en Sciences Agronomique et Ingénierie biologique –Option : Phytopathologie.
- DES International en Protection des Cultures Tropicales et Subtropicales, Faculté Universitaire des Sciences Agronomiques de Gembloux (FUSAGx), Belgique

Cher maître

Nous avons admiré la spontanéité avec laquelle vous avez accepté de juger ce travail. Nous avons apprécié votre disponibilité malgré vos multiples occupations. Veuillez trouver ici, cher maître l'expression de notre profonde gratitude.

A NOTRE MAITRE ET DIRECTRICE DE THESE : Pr Rokia SANOGO

- Docteur en Pharmacie PhD en Pharmacognosie ;
- Professeure Titulaire du CAMES ;
- Enseignante chercheure de Pharmacognosie, Phytothérapie et Médecine Traditionnelle ;
- Coordinatrice de formation doctorale de l'Ecole Doctorale de l'USTTB ;
- Enseignante de la Médecine Traditionnelle en Médecine et en Pharmacie dans les Universités de Ouagadougou Joseph Ki ZERBO (Burkina Faso), Abdou Moumouni de Niamey (Niger), Felix Houphouët BOIGNY (Côte d'Ivoire) ;
- Chef de DER des Sciences Pharmaceutiques de la Faculté de Pharmacie de l'USTTB ;
- Chef du Département Médecine Traditionnelle de l'ex INRSP ;
- Experte de l'Organisation Ouest Africaine de Santé (OOAS), espace CEDEAO depuis 2009 ;
- Présidente du comité scientifique interne et membre du comité scientifique et technique de l'ex INRSP de 2013 à 2019 ;
- Lauréate du tableau d'honneur du Conseil National de l'Ordre des Pharmaciens (CNOP) du Mali et lauréate du Caducée de la Recherche du SYNAPPO en 2009 et Membre de la commission scientifique de l'Ordre des Pharmaciens du Mali ;
- Membre du comité technique spécialisé de Médecine et Pharmacie du CAMES pour l'évaluation des dossiers des enseignants chercheurs du CAMES depuis 2015 ;
- Lauréate du Prix Scientifique Kwamé Nkrumah de l'Union Africaine pour les femmes scientifiques, édition 2016 ;
- Tableau d'honneur au 08 mars 2017 et SADIO 2017 pour la Science par le Ministère de la promotion de la femme et partenaires ;
- Membre du Comité de Pilotage du Réseau Francophone en Conseil Scientifique, 2017 ;
- Membre titulaire de l'Académie des Sciences du Mali, avril 2018 ;
- Membre du jury du concours d'agrégation du CAMES pour la Pharmacie en 2018 ;
- Experte du programme régional d'Afrique subsaharienne Oréal-UNESCO Pour les Femmes et la Science en 2019 ;
- Lauréate du Prix Next Einstein Forum (NEF) pour la meilleure femme en recherche en Pharmacie, Médecine et santé, édition 2019.

- Coordinatrice du PTR Pharmacopée et Médecine Traditionnelle Africaines du CAMES, 2019
- Membre de la commission scientifique d'évaluation des projets soumis dans le cadre de la lutte contre la maladie à coronavirus (COVID-19), 21 mai 2020, Ministère en charge de recherche ;
- Membre du comité régional d'experts de l'OMS sur la médecine traditionnelle dans la riposte contre la covid-19.

Chère maître,

Votre rigueur scientifique, votre générosité associée à votre amour du travail bien fait font de vous un maître respecter et admirer de tous.

Veuillez trouver ici l'expression de nos sincères remerciements et de notre profond respect.

LISTE DES SIGLES ET ABREVIATIONS

< : Inférieur

% : Pourcentage

µg /ML : microgramme par millilitre

A. afra : *Artemisia afra*

A. annua : *Artemisia annua*

ASAQ : Artésunate-Amodiaquine

CI50 : Concentration Inhibitrice 50

cm : Centimètre

Covid-19 : Coronavirus 2019

DMT : Département Médicine Traditionnelle

DPPH : Diphénylpicrylhydrazyle

g : Gramme

g/kg : Gramme par Kilogramme

g/kg/j : Gramme par Kilogramme par Jour

INRSP : Institut National de Recherche en Santé Publique

INSP : Institut National de Santé Publique

m : Mètre

mg : Milligramme

ml /j: Millilitre par jour

mm : Millimètre

MTA : Médicament Traditionnelle Améliorée

OMS : Organisation Mondiale de la Santé

OOAS : Organisation Ouest Africaine de la santé

RDC : République Démographique du Congo

VIH : Virus Immunodéficience Humaine

TABLE DES MATIERES

LISTE DES TABLEAUX

LISTE DES FIGURES

INTRODUCTION

Artemisia afra est l'une des plantes médicinales les plus populaires et les plus couramment utilisées en Afrique du Sud. Face au succès de *Artemisia annua*, de nombreuses investigations ont été menées à travers le monde sur cette espèce africaine (Liu et coll., 2009 ; Patil et coll., 2011) (voir annexe 1 et 2).

La liste des utilisations couvre un large éventail de maladies notamment toux, rhume, fièvre, perte d'appétit, coliques, maux de tête, maux d'oreilles, vers intestinaux et paludisme. *Artemisia afra* est utilisée de différentes manières et l'une des pratiques les plus courantes consiste à insérer des feuilles fraiches dans les narines pour dégager les voies nasales obstruées (Wyk et coll., 1997).

C'est une plante pérenne qu'on peut récolter au besoin tout au long de sa croissance. Cependant, elle produit difficilement des graines viables. C'est pourquoi sa multiplication se fait essentiellement par marcottage ou bouturage.

De nombreuses études ont évalué l'efficacité clinique de la tisane de *Artemisia annua* (Willcox et coll. 2004 ; Mueller et coll., 2004 ; Mueller et coll., 2000).

Vu l'efficacité de la tisane de *Artemisia annua,* il y a eu un intérêt pour l'utilisation d'autre Artemisia notamment l'espèce africaine *Artemisia afra* dépourvue de l'artémisinine mais des études cliniques montrent l'efficacité de cette tisane pour la prise en charge des différentes parasitoses dont le paludisme et la schistosomiase (Munyangi et coll., 2019 ; Munyangi et coll., 2018). Dans la thèse de Kamaté, un échantillon de *A. afra* a fait l'objet de contrôle de qualité et recueil d'informations sur la prise en charge des schistosomiases (Kamaté, 2018).

De nos jours une forte mobilisation pour la culture et l'utilisation de la tisane des Artemisia (*A. annua* et *A. afra*) dans la prise en charge des différentes maladies mais l'OMS ne recommande pas l'utilisation de la forme non pharmaceutique des Artemisia.

Au Mali à l'instar des autres pays d'Afrique il existe des activités de culture et de consommation de la tisane de *Artemisia afra*.

Le contrôle de qualité des échantillons provenant des essais de culture de *Artemisia afra* effectués par les institutions de recherche, les organisations non gouvernementales et des opérateurs économiques n'a pas été faite mais le DMT le souhaite.

La présente étude a pour but de faire un état des lieux des études menées sur *Artemisia afra,* notamment les données de sécurité, d'efficacité et de qualité dans la perspective de son utilisation comme un phytomédicament dans la prise en charge des différentes pathologies.

OBJECTIFS

1. OBJECTIF GENERAL

Faire l'état de lieu des données de sécurité, d'efficacité et de qualité sur *Artemisia afra*.

2. OBJECTIFS SPECIFICIQUES

- Recenser les différentes utilisations traditionnelles de *Artemisia afra*
- Rédiger une monographie de *Artemisia afra*
- Recenser les données d'efficacités cliniques de *Artemisia afra* dans la prise en charge des pathologies.

GENERALITE :

Aujourd'hui, les médicaments antipaludiques utilisés sont basés sur des molécules issues de plantes médicinales issues de pharmacopées traditionnelles : la quinine et ses dérivés issus de l'écorce de Quinquina (*Cinchona* sp) de l'Amérique du Sud ou l'artémisinine et ses dérivés issus d'une plante médicinale chinoise, *Artemisia annua.*

- **Quinquina**

Les quinquinas sont des arbres de la Cordillère des Andes poussant en haute altitude. Ils font partie du genre Cinchona parmi lesquels seuls le quinquina rouge et quinquina jaune ont des propriétés antipaludiques. L'écorce de quinquina était connue, et dès le XVIIème siècle, pour guérir la fièvre tierce ; ses vertus furent mentionnées pour la première fois en 1639.

Son usage fut rapporté à Rome pour soulager les fièvres intermittentes qui faisaient rage tous les étés dans cette ville, et la popularisèrent ensuite en Europe (Fiammetta et coll. 2006).

En 1820, deux pharmaciens de la faculté de Paris, Pelletier et Caventou, extraient les principes actifs de l'écorce de quinquina rouge (Cinchona succirubra) ou jaune (Cinchona calisaya). (Wikipédia).

La synthèse des amino-4-quinoléines a été réalisé dès 1938 pour la dérive chlore, la chloroquine et en 1946 pour l'amodiaquine. Considères comme les antipaludiques de choix jusqu'à la survenue et l'extension des phénomènes de résistance, ces produits ont une action schizonticides excellente et demeurent, même actuellement, les antipaludiques les produits utilises.

Les amino-alcools (quinine et ses dérivés) : la quinine est un antipaludique naturel exerçant une activité schizonticide sanguine rapide sur les différentes espèces plasmodiées.

Deux molécules nées de la recherche intense menée devant l'apparition et l'extension de la chloroquino-résistance ont été récemment développées ; la méfloquine (Lariam), l'halofantrine (Halfan). Toutes deux sont des aminoalcools, proches de la quinine.

- **Le Qinghao (Artémisinine) et ses dérivés :**

La plante, qui appartient à la famille des *Astéraceae*, est utilisée en herbologie chinoise depuis plus de 2000 ans. Après l'étude de plus de 2000 remèdes traditionnels et le test de 380 extraits, l'isolement de l'artemisinine fut réussi, sous la direction du professeur Tu (Mckenna, 15 novembre 2011).

Ce n'est qu'après le constat, au début des années 1990, de l'aggravation des phénomènes de résistance du parasite envers les médicaments classiques comme la chloroquine et l'amodiaquine que les laboratoires pharmaceutiques ont commencé à s'y intéresser, et il fallut attendre 2001 pour que l'Organisation Mondiale de la Santé (OMS) déclare l'artémisinine « le

plus grand espoir mondial contre le paludisme ». En 2006, elle recommandait toute fois d'arrêter la monothérapie afin d'éviter les risques de résistance : l'artémisinine affaiblit le parasite mais ne le tue pas systématiquement, et elle présente son efficacité maximale en association avec d'autres anti-paludiques (OMS, 19 janvier 2006).

Malgré cela, en mai 2009 deux études indépendantes ont rapporté pour la première fois une augmentation significative de résistance à l'artémisinine de *Plasmodium falciparum* sur le terrain, au Cambodge, probablement en conséquence de pratiques et de traitements incorrects, tel que cela avait été prédit en 2006 par l'OMS (Nosten et coll., 2009).

En 2021, cette résistance partielle est confirmée au Rwanda (Uwimana et coll., 14 avril 2021).

EN 2015 Tu Youyou reçu un prix Nobel de médicine pour sa découverte.

METHODOLOGIE

1. CADRE D'ETUDE

Le présent travail a été effectué au Département Médecine Traditionnelle (DMT) de l'ex Institut National de Recherche en Santé Publique (INRSP), actuel Institut National de Santé Publique (INSP). Le DMT est un centre collaborateur de l'Organisation Mondiale de la Santé (OMS) en matière de médecine traditionnelle depuis 1981 et est un centre d'excellence de l'Organisation Ouest Africaine de la Santé (OOAS) depuis 2014.

Le DMT est une structure composée de trois services :

- **Un service ethnobotanique et matières premières** :

Ce service est chargé de la conception des herbiers et droguiers, la culture expérimentale des plantes médicinales, approvisionnement en matière premières et le recensement des tradipraticiens de santé et des herboristes,

- **Un service des sciences pharmaceutiques** :

Ce service est chargé de la recherche scientifique (phytochimie, galénique, pharmacologie, toxicologie) sur des plantes utilisées en médecine traditionnelle et de la formation des étudiants,

- **Un service des sciences médicales** :

Ce service est chargé de la consultation, la dispensation des MTA, de la réalisation des essais cliniques et de l'évaluation de l'évidence ethnomédicale.

En plus de ces 3 services, il existe un centre régional de médecine traditionnelle situé à Bandiagara.

Le DMT a pour missions :

- De contribuer à l'amélioration de l'état de santé des populations par l'utilisation des ressources locales,
- D'organiser la médicine traditionnelle pour assurer une bonne collaboration entre les systèmes de médicine traditionnelle et médicine conventionnelle.

Les objectifs spécifiques du DMT sont :

- Recenser les thérapeutes traditionnels
- Recenser les plantes médicinales
- Etablir les cartes des zones de peuplement naturel des plantes médicinales
- Réaliser un herbier de plantes médicinales maliennes
- Formuler et produire des médicaments traditionnels améliorés
- Collaborer avec les thérapeutes traditionnels.

Le personnel du DMT est composé de spécialiste en pharmacognosie, médecin gastroentérologue, d'ingénieur des eaux et forêt, de techniciens de laboratoire et de préparateurs de phytomédicaments. Aussi, des pharmaciens assistants et maîtres-assistants en pharmacognosie de la Faculté de pharmacie de l'USTTB, pharmacien génie moléculaire et pharmaciens bénévoles appuient le DMT dans certaines activités, notamment celles relatives à l'encadrement des stages des étudiants de la faculté de pharmacie et aux activités pédagogiques de la faculté.

2. TYPE ET PERIODE D'ETUDE

C'est une étude bibliographique qui s'est déroulée de janvier 2020 à janvier 2021 soit une année.

3. MATERIEL ET METHODES

3.1. Matériel

Les mots clés suivants ont été utilisés :

- *Artemisia afra*,
- Utilisations traditionnelles de *Artemisia afra*,
- Composition chimique de *Artemisia afra*,
- Données pharmacologiques de *Artemisia afra*,
- Données toxicologiques de *Artemisia afra*,
- *Artemisia afra* et COVID-19

Les moteurs de recherche suivant ont été utilisés :

- Google scholar,
- PubMed

3.2. Méthodes

Les différents mots clés ont été utilisés en consultants les différents moteurs de recherche.

- **Collecte des données**

Une revue de la littérature a été faite pour collecter des informations sur *Artemisia afra* par rapport aux :

- **Utilisations traditionnelles**,
- **Données de qualité botaniques et physicochimiques** (teneurs et la composition chimique),
- **Données d'efficacités** (les propriétés pharmacologiques, les données cliniques)
- **Données de sécurité** (données toxicologiques)

- **Organisation des données**

Les informations collectées ont été organisées comme suit :

- **Données d'utilisation de *Artemisia afra*** :

Ces données comprennent les différentes indications, les parties utilisées et les formes d'utilisation traditionnelle.

- **Données de monographie :** La monographie a été rédigée selon le plan suivant :
  - Systématique
  - Synonymes
  - Dénominations françaises et étrangères
  - Description botanique de la plante
  - Répartition géographique et habitat
  - Données de qualité botaniques
  - Données de qualités physicochimiques
  - Données pharmacologiques
  - Données toxicologiques
- **Données d'efficacité de *Artemisia afra* dans la prise en charge du paludisme**
- **Données d'efficacité de *Artemisia afra* dans la prise en charge des schistosomiases.**

RESULTATS

1. DONNEES D'UTILISATION

1.1. INDICATIONS

La revue de la littérature a permis de recenser plusieurs indications de *Artemisia afra*. Les indications les plus fréquentes étaient les infections bactériennes (12 citations), suivies du paludisme (10), du diabète (5), de la fatigue (3) et de l'hypertension artérielle, et l'infection virale avec 3 citations chacune (voir tableau I).

Tableau I: Indications de *Artemisia afra*

Indications	**Nombre de citation**	**Références**
Infection bactérienne	**12**	**[1-2,4-10, 25-27]**
Paludisme	**10**	**[11-19, 47]**
Diabète	**5**	**[20-24]**
Fatigue	**3**	**[1, 28-29]**
Hypertension	**3**	**[30-32]**
Infection virale	**3**	**[2- 3, 6]**
Aménorrhée et Dysménorrhée	2	[33-34]
Cancer	2	[26,35]
Fièvre	2	[6, 36]
Inflammation	2	[6, 37]
Schistosomiase	2	[38-39]
Toux et Rhume	2	[16, 40]
Allergie	1	[41]
Asthme	1	[43]
Dépression	1	[45]
Helminthiases	1	[42]
Maux de tête	1	[6]
Spasme intestinale et maux d'estomac	1	[44]
Troubles mentaux	1	[46]

[1] : Elias, 2018 ; [2] : Van de Venter et coll., 2014 ; [3] : James et coll., 2010 : [4] : Suliman et coll., 2010 ; [5] : More et coll., 2012 ; [6] : Lui et coll., 2009 ; [7] : Jäger, 2003 ; [8] : Mangena et Muyima, 1999 ; [9] : Graven et coll., 1992 ; [10] : Degu et coll., 2016. [11] : Kane et coll., 2019 ; [12] : Moyo et coll., 2019 ; [13] : Munyangi et coll., 2019 ; [14] : Okello et coll., 2010 ; [15] : Gathirwa et coll., 2007 ; [16] : Van der Kooy et coll., 2007.

[17] : Clarkson et coll., 2004 ; [18] : Kraft et coll., 2003 ; [19] : Abrahams, 1993 ; [20] : Erasto et coll., 2005 ; [21] : Mahop et Mayet, 2007 ; [22] : Issa et Mohamed, 2015 ; [23] : Afolayan et Sunmonu, 2010 ; [24] : Liebenberg, 2019 ; [25] : Maria Carla Martini et coll., 2020 ; [26] : Mativandlela et coll., 2008 ; [27] : Ntutela et coll., 2009 ; [28] : Sunmonu et Afolayan, 2012 ; [29] : Burits et coll., 2001 ; [30] : Lutgen, 2019 ; [31] : Mungho et coll., 2018 ; [32] : Guantai et Addae-Mensah, 1999 ; [33] : Steenkamp, 2003 ; [34] : Gericke, 2000 ; [35] : Fouche, et coll., 2008 ; [36] : Watt et Breyer-Brandwijk, 1962 ; [37] : Mavuto et coll., 2018 ; [38] : Munyangi et coll., 2018 ; [39] : Xavier A., 2019 ; [40] : Liu et Van der Kooy, 2009 ; [41] : Hutchings et coll., 1996 ; [42] : Molefe et coll., 2012 ; [43] : Felhaber 1997 ; [44] : Mulatu et Mekonnen, 2007 ; [45] : Nielsen et al., 2004 ; [46] : Stafford et coll., 2005 ; [47] : Snider et Weathers, 2021

1.2. PARTIES UTILISEES

Les feuilles (30 citations) étaient la partie la plus citée selon les données de la littérature (voir tableau II)

Tableau II: Partie utilisée de *Artemisia afra*

Partie utilisée	Nombre de citation
Feuilles	30
Partie aérienne	4
Plante entière	3
Feuille et racine	2
Feuilles et fleur	1

1.3. MODE D'UTILISATION

Dans la majorité des documents consultés le mode d'utilisation n'était pas précisé. Cependant l'infusion (11 citations) était le mode d'utilisation le plus mentionné dans les cas où le mode d'utilisation était précisé (voir tableau III).

Tableau III : Mode d'utilisation de *Artemisia afra*

Mode d'utilisation	Nombre de citation
Infusion	11
Décoction	6
Non précisé	25

2. MONOGRAPHIE

2.1. SYSTEMATIQUE (Liu et coll., 2009)

- Règne : Plantae
- Sous règne : Tracheobionta
- Division : Magnoliophyta
- Classe : Magnoliopsida
- Sous classe : Asteridae
- Ordre : Asterales
- Famille : Compositae
- Genre : Artemisia
- Espèce : *afra*

2.2. SYNONYMES (Roberts, 1990)

- *Artemisia afra* var. afra ;
- *Absinthium ponticum* (L.) Garsault ;
- *Artemisia altaica* Desf

2.3. DENOMINATIONS FRANÇAISES ET ETRANGERES

- **Français :** Armoise africaine
- **Anglais :** Wormwood, African wormwood

2.4. DESCRIPTION BOTANIQUE DE LA PLANTE (Liu et coll., 2009 ; Kokopelli, 2018 ; wormwood, 2009)

La morphologie de *Artemisia afra* varie énormément à l'échelle de l'individu :

- Arbuste ligneux, formant des buissons vivaces dont la hauteur varie de 0,6 à 2 m.
- Tiges multiples, striées et velues.
- Tiges plus épaisses et devenant ligneuses à la base.
- De nombreuses branches latérales plus petites poussent des tiges principales.
- Feuilles pétiolées finement divisées de manière semblable à *Artemisia annua* pouvant aller jusqu'à 8 cm de long, 4 cm de large.
- Les feuilles sont de couleur vert sur la face supérieure. Par contre, elles sont couvertes de petits poils blanc donnant une couleur verte plus clair sur la face inférieure. Ces poils présents aussi sur les tiges donnent à *Artemisia afra* une couleur « gris-argenté » caractéristique qui la différencie de *Artemisia annua*.
- Odeur aromatique facilement identifiable.
- Ramification extrêmement importante en cas de recépage de la plante.
- Inflorescences en panicules vert-jaune qui apparaissent sur certaines branches de la plante.
- Fleurs jaunes-crème, très petites et agencées en capitules globuleux de plus ou moins 3 mm de diamètre.
- Fruits de 1 mm de long.
- Chaque ovaire donnera un akène de très petite taille.
- Jusqu'à présent, l'obtention de semences viables semble difficile.

Figure 1 : Feuilles de *Artemisia afra*

2.5. DISTRIBUTION GEOGRAPHIQUE ET HABITAT

Artemisia afra est l'une des plantes médicinales les plus anciennement connues et largement utilisées dans le Sud de l'Afrique. Elle pousse naturellement dans les régions montagneuses d'Afrique de l'Est et du Sud entre 1500 et 3000 m d'altitude : Ethiopie, Kenya, Tanzanie, Ouganda, RDC, Zambie, Zimbabwe, Angola, Namibie, Swaziland, Lesotho et Afrique du Sud. C'est la seule espèce indigène (naturellement originaire de cette région) du genre Artemisia **(Patil, 2011 ; Liu et coll., 2009).**

2.6. PARTIES UTILISEES :

- Feuilles
- Plante entière

2.7. DONNEES DE QUALITE BOTANIQUE

Les éléments microscopiques suivants ont été identifiés dans la poudre de la plante entière de *Artemisia afra* récoltée en Afrique du Sud (voir figure 2) **(Scott et coll., 2004).**



Figure 2: Eléments microscopique de la poudre de la plante entière de *Artemisia afra*

[1] : Couche fibreuse d'anthère ; **[2] :** Corolle montrant l'épiderme interne ; **[3] :** Grains de pollen jaune – brun **; [4] :** Cellules épidermiques polygonales du limbe supérieur de la feuille **; [5] :** Petites cellules en forme de bloc de filament d'étamine **; [6] :** Cellules épidermiques du limbe foliaire inférieur à parois sinueuses légèrement épaissies ; **[7] :** Fragment de corolle avec des microcristaux d'oxalate de calcium **; [8] :** Vaisseaux de filament d'étamine ; **[9] :** Fragments de corolle à épiderme externe strié.

2.8. DONNEES DE QUALITE PHYSICOCHIMIQUES

2.8.1. TESTS D'IDENTITE ET DE PURETE

Les paramètres physicochimiques de la poudre des feuilles de *Artemisia afra* récoltée au Mali déterminés étaient **(Kamaté, 2018) :**

- Teneur en eau < 10%
- Teneur en cendres totales : 8,9%
- Teneur en cendres insolubles dans l'acide chlorhydrique 10% : < 1%.

2.8.2. CONSTITUANTS CHIMIQUES

Le criblage phytochimique de la poudre des feuilles de *Artemisia afra* a révélé la présence de constituants chimiques (voir tableau IV).

Tableau IV: Constituants chimiques caractérisés dans les différentes parties de *Artemisia afra* selon la littérature

Constituants chimiques	Feuilles	Partie aérienne	Tiges	Référence
Alcaloïdes	+	+		[2, 4]
Flavonoïdes		+		[2]
Glycosides	+		+	[1, 4]
Huiles essentielles		+		[3]
Phénols	+	+	+	[1, 2]
Saponines	+		+	[1, 4]
Terpénoïdes	+	+	+	[1, 2, 4-5]
Tanins	+		+	[1, 4, 5]

+ : Présence. [1] : Mungho et coll., 2018. [2] : Credo et coll., 2020 ; [3] : Falowo et coll., 2019 ; [4] : Kane et coll., 2019 ; [5] : Kamaté, 2018

Des molécules ont été isolées de l'extrait éthanolique de la partie aérienne de *Artemisia afra*. Certaines de ces composés sont : acacetin (1), 12α,4α-dihydroxybishopsolicepolide (2), scopoletin (3), α-amyrin (4), phytol (5), and a pentacyclic triterpenoid betulinic acid (6) (voir figure 3) (More et coll., 2012). Des flavonoïdes (voir figure 4) et des sesquiterpènes lactones (voir figure 5) ont été aussi isolés de la partie aérienne de *Artemisia afra* (Kraft et coll., 2003).



Figure 3: Différents constituants chimiques isolés dans la partie aérienne de *Artemisia afra*





		R_1	R_2	R_3
7-Methoxyacacetin	(3)	OCH_3	OCH_3	H
Acacetin	(6)	OH	OCH_3	H
Genkwanin	(7)	OCH_3	OH	H
Apigenin	(10)	OH	OH	H
Chrysoeriol	(11)	OH	OH	OCH_3
Diosmetin	(12)	OH	OCH_3	OH

Tamarixetin (9)

Figure 4: Flavonoïdes isolées de la partie aérienne de *Artemisia afra*



		R	Δ
1-Desoxy-1α-peroxy-rupicolin A-8-O-acetate	(1)	OH	10
1-Desoxy-1α-peroxy-rupicolin B-8-O-acetate	(2)	OH	9
Rupicolin A-8-O-acetate	(4)	H	10
Rupicolin B-8-O-acetate	(5)	H	9



11,13-Dehydromatricarin (**8**)



1α,4α-Dihydroxybishopsoliicepolide (Δ10) (**13**)
1α,4α-8α-Trihydroxyguaia-2,9,11(13)-triene-12,6α-olide-8-O-acetate (**14**)



Eudesmanfraglaucolide (**15**)

Figure 5: Sesquiterpènes isolées de la partie aérienne de *Artemisia afra*

2.9. DONNEES PHARMACOLOGIQUES

- **Activité antiplasmodiale**

L'activité antiplasmodiale des extraits des feuilles de *Artemisia afra* récoltées dans cinq pays d'Afrique (Burundi, Kenya, Sénégal, Sud-Afrique et Tanzanie) a été évaluée sur des souches de *Plasmodium falciparum* W2 et D6. Les résultats de l'étude ont montré une meilleure activité antiplasmodiale avec les extraits éthanoliques, dichlorométhane et hexane. L'extrait aqueux a démontré une faible activité antiplasmodiale **(Kane et coll., 2019).** D'autres études ont démontré l'activité antiplasmodiale des extraits et des molécules isolées des feuilles de *Artemisia afra* sur d'autres souches de *Plasmodium falciparum* **(Snider et Weathers, 2021 ; Moyo et coll., 2019 ; Kraft et coll., 2003)**

- **Activité antibactérienne**

De nombreuses études ont démontré l'activité antibactérienne des extraits, des huiles essentielles et des molécules isolées des feuilles de *Artemisia afra* sur plusieurs souches de bactérie **(Muleya et coll., 2014 ; More et coll., 2012 ; Mangena et Muyima, 1999).**

Plusieurs auteurs ont évalué l'activité anti-Mycobacterium des extraits des feuilles de *Artemisia afra*. Les résultats de ces études ont montré que les extraits des feuilles inhibent plusieurs souches de Mycobacterium **(Carla Martini et coll., 2020 ; Van de Venter et coll., 2014 ; Pruissen, 2013 ; Ntutela et coll., 2009 ; Mativandlela et coll., 2008).**

- **Activité antivirale**

L'efficacité de l'extrait éthanolique 70% des feuilles de *Artemisia afra* a été évaluée *in vitro* contre une souche clinique de SARS-CoV-2 et une souche de coronavirus félin (FCoV). Les résultats de l'étude ont montré que l'extrait éthanolique inhibe FCoV et SARS-CoV-2 avec une concentration efficace 50 respective de 4,10 ± 1,27 mg/mL et 0,65 ± 0,21 mg/mL **(Nie et coll., 2021).**

Van de Venter et coll. (2014) ont démontré *in vitro* l'activité anti-VIH1 des extraits aqueux et éthanoliques de *Artemisia afra*.

- **Activité antioxydante**

Les extraits et les huiles essentielles de *Artemisia afra* ont démontré une activité antiradicalaire en réduisant le radical DPPH, le radical ABTS et le fer **(Falowo et coll., 2019 ; Muleya et coll., 2014 ; Sunmonu et Afolayan, 2012 ; Burits et coll., 2001).**

L'extrait aqueux des feuilles de *Artemisia afra* à des doses de 50 – 100 mg/kg a démontré une activité antioxydante en améliorant l'activité des antioxydants endogènes chez des rats rendus diabétiques par administration de la streptozotocine **(Afolayan et Sunmonu, 2011).**

- **Activité antihypertensive**

L'activité antihypertensive des feuilles a été démontrée chez des rats par plusieurs études **(Mungho et coll., 2018 ; Guantai et Addae-Mensah, 1999).**

- **Activité antidiabétique**

L'activité antidiabétique de l'extrait aqueux des feuilles a été évaluée chez des rats rendus diabétiques par administration de la streptozotocine. Les résultats de l'étude ont montré que les extraits (50 – 100 mg/kg) réduisent la glycémie et augmentent la concentration d'insuline dans le sérum. Selon les auteurs les extraits exercent un effet antidiabétique en régénérant les cellules bêta stimulant ainsi la libération de l'insuline **(Afolayan et Sunmonu, 2011).**

L'activité anti-hyperglycémiante de l'extrait hydroéthanolique 80% de la partie aérienne de *Artemisia afra* a été évaluée en utilisant le test de tolérance au glucose par voie orale chez des souris. Les résultats de l'étude ont montré une réduction de l'hyperglycémie 4 heures après l'administration des extraits (Credo et coll., 2020).

Issa et Bule, (2015) ont aussi démontré que les extraits de *Artemisia afra* réduisent hyperglycémie induite par l'alloxan chez des souris.

- **Activité antiproliférative**

L'extrait éthanolique des feuilles de *Artemisia afra* a été évaluée *in vitro* sur deux lignées cancéreuses (cellules Hela : et cellules U937). Les résultats de l'étude ont montré une activité antiproliférative avec une CI_{50} de 18,21 µg/mL (cellules U937) et 31,88 µg/mL. Selon les auteurs, l'extrait induit l'apoptose par activation des caspases (Spies et coll., 2013). Venables et coll. (2016) ont démontré que l'activité anticancéreuse des extraits sur les cellules Hela est due en partie à un sesquiterpène lactone (Isoalantolactone).

- **Activité antalgique et antiinflammatoire**

L'extrait aqueux de la plante entière de *Artemisia afra* a démontré une activité antiinflammatoire et antalgique en inhibant respectivement l'œdème de la patte induite par la carraghénine et les douleurs induites par l'acide acétique et la plaque chauffante à des doses de 100, 200 – 400 mg/kg chez des souris (Gondwe et coll., 2018).

Muleya et coll. (2014) ont aussi démontré l'activité antiinflammatoire des extraits de *Artemisia afra*.

- **Activités diverses**

Artemisia afra a fait l'objet de nombreuses recherches pour son utilisation possible dans les maladies comme le diabète, maux de tête, épilepsie, aménorrhée, dysménorrhée, crampes menstruelles, indigestion, flatulence, gastrite, dyspepsie, vers intestinaux, les maladies cardiovasculaires, le cancer, et les maladies respiratoires… (Patil, 2011).

2.10. DONNEES TOXICOLOGIQUES

De nombreuses études ont évalué la toxicité aiguë et chronique de *Artemisia afra in vivo* sur des rongeurs (souris, rats). Les résultats de ces études ont montré que l'administration d'une dose unique (5 g/kg) ou d'une dose répétée (1 – 1,8 g/kg/j pendant 28 – 90 jours) des extraits aqueux des feuilles et des parties aériennes sont sûrs chez des souris et des rats (Meckonen et coll., 2020 ; Eshetu et coll., 2016 ; Mukinda et Syce, 2007). Un résultat similaire a été obtenu avec l'extrait hydroéthanolique des feuilles (Mungho et coll., 2018).

3. DONNEES D'EFFICACITES CLINIQUES DANS LA PRISE EN CHARGE DU PALUDISME

Une étude clinique visant à comparer l'efficacité curative de la tisane de *Artemisia afra* vs Artésunate-Amodiaquine (ASAQ) contre le paludisme a été réalisée en République Démocratique de Congo (RDC). Les résultats de l'étude ont montré que l'administration orale de la tisane (5 g de poudre dans 1 L d'eau distillée bouillante) à la dose de 330 ml/j pendant 7 jours chez 223 patients (51 patients de 5 – 15 ans et 172 patients de 16 – 65 ans) est meilleur

que Artésunate-Amodiaquine (4 mg d'Artésunate et 10 mg d'Amodiaquine par kg une fois par jour pendant 3 jours). Les taux de guérison aux jours 14 et 28 étaient respectivement de 81,2% et 88,8% pour la tisane contre 34,1% et 34,3% pour ASAQ (Munyangi et coll., 2019).

4. DONNEES D'EFFICACITES CLINIQUES DANS LA PRISE EN CHARGE DE LA SCHISTOSOMIASE

Une étude clinique visant à évaluer l'efficacité curative de la tisane de *Artemisia afra* contre la schistosomiase a été réalisée en République Démocratique de Congo (RDC). Les résultats de l'étude ont montré que l'administration orale de la tisane (5 g de poudre dans 1 L d'eau distillée bouillante) à la dose de 330 mL trois fois par jour pendant 7 jours chez 178 patients élimine les œufs de schistosomes des selles des patients de façon similaire que le Praziquantel (60 mg/kg/jour pendant 3 jours). L'élimination des œufs était plus rapide chez les patients traités avec la tisane avec moins d'effets secondaires que chez les patients traités par le Praziquantel (Munyangi et coll., 2018).

DISCUSSIONS

Ce travail avait pour but de faire un état de lieu par rapport aux données d'efficacité, de qualité et de sécurité de *Artemisia afra*.

Pour cela nous avons fait une revue de la littérature enfin de

- Déterminer les utilisations traditionnelles,
- Rédiger la monographie
- Recenser les données d'efficacité cliniques dans la prise en charge du paludisme et des schistosomiases.

Par rapport aux utilisations traditionnelles, les données de la littérature ont montré que *Artemisia afra* est utilisée en médecine traditionnelle dans le traitement de nombreuses maladies. Les indications les plus fréquentes sont les **infections microbiennes, le paludisme, et le diabète**.

Il existe des données pharmacologiques pouvant justifier ces principales indications traditionnelles.

Pour **les infections microbiennes**, il a été démontré que les extraits de *Artemisia afra* inhibent *in vitro* plusieurs souches de bactérie plus particulièrement des souches de Mycobacterium **(Carla Martini et coll., 2020 ; Van de Venter et coll., 2014 ; Pruissen, 2013 ; Ntutela et coll., 2009 ; Mativandlela et coll., 2008)** et des souches de virus dont le VIH et le SARS-COV-2 **(Nie et coll., 2021 ; Van de Venter et coll., 2014).**

L'effet antiviral *in vitro* de ces extraits pourrait être bénéfique dans le cadre de traitement contre l'infection au coronavirus.

L'activité antimicrobienne des extraits de *Artemisia afra* pourrait être due en partie à la présence des huiles essentielles, saponosides et des tanins **(Muleya et coll., 2014 ; More et coll., 2012 ; Mangena et Muyima, 1999).**

Quant au paludisme, des études pharmacologiques ont démontré les propriétés antiplasmodiales des extraits de *Artemisia afra* **(Snider et Weathers, 2021 ; Kane et coll., 2019 ; Moyo et coll., 2019 ; Kraft et coll., 2003)**. Cette activité serait due en partie à la présence des flavonoïdes. En effet il a été démontré que les flavonoïdes d'une autre espèce de Artemisia (*Artemisia annua*) ont un effet un antiplasmodiale *in vitro* (Mesa et coll., 2015).

Et enfin pour le diabète, il a été démontré que les extraits de *Artemisia afra* réduisent l'hyperglycémie dans plusieurs modèles expérimentaux de diabètes chez des rongeurs **(Credo et coll., 2020 ; Issa et Bule, 2015 ; Afolayan et Sunmonu, 2011).** Cette activité serait due en partie à la présence des polyphénols (tanins et flavonoïdes). L'activité antioxydante (**Falowo et coll., 2019 ; Muleya et coll., 2014 ; Sunmonu et Afolayan, 2012 ; Afolayan et**

Sunmonu, 2011 ; Burits et coll., 2001) de ces extraits pourrait être bénéfique aussi dans la prise en charge du diabète. En effet de nombreuses études ont démontré que le stress oxydant joue un rôle dans la pathogenèse et les complications du diabète **(Saeidnia et Abdollah, 2013 ; Kaneto et coll., 2010 ; Martim et coll., 2003).**

Les feuilles constituent la partie de la plante la plus utilisée. Selon Tahri et coll. (2012), la forte fréquence d'utilisation des feuilles en médecine traditionnelle peut être expliquée par l'aisance et la rapidité de la récolte mais aussi par le fait qu'elles sont le siège de la photosynthèse et parfois du stockage des métabolites secondaires responsables des propriétés biologiques de la plante.

L'infusion est la forme d'utilisation la plus fréquente. Cette technique d'extraction est généralement utilisée pour des drogues fragiles contenant des principes actifs volatils ou sensibles à la chaleur ou pour des drogues dont le principe actif est libéré rapidement **(Kamil Hussain et coll., 2019).**

Les données de la littérature nous a permis de rédiger une monographie de la plante qui fait ressortir les données de qualités botanique et physicochimique et les données de sécurités.

Des essais cliniques réalisés en Afrique (RDC) ont démontré l'efficacité clinique de la tisane en cas de paludisme **(Munyangi et coll., 2019)** et de schistosomiases **(Munyangi et coll., 2018).** Selon un rapport de l'OMS publié en 2019, les essais cliniques réalisés sur les espèces de Artemisia (*Artemisia afra* et *Artemisia annua*) sont de qualité médiocre. D'où la recommandation de l'OMS d'éviter les tisanes à base de Artemisia dans la prise en charge du paludisme surtout pour ne pas développer une résistance du Plasmodium face à l'Artémisinine.

Cependant, il a été démontré que l'activité antiplasmodiale de la tisane ne serait pas due à la présence de l'Artémisinine seulement qui existe en quantité très faible dans les feuilles de *Artemisia afra*.

Il serait donc important de s'assurer surtout de la qualité des feuilles utilisées car l'efficacité et la sécurité d'un médicament en base de plante dépendent de la qualité de la matière première.

CONCLUSION

Au terme de cette étude, il ressort que la tisane de *Artemisia afra* est utilisée dans la prise en charge de nombreuses maladies dont les infections microbiennes, le paludisme et le diabète en Afrique. Il existe des données de sécurité, de qualité et d'efficacité sur *Artemisia afra* permettant son utilisation dans la prise en charge de ces principales pathologies.

RECOMMADATIONS

- **AU DMT**

Contrôler la qualité des feuilles de *Artemisia afra* provenant de plusieurs localités du Mali enfin de pouvoir établir les normes de qualité d'un bon échantillon.

- **A LA POPULATION**

De ne pas abuser de l'utilisation des espèces de *Artemisia.*

REFERENCES

1. "L'OMS demande l'arrêt immédiat de la commercialisation des comprimés antipaludiques comportant uniquement de l'artémisinine", centre des medias, sur who.int, OMS, 19 janvier 2006.
2. Afolayan, Anthony Jide & Sunmonu, Taofik Olatunde. *Artemisia afra* Jacq. (2011) Ameliorztes oxidative stress in the pancreas of streptozotocin-induced diabetic Wistar rats. Bioscience, biotechnology, and biochemistry, 75(11), 2083-2086.
3. Argemi, X., Hansmann, Y., Gaudart, J., Gillibert, A., Caumes, E. Jauréguiberry, S., & Meyer, N. (2019). Comment on"Effect of *Artemisia annua* and *Artemisia afra* tea infusions on schistosomiasis in a large clinical trial". Phytomedicine, 62, 152943.
4. *Artemisia afra* Herba Monograph (1999) Traditional Medicine, South African Medical Council Research, SAHealth Info.
5. Breyer-Brandwijk M. G. (1962). The medicinal and poisonous plants of Southern and Eastern Africa being an Account of their Medicinal and other Uses, Chemical Composition, Pharmacological Effects and Toxicology in Man and Animal, 59, 1125.
6. Burits, M., Asres, K., & Bucar, F. (2001). The antioxidant activity of the essential oils of *Artemisia afra*, *Artemisia abyssinica* and *Juniperus procera*. Phytotherapy Reseach, 15(2) 103-108.
7. Bwire, R. (2006). Fiammetta Rocco. Quinine: Malaria and the Quest for a Cure that Changed the World. HarperCollins Pub. Ltd., 2004. 348 pp. §13.95.
8. Clarkson C., Maharaj V. J., Crouch N. R., Grace O. M., Pillay P., Matsabisa, M. G., …& Folb, P. I. (2004) . In vitro antiplasmodial activity of medicinal plants native to or naturalised in South Africa. Journal of ethnopharmacol 92(2-3), 177-191.
9. Credo, D., Machumi, F., Masimba, P. J., & Mwakigonja, A. R. (2020). Comparative evaluation of hypoglycemic activity and phytochemical contents of three Tanzanian medicinal plants International Journal of Herbal Medicine, 8(1), 58-62.
10. Dondrop, A. M., Nosten F., Yi, P., Das, D., Phyo, A. P., Tarning, J. … & White, N. J. (2009). Artemisinin resistance in *Plasmodium falciparum* Malaria. New England Journal of Medicine, 361(5), 455-467.
11. Elemike, E. E., Onwudiwe, D. C. Ekennia, A. C., & Jordaan, A. (2018). Synthesis and characterisation of silver nanoparticles using leaf extract of *Artemisia afra* and their in vitro antimicrobial and antioxidant activities. Intitution of Engineering and Technology nanobiotechnology, 12(6), 722-726.

12. Erasto P., Adebola P. O., Grierson D. S., Afolayan A. J. (2005). An ethnobotanical study of plants used for the treatment of diabetes in the Eastern Cape Province, South Africa. African Journal of Biotechnology, 4(12), 1458-1460.
13. Eshetu, N., Afework, M., Makonnen, E., Debella, A., Ergete, W., & Tolessa, T. (2016). Evaluation of the acute and sub-chronic toxic effects of aqueous leaf extracts of *artemisia afra* on liver, kidney and some blood parameters in Wistar Rats. Advances in Bioscience and Bioengineering, 1(1), 1-9.
14. Falowo, A. B., Mukumbo, F. E., & Muchenje, V. (2019). Phytochemical constituents and antioxidant activity of *Artemisia afra* and Bidens pilosa essential oil in ground pork. Journal of Essential Oil Bearing Plants, 22(1), 176-186.
15. Felhaber, T. ed. (1997). South African Traditional Healers' Primary Healthcare Handbook. Traditional aspects compiled by I. Mayeng. Kagiso, Cape Town, 48-57.
16. Fouche G., Khorombi, T. E., Kolesnikova N. I., Maharaj V. J., Nthambeleni R., & Van der Merve, M. R. (2006). Investigation of South African plants for anticancer properties. Pharmacologyonline 3: 494-500.
17. Gondwe, M. A. V. U. T. O., Mpalala, A. N. D. A., Zongo, L. U. S. A. N. D. A., Kamadyaapa, D. A. V. I. D., Ndebia, E. U. G. E. N. E., Sewani-Rusike, C. O. N. S. T. A. N. C. E., …& Iputo, J. E. H. U. (2018). Investigation of anti-inflammatory and antinoceptive effects of aqueous extracts of *Artemisia afra* in wistar rats, Asian Journal of Pharmaceutical and Clinical Research, 11(12), 190-193.
18. Graven E. H., Dean S. G., Svoboda, K. P., Mavi, S., & Gundidza, M. G. (1992). Antimicrobial and antioxidative properties of the volatile (essential) oil of *Artemisia afra* Jacq. Flavour and Frangrance Journal, 7(3), 121-123.
19. Guantai AN, Addae-Mensah I (1999) Cardiovascular effect of *Artemisa Afra* and its Constituents. Pharmaceutical Biology 37: 351-356
20. Hussain, M. K., Saquib, M., & Khan, M. F. (2019). Techniques for Extraction, Isolation, and Coumpounds from Medicinal Plants. In Natural Bioactive Coumpounds (pp. 179-200). Springer, Singapore.
21. Hutchings A., Scott A. H., Lewis G., Cunningham A. (1996). Zulu Medicinal plants: An inventory. South Africa, University of Natal press, Scottsville: 327: 195-196.
22. Issa, Idriss Ahmed, and Mohamed Hussen Bule."Hypogycemic effect of aqueous and methanolic extract of *Artemisia afra* on alloxan induced diabetic Swiss albino mice." Evidence-based complementary and alternative medicine, 2015, vol. 2015.

23. Jäger A. K. (2003) “Evaluation of antibacterial activity of traditionally prepared South African remedies for infections” South Africa Journal of Botany, 69(4), 595-598.
24. Kamaté, A., (2018). Contrôle de qualité des feuilles de *Artemisia afra* jack ex. willd (compositae) utilsé dans le traitement traditionnel de la schistosomiase. Thèse pharmacie Bamako 79P ; N35.
25. Kane, N.F., Kyama, M.C., Nganga, J.K., Hassanali, A., Diallo, M., and Kimani, F.T. (2019). Comparison of phytochemical profiles and antimalarial activities of *Artemisia afra* plant collected from five countries in Africa. South African Journal of Botany, 125, 126-133.
26. Keshebo, D. L., Washe, A. P., & Alemu, Fikadu, F. (2016). Determination of antimicrobial and antioxydant activities of extracts from selected medicinal plants. American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS), 16(1), 212-222.
27. Kraft C., Jenett-Siems K., Siems K., Jakupovic J., Mavi S., Bienzle, U., & Eich, E. (2003). In vitro antiplasmodial evaluation of medicinal plants from Zimbabwe. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives, 17(2), 123-128.
28. Liu, N. Q., Cao, M., Frédérich, M. Choi, Y. H., Verpoorte, R., & van der kooy, F. (2010). Metabolomic investigation of the ethnopharmacological use of *Artemisia afra* with NMR spectroscopy and multivariate data analysis. Journal of ethnopharmacology, 128(1), 230-235.
29. Liu, N.Q., Van der Kooy, F., & Verpoorte R. (2009). *Artemisia afra*: A potential flagship for African medicinal plants. South African Journal of Botany, 75(2), 185–195.
30. Lutgen, P. *Artemisia afra* and hypertention. (2019). Pharmacy Pharmacology International Journal, 7(6), 297-300.
31. Mangena, T. & Muyima, N. Y. O. (1999). Comparative evaluation of the antimicrobial activities of essential oils of *Artemisia afra*, *Pteronia incana* and *Rosmarinus officinalis* on selected bacteria and yeast strains. Letters in applied microbiology, 28(4), 291-296.
32. Martini, M. C., Zhang, T., Williams, J. T., Abramovitch, R. B., Weathers, P. J., & Shell, S. S. (2020). *Artemisia annua* and *Artemisia afra* extracts exhibit strong bactericidal activity against *Mycobacterium tuberculosis*. Journal of Ethnopharmacology, 262, 113-191.
33. Mativandlela, S. P. N., Meyer, J. J. M., Hussein, A. A., Houghton, P. J., Hamilton, C. J., & Lall, N.(2008). Activity againt *Mycobacterium smegmatis* and *Mycobacterium tuberculosis* by extract of South African ùedicinal plants. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives, 22(6) 841-845.

34. McGaw L. J., Jäger A. K., & Van Staden J. (2000). Antibacterial, anthelmintic and antiamoebic activity in South African medicinal plants. Journal of ethnopharmacology, 72(1), 247-263.
35. Molefe N. I., Tsotetsi A. M., Ashafa A. O. T., Thekisoe O. M. M. (2012). In vitro anthelmintic effects of *Artemisia afra* and Mentha longifolia against parasitic gastrointestinal nematodes of livestock. Bangladesh Journal of Pharmacology, 7(3), 157-163.
36. Mondiale de la Santé O. (2019). Utilisation des formes non pharmaceutiques d'Artemisia (NO WHO/CDS/2019.14). Organisation Mondiale de la Santé.
37. More, G., Lall, N., Hussein, A., & Tshikalange, T. E. (2012). Antimicrobial Constituents of *Artemisia afra* Jacq.ex Willd against Periodontal Pathogens. Evidence-Based Complementary and Alternative Medicine, 2012, 252-758.
38. Mueller, M. S., Karhagomba, I. B., Hirt, H. M., & Wemakor, E. (2000). The potential of *Artemisia annua* L. as a locally produced remedy for malaria in tropics: agricultural, chemical and clinical aspects. Journal of ethnopharmacology, 73(3), 487-493.
39. Mueller, M. S., Runyambo, N., Wagner, I., Borrmann, S., Dietz, K., & Heide, L. (2004). Randomized controlled trial of a traditional preparation of *Artemisia annua* L. (Annual Wormwood) in the treatment of malaria. Transactions of the Royal Society of tropical Medicine and Hygiene, 98(5), 318-321.
40. Mukinda, J. T. & Syce, J. A. (2007). Acute and chronic toxicity of the aqueous axtracts of *Artemisia afra* in rodents. Journal of ethnopharmacology, 112(1), 138-144.
41. Mukinda, J. T., Syce, J. A., Fisher, D., & Meyer, M. (2010). Effect of the plant matrix on the uptake of luteolin derivatives-containing *Artemisia afra* aqueousextract in Caco-2 cells. Journal of ethnopharmacology, 130(3), 439-449.
42. Mulatu, A., & Mekonnen, Y. (2007). Spasmolytic effects of *Artemisia afra* and Artemisia rehan in tissue preparations. Ethiopian medical journal, 45(4), 371-376.
43. Munyangi J., Cornet-Vernet L., Idumbo M., Lu C., Lutgen P., Perronne C., & Weathers, P., (2019). *Artemisia annua* and *Artemisia afra* tea infusions vs. artesunate-amodiaquine (ASAQ) in treating *Plasmodium falciparum* malaria in a large scale, double blind, randomized clinical trial. Phytomedicine: International journal of phytotherapy and pharmacology, 57, 49.
44. Munyangi, j., Cornet-Vernet, L., Idumbo, M., Lu, C., Lutgen, P., Perronne, C. …& Weathers, P. (2018). Effect of *Artemisia annua* and *Artemisia afra* tea infusions on schistosomiasis in a large clinical trial. Phytomedicine: international journal of phytotherapy and phytopharmacology, 51, 233.

45. Muthaura, C. N., Rukunga, G. M., Chhabra, S. C., Omar, S. A., Guantai, A. N., Gathirwa, J. W., …& Njagi, E. N. M. (2007). Antimalarial activity of some plants traditionally used in Meru district of Kenya. Phytotherapy Research: An International Journal devoted to Pharmacological and Toxicological Evaluation of National Product Derivatives, 21(9), 860-867.
46. Nie C., Trimpert J., Moon S., Haag R., Gilmore K., Kaufer B. B., & Seeberger P. H. (2021). In Vitro Efficacy of Artemisia extracts against SARS-CoV-2. BioRxiv. Journal of Virology.
47. Ntutela, S., Smith, P., Matika, L., Matika, L., Mukinda, J., Arendse, H., Allie, N. … & Jacobs, M. (2009). Efficacy of *Artemisia afra* phytotherapy in experimental tuberculosis. Tuberculosis, 89, S33-S40.
48. Okello, S. V., Nyunja, R. O., Netondo, G. W., & Onyango, J. C. (2010). Ethnobotanical study of medicinal plants used by Sabaots of Mt. Elgon Kenya. African Journal of Traditional, Complementary and Alternative Medicines, 7(1).
49. Patil, G. V., Dass, S. K., & Chandra, R. (2011). *Artemisia afra* and modern Diseases. J Pharmacologenom, Pharmacoproteomics, 2(105), 2153-0645.
50. Phil Mckenna, « The modest woman who beat malaria for China »; Health, sur newscientist.com, new scientist, 15 novembre 2011.
51. Saitou, M., Osonoi, T., Kawamori, R., Katakami, N., Kaneto, H., Matsuhisa, M., & Yamasaki, Y. (2010). Genetic Risk Factors and the Anti-Atherosclerotic Effect of Pioglitazone on Carotid Atherosclerosis of Subjects with Type 2 Diabetes-A Retrospective Study-Journal of atherosclerosis and thrombosis, 17(4), 386-394.
52. Scott, G., Springfield, E. P., & Coldrey, N. (2004). A pharmacognostical study of 26 South African plant species used as traditional medicines. Pharmaceutical Biology, 42(3), 186-213.
53. Snider, Danielle & Weathers, P. J. (2021). In vitro reduction of *Plasmodium falciparum* gametocytes by Artemisia spp. Tea infusions vs. artemisinin. Journal of Ethnopharmacology, 268, 113638.
54. Spies, L., Koekemoer, T. C., Sowemino, A. A., Goosen, E. D., and Venter, M. (2013). Caspase-dependent apoptosis is induced by *Artemisia afra* Jacq.ex Willd in a mitochondria-dependent manner after G2/M arrest. South African Journal of Botany, 84, 104-109.
55. Steenkamp V (2003) Traditional herbal remedies used by South African women for gynaecological complaints. Journal of ethnopharmacol 86(1), 97-108.
56. Suliman, S., Van Vuuren, S. F. & Viljoen A. M. (2010). Validating the in vitro antimicrobial activity of *Artemisia afra* in polyherbal combinations to treat respiratory infactions. South African Journal of Botany, 76(4), 655-661.

57. Sunmonu, T. O. & Afolayan, A. J. (2012). Evaluation of Polyphenolic Content and Antioxidant Activity of *Artemisia Afra* Jacq. Ex Willd. Aqueous Extract, Pakistan Journal of Nutrition, 11(7), 520.
58. Uwimana, A., Umulisa, N., Venkatesan, M., Svigel, S. S., Zhiyong Z., Munyaneza, T. …& Lucchi, N. W. (2021), Association of *Plasmodium falciparum* kelch13R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre,therapeutic efficacy study , The Lancet Infectious Diseases. 142(21), 1473-3099.
59. Van de Venter, M., Pruissen, M., Koekemoer, T., Sowemimo, A., & Govender, S. (2014). In vitro anti'HIV and-TB activities of *Annona muricata* and *Artemisia afra* extracts. Planta Medica, 80(16) P1L29.
60. Van Wyk B. E., Gericke N. (2000) People's Plants: A Guide to Useful Plants of Southern Africa. Briza Publications, Pretoria, South Africa, 351.
61. Van Wyk, B. E., Oudtshoorn, B. V., & Gericke, N. 1997, Medicinal plants of South Africa, Briza Publications, Pretoria.
62. Venables, L., Koekemoer, T. C., Van de Venter, M., and Goosen, E. D. (2016). Isoalantolactone, a sesquiterpene lactone from *Artemisia afra* Jacq. Ex Willd and its in vitro mechanism of induced cells. South African Journal of Botany, 103, 216-221.
63. Willcox, M., Bodeker, G., Bourdy, G., Dhingra, V., Falquet, J., Ferreira, J. F. …& Wright, C. W. (2004). *Artemisia annua* as aTraditional medicinal plants and malaria, 4, 43-59.

ANNEXE 1: *Artemisia Afra*

A potential flagship for African medicinal plants Un produit phare présent dans plusieurs africains et bientôt au Burundi

Artemisia Afra

A potential flagship for African médicinal plants

Un produit phare présent dans plusieurs africains et bientôt au Burundi

presented by Pierre Lutgen IFBV-BELHERB. Luxembourg

SASA conference Rwanda October 4-6 2017

The key message

Artemisia afra kills all gametocytes and stops transmission

Growing from the Cape to Addis Abeba and Kinshasa Waiting to be harvested

In the wild it grows in mountainous areas, at altitudes of up to 2 500 m on damp slopes, along stream edges and forest margins.

WHO opened the door for traditional medicine

WHO Traditional Medicine Strategy 2014 - 2023

apps.who.int/iris/bitstream/10665/92455/1/9789241506090_eng.pdf

•**WHO/EDM/TRM/2000.1** Traditional use refers to documentary evidence that a substance **has been used over three or more generations** of recorded use for a specific health related ormedicinal purpose.

•In this case WHO maintains its position that there is no requirement for pre-clinical toxicity testing.

•Pre-clinical toxicity testing is only required for new medicinal herbal products which contain herbs of no traditional history of use

MAP 7 - Geographic distribution of Artemisia afra



FOOD

AND

AGRICULTURE
ORGANIZATION
OF THE UNITED
NATIONS

1986

Global Bîodjversity Information Facility

DISTRIBUTION ARTEMISIA AFRA

2 - Africa, 23 - West-Central Tropical Africa, **Zaire** (ZAI), Zaire (ZAI-OO); 2 - Africa, 24 - Northeast Tropical Africa, Ethiopia (ETH), Ethiopia (ETH-OO); 2 - Africa, 27 - Southern Africa, Cape Provinces (CPP), ; 2 - Africa, 25 - East Tropical Africa, Tanzania (TAN), Tanzania (TAN-OO); 2 - Africa, 26 - South Tropical Africa, Malawi (MLW), Malawi (MLW-OO); 2 - Africa, 26 - South Tropical Africa, Mozambique (MOZ), Mozambique (MOZ-OO); 2 - Africa,

26 - South Tropical Africa, Zambia (ZAM), Zambia (ZAM-OO); 2 - Africa, 27 - Southern Africa, Namibia (NAM), Namibia (NAM-OO); 2 - Africa, 25 - East Tropical Africa, Kenya (KEN), Kenya (KEN-OO); 2 - Africa, 26 - South Tropical Africa, Angola (ANG), Angola (ANG-OO); 2 - Africa, 26 - South Tropical Africa, Zimbabwe (ZIM), Zimbabwe (ZIM-OO); 2 - Africa, 25 - East Tropical Africa, Uganda (uGa), Uganda (UGA-OO);

UGANDA. KanLinnja District Ml Kadam [Dcbuien], Jan, 19Ï7, ***AS, Tlwnia'i*** 'JiWSÏ!: MîhIc Disirici: EJgon, Nom I9^3$_h$ ***TbMUM***263 kMudanpi [Matlangi], Nov. MJ39, ***DakU****49*\

KENYA* Hgcyo District: Chcrïmgaxii Ililts, Arror Valley, Aug. 1965^ *Mablunky à? MtGàü* SÎ41!: Naivasha D^trict Lnngoncit summh, jan, 198^. Ufrwmi 3/8SI; N Nym District: Mi Kenya* NW dope al ong Sirimon Track, Oct, i%7, fMfn;43£5|

ÎANUNlA. [.Lhlioto District; Kaiif'vi ȷune L983$_h$ *Ki\nm & Ruffo* 131!; Ullpn District: âumhuwnngat Mbtzï Forçat Rc*erve$_h$ Oct, 1967, *Ruffo if* Jftmrt 2^23'; irimgj Dû trier Kîluto Plateau, M;ir. 199L, **ÆdAûua** ÛfAm4t29I

[Artemisia afra](#) [Malawi](#)

Northern Region, Rumpi District. Nyika Plateau, esat of Chelinda Camp on road to Dembo River

. Bale Mountain National park in **Ethiopia**

Relatively higher parts are covered with low bush vegetation, dominated by Artemesia afra and Helichrysum splendium.

Zambia : A Biegele, Rhodesia Agric J, 1972, 25,3.

H Beentje, Flora of Tropical east Africa, Science, 2002 **DtSTRr U),**

S: K 3—7; **T** 2-^4, 7; S Con^o (Kinshasa^ Ethlupia» Angola» Zambia. Malawi, Mozambique, Zimhalnve, Nimikhia <md Smith Alriu

Handbook of African Medicinal Plants Pharmacopeia of South Africa p121 IPC codes for

Artemisia afra B50- *Plasmodium falciparum* malaria

B51- *Plasmodium vivax* malaria

Agnew AD. Q. (1974). "Upland Kenya Wild Flowers: A flora of the Ferns and Herbaceous Flowering Plants of Upland Kenya." Oxford University Press, 46-7.

Kokwaro J O Medicinal plants of east Africa (Kenya, Uganda, Tanzania)

1976

East African Literature Bureau

Ethiopia

Auteur: Mesfin, F., S. Demissel, **T.** Teklehaymanot

An ethnobotanical studv of médicinal plants in

wwwwwwwwwwwwwwwwwwwwww y y y y y y y y y y y y b wwwwwwwwwwwwwwws |

Wonago Woreda, SNNPR, Ethiopia Journal of

I ■ A BVjffjk, ■ f ŕ ŕ ŕ m « ·----------m.------- --------

1 Ethnobiology and Ethnomedicine . 5:28

8BSBSBSBSBSBBBSBSBSBSBSBSBSBSBSBBBSBSBSBSBBBSBSBSBSBSBSBSBSBSBSBSBSBSBSBBBBBB yb ■ ŕl ■

doi: 10.1186/1746-4269-5-28

(2009) **Symptômes:** 1-1(018), 1-1(051), H(104)

H(018) maux de tête, mâcher des feuilles fraîches de Artemisiia afra et VO.

1-1(051) **paludisme, piler des feuilles fraîches et séchées avec** du beurre VO. **Recettes:** avec du café avant le repas du matin durant 3 jours

1-1(104) douleurs abdominales, feuilles fraîches écrasées ou pilées de Artemisia afra bouillir dans H20 . filtrer et boire chaud

de l'est

Pays: Ethiopie (région de Wonago Woreda)

Registered by the Ministry of Health in Tanzania

Experience on the use of Tanzanian médicinal plants for the last decade (1979“1989

Traditional Medicinal Plants. Dar Es Salaam University Press - Ministry of Health - Tanzania, 391 p. (1991)

Author N.E.N Shauri

Artemisia afra (Fivi)

This is used as an antimalarial. For its preparation, green or dried leaves are boiled for 20 minutes. Alternatively a powder of dried leaves is placed in a hot water decoction for 15 minutes and filtered with clean cloth. The dosage recommended is 100 ml tds for adults, and 15 to 20 to 40 ml tds for children over 5 years. If in powder form, 1 tablespoonful is added to 100 ml of a hot water decoction.

Auteur: Okello, S.V., Nyunja R.O., Netondo G.W. & Onyanqo

wwwwwwwww vwwwwwww " ^wwBWVWwjLwv ^wwwwwwwwwws ıı ıı ıı ıı ıı ıı ıı ıı ıı ıı Jı ıı ıı ıı ıı ıı ıı "hm ıı ıı ıı ıı

J.C.

Titre: Ethnobotanical study of médicinal plants used by Sabaot of Mt. Elgon Kenya African Journal of Traditional, Compiementary and Alternative Medicines Volume 7, No. 1, pp 1 -10 {2010)

Symptômes: **H{051)**

Recettes: 1-1(051) **paludisme,** décoction de feuilles de Artemisia afra, RNS. {Probablement VO.)

Région: Afrique de l'est

Pays: Kenya {région de la montagne Elgon)

^nwwwwJwwwnww J \ "'mmF V ^ ▪▪▪▪ iflP ▪▪▪▪▪▪ f

Nom vernaculaire: **sisimwet (Sabaot)**

KENYA

Is also planted as cash crop for essential oils.

agriculture, forestry & fisheries

Department:
Agriculture, Forestry and Fisheries
REPUBLIC OF SOUTH AFRICA

Production levels

Some 10 to 20 tons of leaf material per hectare per year can be expected.

Perennial, prune regularly to prevent spreading.
Height: 60 to 120 cm. Hardiness:

In a study of 8 medicinal plants from Zimbabwe *Artemisia afra* was among the strongest against various strains of *Plasmodium falciparum*

C Kraft et al ., Phytotherapy Research 17, 123-128, 2003

Clarkson et al (J Pharmacogenom Pharmacoproteonics 2011) studied 134

species of plants native to South Africa for antiplasmodial activities. A

afra was among the **19** highly active plants (IC**50**> 5^/mL) against malaria.

ivi i nucuncgu iiieoio univcioiiy oi Kwdzuiu-Nâiai, *2013*

The discovery and characterization of antiprotozoal compounds from South African médicinal plants

					T, b. rimdeiieiKe		r		***difimani***		***P.falcipanmi***	
					CrüKUi Inhibilimi		CrüKlh Inhlbiiiujt w		CrüKUi Inhibilirm (fl)		CrüHUi InhibLlimt W	
Kjinily		Vwia nimber	rijnt JIJII	Kü^tl 11. pL-	I.T fflW	' l.fi Mî/ml	I.T MI!/ml	IJG	*7	' l.fi	I.7	IJS liftai
Amanactae	***brtuk/pelahis Rtntk***	P02259c	Tivi^i/Ltiivrs		**10**	0.S	**0.0**	J.I	15. S	3.1	**0.0**	UJQ
Amanactae	***ArtdSSryt*** rnïrilfj'tïKif <îf(V.	PI£314b	Lcuvcs	DCMAtaQH(LL)		0.0	***91***	***79***	I5.0	5.!	40.5	**0j0**
Amanactae	***ArtabSTfi*** HUtàftaMf ÜHV.	PJS3J4c	Ltuvcs	AfHDI	fl.O	AU	15.0	5.1	***m***	[0.3	0.0	**0j0**
Aster»™	AHrinfa/u *afra Jatq.* ***dl*** *Willii.*	***Mm****	Ltuvcs	DCM		0.0	0.0	0.0	JOfl.O	25.I	Jtt.5	SJO
Astersctae	*AHetaisia afra Jatq. dl Willii.*	P004K4b	Lcivcs	DCMAtaQH(l'L)	***%.l***	Q.I	0.0	0.0	JOfl.O	43.5	77.1	3J0
Astersctæ	*AHelnisiu afra* ***Juiij.*** el WW	FWWE	Lcivcs	McOH	***%2***	3J	0.0	0.0	SI.2	0.5	I5.3	**0j0**
Aüpjrajycwf	*Atparaÿa riryuiiLt* Ad*a*	***mi\ùb***	Whgle pLrni		10.5	***91***	**0.0**	109	34 J»	14.1	54.5	***il***
Aanthactae	*Asytitulu xuhxclit'u T.AndcHun*	Püiüiib	Lcivcs	DCM/VcOH|I:l)	<1.0	0.0	J.T	0.0	IS.5	0.0	***m***	51.4

Artemisia afra and other
Asteraceae top ranking amonst 60
different plants

La médecine traditionnelle au centre et à

l'ouest de

l'Angola. Ministério da ciênciae

da tecnologia. Instituto de investigaçâo

cientifica tropical. Lisboa - p. 531 (1996)

(ISBN : 972672-858-4)

o ss ard Aute

paludisme (convalescence), infusion de feuilles de Artemisia afra, VO. helminthiase, infusion de feuilles de Artemisia afra + poudre dans la nourriture, VO.

Globale Epidemien - Lokale Antworten: Eine Ethnographie der Heilpflanze Artemisia... in Tanzanien

Caroline Meier zu Biesen

Book, Frankfurt, New York Campus **November 2013.**

A local plant against malaria: ***Artemisia afra***

The local ***Artemisia afra*** is one of the most used medicinal herbs in Africa, since ages. In Tanzania it is the sole representative of the Artemisia family. The different parts of the plant, including the root, are used as beverage in the form of decoction, infusion, but also as inhalation (smoke or vapors), or to wash ailing parts of the body. The essential oil is known for its bactericidal and antioxidant properties and is used as pain killer against arthritis or rheuma. It is widely used against flue symptoms. But the major use is against malaria.

Es stimmt, dass wir schon sehr viel *Artemisia afra* zur Behandlung verschiedenster Krankheiten in erster Linie Malaria, verwendet haben.
Da die Pflanze ja hier heimisch ist und es schon viele Untersuchungen gab, war es nicht schwierig in den Usambara Bergen Ableger zu bekommen. Seitdem haben wir nur mit Ablegern in vielen Gegenden **Nordtanzanias** *Artemisia afra* anbauen koennen.
Sie ist sehr wiederstandsfaehig und ergibt sehr viel mehr Ernte denn Artemisia annua.

Viele haben die Pflanze inzwischen in ihrem Garten und nehmen sie als frischen Tee entsprechend unseren Angaben. Aber darüber gibt es natürlich keine Aufzeichnungen.

So wird ihnen meine Aussage, dass ***Artemisia afra*** **sehr viel wirksamer ist denn *Artemisia annua,*** nicht viel helfen konnen.

Many people find that Artemisia afra is more efficient against malaria than Artemisia annua

Mechthild Keller Tanzania 2012

SJNET: Ethiop. J. Sci., 21(l);81-89, 1998
 ISSN: 0379-2897

IN VITRO TEST OF FIVE ETffIOPIAN MEDICINAL PLANTS FOR ANTIMALARIAL ACTIVITY AGAINST *PLASMODIUM FALCIPARUM*

Moges Kassa[1], Robert Mshana[2], Azeb Regassa[1] and Getachew Assefâ[1]

1.56

Extract concentration [/ig(ml)'^{1}]

Eflect of crude ex tracts of some Kthiopian médicinal plants ***in vitro*** on ***P. fol*,**
***iparum* FAC-2**/Ethiopia.
J Nil Med (2007) 61361-268

Fiant	E*tract	Parasitemia w	Çbemo-aippressjcn w	Meati suivlval tinte (days)
Aïlétiàliù qfrei P	MeQH	R.45 ± 0.27	77.45 ± 3.4k»	19.21 ± 3.57
	HO	11.15 ± 3JU1	70.25 ± 5.59	I7ȷS5 ± 2.H1
Bascia saikifm in	MeQH	*5 M ± i m*	K6.50 ± 4.37	L9-08 ± 4.22
	HvO	21.0K ± 4.52	43.75 ±6.90	15.71 ±5.4]
Culhiircinlhii.', fO&uî	MeOH	24.51 ± 4.32	34.60 ± 1.77	10. ELI ±2.50
	HȷO	21.6(1 ±2.51	42.36 ± 4.S7	12.39 ± 2.95
Chil ta robuxSa	MtOlt	2B.BI ± 1.441	23.10 ± 6.43	14)45 ±3.25
	HvO	21.6(1 ±2.39	42.35 ±2.15	I2.R2 + 4.70
Cyalhula sdiktiperkuià	MeOH	20.5 K± 1.69	45.06 ± 6.93	15*3® *4.1®
	HȷO	30.33 ±2.45	I9.4kt ± 5.33	7.65 ± I.R9
Rhii.% itûlûlensis	MtOlt	16.441 ± I.B2	56.24 ± 4.H5	13.43 ± 5.24
	HvO	6.31 ± 0.97	S3.I5 ± 3.61	16.52 ± LS7
Ximenia ameruana	MeOH	23.H0 ± 7.30	36.49 ± 0.2S	7.R5 ± 1.59
	HȷO	29.441 ± 3.H9	21.55 ±6.27	6.72 ± 1.52
CQ diphosphale		0.3S±0.43®	99.02 ± 1.26®	21.25 ±5.2R
rcs		37.47 ± 6.62®	0.00	7.14 ±2.14

Table 3 Efietl (if extraits (14)41 rtt^/ ke. dav) of selected medifituid plants au *P. bernai* infected mire

PBS phosphate btiffered saline (oejative ctorUrol). chloroquitie diphosphate (standard dnig) admlnisleued at 5 rng/kg day: ***n = 5***

In a study on several herbal medicines A afra showed the best antimalarial properties Thesis Simiyu Khamala Kenya 2004

Médicinal plants traditionally used for treatment of **malaria** in Kenya

CN Muthaura et al., Exp Parasit 201, 127 609-625

Of particular interest was ***Artemisia afra*** which grows in upland bushes and forest edges in Kenya... It was interesting to note that the water extract skowed twofold activity for the resistant strain W2 (4.65 mg/L) compared to the sensistive strain D6 (11,23 mg/L).

The authors conclude that the activity of ***A afra*** was due to the complex mixture of substances, which act additively or synergistically.

The active substances of *Artemisia afra* are luteolin, davanone, scopoletin,caffeoylquinic acids. not artemisinin

Artemisia afra is the plant with the highest luteolin content known: 1.9mg/g

(A Dube, Thesis, 2006, Uni Western Cape)

Buckwheat contains 1.1 mg/g and all other vegetables and plants including Artemisia annua not more than 0,2 mg/g

Among flavonoids luteolin has the strongest antiplasmodial activity (A Lehane et al., BMC Res Notes 2008, 1:26)



Concentration of luteolin in monkey plasma after oral administration of luteolin in pure and plant form R MUGANGA, Etudes Rwandaises N0 14, 2007.

r



Figure 5 DPPH radical scavenging profiles of the active comportants.

Evid Based Complément Alternat Med. 2016; 2016: 3401269.

Published online 2016 Feb 4. doi: 10.1155/2016/3401269



Normal H_20_2 10 20 40 10 20 40 20

Orientin Luteolin VC

(^g/mL)

Both orientin and luteolin protect against oxidative stress

Luteolin has stronger inhibition of the inflammatory uric acid generated by plasmodium, than other flavonoids or even the drug allopurinol.

JM Pauff et al, J Nat Prod « 009 72, 725-31)


2.5
2.0
1.5
1.0
0.5
0
0
1
5
10
*
*
Luteolin: umol/L

Hongwei Si, Richard P. Wyeth, and Dongmin Liu. The flavonoid luteolin induces nitric oxide production and arterial relaxation, Eur J Nutr. 2014 Feb; 53(1): 269-275.



	Alfalfa hay	A. ah<iinth, lus	Sumac bernes	A, uulgaris lus	A. annua Ivs	A. afra Ivs	Oregano lus	Sumac lus
■ TAC (HydrotLipo)	171,1	*27* 0,4	320,2	431,4	1124.6	2095	2838,3	5338.7
■ % Lipû of TAC	2,93	32,29	5 >68	8.02	3.08	2,05	0.64	1,90
% Hydro of TAC	97,02	67,71	94,32	91,98	96,92	97,95	99,36	93,10

Total Antioxidant Capacity (TAC) Jorge F Ferreira USDA



There are more chlorogenic & caffeoylquinic acids in stems than in leaves

The PhD thesis from South Africa (Meryl A Abrahams, 1996, UCT) is based on an assay which measures the inhibition of radiolabelled hypoxanthine uptake by parasites. They found

that **hydroxydavanone,** a molecule present in Artemisia afra at concentration 0.1-1.0 ng had an inhibitory effect stronger than artemisinine, and much stronger than chloroquine or mefloquine. At these low concentrations the latter 3 antimalarials even show an increase in hypoxanthine uptake. It is likely that with some antimalarials the hormetic range is very narrow

Artemisia afra is rich in pentacyclic triterpenes: alpha-amyrine, betulinic acid with strong immune-modulating, antimalarial activity

Yusra Kriel Thesis , University of Western cape May 2010

Artemisia afra

Efficient in other diseases

Tuberculosis (Edinb). 2009 Dec; 89(Suppl 1): S33-S40.

Efficacy of *Artemisia afra* phytotherapy in experimental tuberculosis

Siyabulela Ntutela,[a]

A Lubbe, Fr Van der Kooy et al.,

Journal of Ethnopharmacology, 2012

This is the first scientific report of *Artemisia afra* possessing significant *in vitro* anti-HIV activity and adds credence to similar *in vivo* reports in this field.

Table 1
'[rypifiocidaJ and cycouMLt aruvilnes of arcHuiainin antl crade e*:rjc:s früm four *AKWI.HÜ* sperim

PLani Eprciés/cojiLpûUiid	Plaïr po.'[	Erixut type	T h, iruwi 1
AHC;V:IÏI-J tjfasüiirhiii/re [Aitemue)	Aerial pan	MeUH	Ï7.90
		CHitLi	Ï7.D5
Afentila üDtsi.-niLü	Aerial pan	MeUH	JI.Ï6
		CHitLi	]il3
yi/rr.-mïid a/ra	Leavea	MeUH	77.54
		CHitLi	25.2?
yi/rr.-mïid unniJL-	Leavea	MeUH	93,44
		CH^CLi	<11.05
ArtanlsiniD			ü.gi
□inriïnjzene uetunto (ECjndjrd drug)			OJOU

Plea&e cite this article as: Nibnet, E_r Wink, M., Volatile comp orients af four EtfiiopLan ^rreniisw sp* FhytomedjdJie £2009), doi: 10.101 G/j. phyrmed.2 009.07.01 G

Artemisia afra is stronger than Artemisia annua against Trypanosoma brucei

Ryno Freidberg

PhD Thesis 2009

Nelson Mandela Metropolitan

University

Antimicrobial and anticancer activities of *Artemisia afra* and *Artemisia absinthium*

Planta Med 2014; 80 - P1L29 DOI: 10.1055/S-0034-1394687

In vitro anti-HIV and -TB activities of Annona muricata and Artemisia afra extracts

De Venter M et al., Lagos, Nigeria

Conclusion: Based on the results these plants could be an important source of compounds for treatment of M.tuberculosis and HIV.

Artemisia afra acetone and methanol fractions have good inhibitory activities (20 ^g/ml) against E. coli and good-moderate activity ranging 160-320 ^g/ml for the crude extract and all fractions against the organisms tested against Aspergillus fumigatus and Staphylococcus aureus

Muleya E, Ahmed AS, (2014)

Evaluation of Anti-Microbial, Anti-Inflammatory and Anti-Oxidative Properties Artemisia afra, Gunnera perpensa and Eucomis autumnalis. J Nutr Food Sci 4:

312. doi: 10.4172/2155-9600.1000312

Acute doses of *Artemisia afra* are relatively non-toxic in mice and rats irrespective of the route of administration.

At high doses it may have a hepatoprotective effect.

Breakthrough results from our own clinical trials

2014 in Katanga

Study on the therapeutic effects of encapsulated *Artemisia annua* and *Artemisia afra*

Constant Kansango Tchandema MD, Lubumbashi, RDCongo, Pierre Lutgen PhD, IFBV- BELHERB, Luxembourg

GJRA - GLOBAL JOURNAL FOR RESEARCH ANALYSIS 5, Issue-6, June - 2016

In 2014, 82 volunteers suffering from malaria were treated during 7 days with capsules containing powdered leaves of *Artemisia annua* from Luxembourg (AAL) or from Burundi (AAB) and *Artemisia afra (AAF).* Total dose for AAL was 15 gr, for AAB 7.5 gr and for AAF 7.5 gr. Despite these low doses all patients were free of fever after 2 days and 85% were free of parasites after 7 days for AAL, 76% for AAB and 40% for AAF.

This second trial confirms the results obtained in 2013. 54 malaria patients were treated during 10 days with A annua capsules

Most remarkable is the total absence of side effects in these trials

Artemisia afra increases CD4

The immune boosting properties of Artemisia afra were confirmed by Dr Constant Kansango Tchandema in 2014

64 patients carriers of *Plasmodium falciparum* trophozoites were treated during 7 days with capsules containing Artemisia afra powdered leaves.

An average increase of 20% of CD4 was noticed.

In the vast majority of patients trophozoites had completely disappeared on day 11.

No side effects of the treatment were noticed

Similar CD4 increases have been noticed in Uganda (Dr P Ogwang) and in India (Dr F Roelofsen)

Clinical trials Maniema Province, RDCongo By Dr Jerome Munyangi, Dr Michel Idumbo

1000 patients, double blind. randomized A annua and A afra versus ACT

50000 _ 45000 f 40000 | 35000 25000

J 20000

| 15000 % 10000 ª 5000

0

| 30000 E



Artemisia afra strong gametocytocidal

A very recent paper of a South African research team shows that among 8 medicinal plants Artemisia afra has the lowest IC50 for impairing the development of late stage gametocytes (P Moyo et al., J of Ethnopharmacology, accepted 15 March). A very important finding as not many plants have such a significant gametocytocidal effect.

We found the same effect in the trials in Maniama-RDCongo confirmed by PCR

Portage gamétocytaîre





Artemisia afra strongly inhibits beta-hematin formation

Mutaz Akkawi, Al Quds, Jerusalem, Palestine, personal communication

Artemisia defeats Schistosomiasis

[Bilharzia defeated by Artemisia afra]

Preliminary results obtained in Senegal

60 people of all ages, including pregnant women, were treated in an endemic area on the riverbanks of a river. Powdered leaves and twigs of Artemisia afra were administered during seven days as aqueous infusion or as powder mixed with food. After one month complete disappearance of worms was found for over 65% of the patients and probably more, because our partner is not equipped for distinguishing dead worms from living ones.

Clinical trial Artemisia versus Praziquantel in Maniem a (RDCongo)

Abstract.

In a large scale double blind, randomized clinical trial run in Maniema Artemisia vs Praziquantel, on a total of 600 patients the herbal infusion came out with a much higher efficiency against schistosomiasis and no side effects.

Based on the presence of eggs in feces on day 28 the cure rate was 97.7% for Artemisia and 71.4 % for Praziquantel

CANCER and ARTEMISIA

A working relationship has been established between Dr Prof Thomas Efferth, University of Mainz, and the medical team in RDCongo to start clinical trials against breast cancer and prostate cancer



Ulcère de Buruli

In Ghana , Noguchi Institute, 75 herbal preparations were tested against *Mycobacterium ulcerans.* Several showed very promising results

Our associations IFBV-BELHERB from Luxembourg and M4L from Paris have run clinical trials with African partners to study the in vivo effect of Artemisia annua and Artemisia afra on tuberculosis and Buruli ulcer. Screening trials in 2015 had been promising and recent trials have resulted in an obvious therapeutic effect of these plants against Mycobacteria, not only tuberculosis but also Buruli ulcer.

21 patients who followed the treatment: 14 days of **Artemisia afra** infusion and 28 days application of a cream containing A afra extract were completely cured without remaining infirmity

or sequelae. These trials were run in the province of Maniema, RDC Congo.

The stability of the results of the 2016 clinical trials on **Buruli ulcer** in Maniema RDC have been verified and confirmed one year later.

21 patients which were treated by Artemisia afra infusions and creme containing an Artemisia afra aqueous extract were completely cured , without

further chirurgical intervention and no residual restrictions in their muscular movements

Union Africaine Thesis started in 2017 Ndeye Fatou Kane Kenyatta University - UCAD Dakar

In vitro and in vivo effects from Artemisia afra plants from diffrent regions in Africa and evaluation of their active molecules



Nombre publications scientifiques Artemisia afra

ANNEXE 2: *Artemisia afra* and Modern Diseases

ReviewArtice

Gayathri V. Patil[1]1, Sujata K. Dass[2] and Ramesh Chandra[3]

[1]Department of Pharmaceutics, Kasegaon Education Society's Rajarambapu College of Pharmacy, Kasegaon - 415404, India

[2]Department of Medicine, V. P. Chest Institute, University of Delhi, Delhi - 110007, India

[3]Dr. B. R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi - 110007, India

Abstract

Herb *Artemisia afra* **has recently attracted worldwide attention of researchers for its possible use in the modern diseases like diabetes, cardiovascular diseases, cancer, respiratory diseases etc. This review is exhaustive and systematic organization of the available literature on** *Artemisia afra (A. afra)* **from January 1922 to July 2011. The literature survey presents the number of publications with respect to time. Patents are briefly described; the traditional uses are classified and summarized. Some emphasis is given to the data and projections of modern diseases and the ongoing research in this area in the context of title of this review. The pharmacognostic aspects, chemical constituents and factors affecting it, the activity, analysis & quality control, pharmaceutical dosage form etc. is dealt in this review.**

Keywords: *Artemisia afra;* Patents; Traditional uses; Chemical constituents; Activity; Toxicity; Dosage form

Introduction

Man has been able to appreciate through his superior observing and learning capabilities to use and exploit the natural resources, the flora and fauna for his survival and comfort, to alleviate pain and to cure diseases; to constantly improve upon his health and build longevity. WHO [1] reports that *80%* population of Asian and African countries depend on traditional medicine to treat various infectious and chronic disease conditions. The popularity of this system of medicine is due to people's faith in traditional age old methods, its accessibility and affordability [2-4].

South Africa is considered the "hotspot" for its unique and diverse botanical heritage [5,6]. Recent statistics show that about 25% of the total number of higher plants in the world are found in South Africa [7] although its land surface make up less than 1% of the earth [5]. According to the "African Plant Checklist and Database

Project" [8], a total of 50,136 angiosperm taxa occur in tropical and southern Africa. It is estimated [5,9] that about 3000 medicinal plants are used in South Africa by traditional healers with an estimated 27 million consumers

[10] . Of these, only 350 species are most commonly used and about 38 indigenous species have been commercialized to some extent (i.e. they are available as processed materials in modern packaging and in various dosage forms as teas, tinctures, tablets, capsules or ointments). Very few medicinal plants are studied for their potential therapeutic properties [11]. Several others are also produced for multi-million Rand informal markets [12-14]. Basic information about most widely used species can be found in van Wyk et al. [6,9] and Diederichs [15]. It is generally accepted [16] that natural resources will play a major role in the socioeconomic development of the African continent. It is found that herbal treatments are highly lucrative in the international market. The annual revenues in Western Europe reached US $5 billion in 2003-04, in China sales of products totaled

[11] US $14 billion in 2005 and herbal medicine revenue in Brazil was US $160 million in 2007

[1] and involves qualified traditional healers, as well as thousands of commercial gatherers who supply both the formal and informal entrepreneurial sectors of the South-African economy [17-22].

A. afra is one of the important and most widely used herbs in the traditional medicine. In recent years, it has gained significant attention from the scientific community. Studies have been conducted either to verify or substantiate the traditional use of this herb. Further, its use is also being investigated in the modern

diseases like diabetes, cardiovascular diseases, cancer, respiratory diseases etc. With the quantum of work going around and the various properties that are being studied, it was felt to undertake an exhaustive literature survey of this herb *A. afra* from South Africa, and scientifically compile the information in a comprehensive review.

Literature Search

The number of hits on the internet based science-specific search engine "Scirus" [23] up to mid July 2011 for the key words and the details thereof are given in Table 1. The significance of genus *Artemisia* is seen in its number of hits, which is 89,080.

The total number of hits appeared for *"Artemisia afra*" (*A. afra*) were 885 of which, 5 had no dates. Figure 1 is the graph of 162 publications that appeared in Journal Sources classified and plotted on yearly basis from Jan. 1922 to Nov. 2011 for "A. *afra".*

Only two scientific publications based on laboratory work were found in the literature over a span of half a century, first by Goodson in Jan. 1922 [24] and then second by Bohlman and Zdero in 1972 [25]. Both the papers report the constituent's of *A. afra.* Goodson investigated if *A. afra* contained anything that could be regarded as a precursor or a derivative of santonin in consequence of the difficulty of obtaining santonin that was then used as the sole source of anthelmintic. He showed that *A. afra* contains camphor, a wax-ester probably ceryl cerotate, triacontane, scopoletin and quebrachitol and none which

Details	*Artemisia*	*A. afra*	*A. afra* and					
			Activity	Toxicity	Cancer	Diabetes	Cardiovascular	Respiratory
Total Hits	89,080	885	748	160	164	97	16	6
Period of	Dec. 1884 to Sept.	Jan. 1922 to	Mar. 1961 to	Jan. 1980 to Jun.	Jan. 1990 to Nov.	Jan. 2002 to Nov.	Jan. 2005 to Apr. 2011	Jan. 2005 to Apr. 2011
Journal	12,318	163	128	67	49	31	3	-
Preferred	7,172	454	451	19	17	18	5	1
Other web	3,806	268	169	74	98	48	8	5

Table 1: Total hits for Artemisia, publication period and the number of publications.



Figure 1: Number of hits for *Artemisia afra* on Scirus, Science specific search engine on year basis.

could be connected to santonin. While, Bohlman and Zdero [25] investigated to compare other constituents in *A. afra* with those of the old world *Artemisia* species and reported that the roots contained besides isomeric coumarins (mainly (VI)) the known acytylenes (I to V) while the aerial parts contained thujone and umbelliferone- derivatives and no acetylenes (Figure 2). However, Jakupovic et al team [26] of researchers reported additionally 10 new guaianolides and 5 glucolides and also 12-hydroxy-a-cyperone elucidated by high field NMR techniques and some chemical transformations. It can be said that upto 1988, scientific curiosity was generally confined in determining the constituents of *A. afra* essential oil and assigning chemical structure to it.

From Figure 1, it can be said that up to year 2000, *A. afra* did not attract the researchers but only later, especially from 2005 onwards with an average of 18 publications per year. The University of Western Cape and Rhodes University, South Africa is doing lot of research on this plant. The scientific studies made on the plant extracts/ essential oil from 1993 onwards were in the direction of finding out the activity namely antifungal [27], antibacterial [28], antioxidant [29], toxicity [30], anti-cancer [31], antituberculotic [32], antimalarial [33] antitrypanosomal [34], protective myocardial [35], protective intestinal epithelial Caco-2 cells [36], anti-ulcerative [37] effect on Central Nervous System [38] etc. Pharmaceutical efforts were also made to prepare tea bags from the leaves of *A. afra* [39] to liposomal encapsulation of the essential oil [40] for clinical trials. The traditional claims were also scientifically investigated especially for gynecological complaints [4] and in respiratory disorders [41]. The veterinary anti-oxidant use in attenuating coccidoss in broiler chicken was also explored by Naidoo [42].

The quantitative estimations of plant extracts by using modern equipments like GCMS and GC; HPLC and UV absorption and Mass Spectroscopy was taken up by Oyedeji et al. [43] and Avula et al. [44] respectively in 2009. In 1997, the first European patent was granted to Whittle and Skett [45] that relates to administration of compounds for use in the treatment of diabetes and in 2008, two patents viz. Omer [46] and Bobotas et al. [47] were granted. Details are given under the headings "Omer patent to counteract weight loss & treat other diseases in cancer patients" and "Bobotas et al patent for diabetes and cardio-vascular diseases" of this review. Jager et al's [48] patent came in 2009. The literature search [23] for *A. afra* along with the additional key words of pharmacological importance and the number of hits are compiled in Table 1.



Figure 2: Constituents of A. afra. Reprinted from Phytochemistry, 11(7), F. Bohlmann, C. Zdero, Constituents of Artemisia afra, 2329-2330, 1972 with permission from Elsevier [25].

A pubmed data base [49] search till 13th July 2010 with the search key word "Artemisia" contained 1851 hits ofwhich 91 were reviews, and for *"A. afra"* only 24 articles of which 1 was a review entitled "A broad review of commercially important southern African medicinal plants" by van Wyk in Oct. 2008 issue of Journal of Ethanopharmacology [7]. With this background of *A. afra* gaining importance and an objective to compile a comprehensive review with the available scientific information in one paper, this review is being written.

Patents

There are four utility patents given for *A. afra* from Oct. 1997 till July 2011. Two patents each were granted in US and in Europe. Two patents mainly are in diabetes, one in cancer and; one in diabetes and cardiovascular disease. The gist of all the four patents is given below in reverse chronological order. It is expected to give readers some clues for further research and application.

Jager et al patent to prevent/ treat diabetes and associated secondary diseases

The Jager et al. [48] patent relates to a physiologically active composition in pure or mixture form containing *Artemisia* extract of at least one of *A. dracunculus, A. herba-alba, A. judaica, A. vulgaris, A. abysinica, A. absynthicum, A. afra, A. cannariensis, A. pallens, A. annua, A. abrotanum, A. ludoviciana, A. capillaris* or *A. scoparia* to prevent or treat (pre)diabetes and associated accompanying diseases or secondary diseases. The patent claims that at least one of following could happen:

(a) the blood sugar level in a mammal would be lowered, (b) the insulin resistance would be lowered, (c) hepatic glucose release would be lowered, (d) the postprandial glucose level would be lowered, (e) the activity of GLP-1 ("glucagon-like-peptide 1") would be raised, (f) the binding capacity between GLP-1 and the associated receptor would be raised, (g) the conversion of glucose to glycogen would be raised, (h) the expression of the IRS-2 ("insulin receptor substrate 2") polypeptide would be raised, and (i) the insulin-controlled glucose uptake would be raised. The composition can be given as a food supplement, a drink, a food, a dietetic food, a functional food or a sport food wherein the effective daily amount of the composition would be between 0.1 and 500 mg/kg/daily with respect to bodyweight.

Omer patent to counteract weight loss & treat other diseases in cancer patients

The patent assigned solely to Omer [46] based on clinical trial claims to counteract the weight loss and nutritional deficiency of cancer patients, and to treat Hodgkin and Non-Hodgkin lymphomas, autoimmune diseases, IgA-Nephropathy (glomerulonephritis) and human cancers with a herbal preparation containing *Artemisia.* The object of the patent is to (a) circumvent resistance to conventional chemotherapy of these diseases, (b) increase the effectiveness of chemotherapy when added to standard chemotherapy treatment,

(c) provide treatment to those cancer patients and IgA Nephropathy where no effective treatment is available so far, (d) improve nutrition of patients suffering from progressing cancer, as all cancer patients start losing weight at some stage of their disease, (e) provide a composition aforesaid that acts without exerting toxic side effects and (f) provide a disease-specific synergistic composition in convenient dosage form. The preparation could be of any species from *Artemisia* viz., *A. absinthium, A. annua, A. vulgaris* and *A. capillaris* or any bitter or aromatic herb or shrub of the genus *Artemisia* of the family *Asteraceae,* distributed throughout many parts of the world; which shall also contain 10-80% by weight of ginger root *(Zingiber officinale* rhizomes) and 10-80% by weight of large cardamom *(Amomum subulatum*). The amount of herbs in the dose could be sufficient to suppress the progress of the disease. The preparation could be prepared either by grinding (filling the powder in hard gelatin capsules or pressing them in tablets), solvent extraction or distillation (tincture), which may also contain an inert pharmaceutical carrier. This preparation could be used in combination with conventional standard therapy to modulate the immune system of the human body.

The dose for various forms could be: (a) Dried Herbal Powder: 3-6 tablets per day as 750 mg pressed tablets, (b) Liquid Extract: 2 ml three times a day (equivalent to 6 gm of herb), (c) Distilled Preparations: 2 ml three times a day (equivalent to 6 gm of herb) and

(d) Tincture (powdered herbal extracts): 6-9 capsules per day as 450 mg capsules of mixtures.

Bobotas et al patent for diabetes and cardio-vascular diseases

The patent assigned to Bobotas et al. [47] relates to methods of using different compositions comprising a (i) cannabinoid 1 (CB1) antagonist, (ii) a dyslipidemic agent, and/or (iii) a metabolic regulator

useful in treating hypertriglyceridemia, hypercholesteremia, mixed dyslipidemia, vascular disease, artherosclerotic disease, and/or obesity; preventing and/or reducing cardiovascular and/or vascular events; reducing insulin resistance, fasting glucose levels, and/or postprandial glucose levels; and preventing and/or reducing the incidence of and/or delaying the onset of metabolic syndrome. The preferred dyslipidemic agents could be omega-3 fatty acids, peroxisome proliferator-activated receptor (PPAR) agonists/antagonists, microsomal triglyceride transfer protein (MTP) inhibitors, and/or dipeptidyl peptidase-4 (DPP4) inhibitors; and the preferred metabolic regulators could be sarsasapogenin, smilagenin, steroidal glycosides and extracts thereof, and extracts of *Artemisia* spp.; either alone or in combinations with CB1. The dosage form could be a tablet, hard/soft gelatin capsule, powder that could be dispersed in a beverage, liquid or infusion for oral use, and injectables. The dosage can vary from 1-10 units depending on the combination and requirement.

Whittle and skett pharmaceutical patent in diabetes and hyperglycemi

Table 2: Traditional use of A. afra in combination with other plant species for the treatment of respiratory complaints.

Plant in combinations	Uses	Administration
A. afra and *E. globulus*	Respiratory complaints	Crushed leaves or steam from infusions are inhaled or decoctions are taken
A. afra and *A. betulina*	Respiratory complaints	Herbal wine
A. afra and *Zanthoxylum capense*	The Europeans and Africans use it in febrile conditions, and it is used as a treatment for colds	A decoction and an infusion of the leaf is used
A. afra and *O. asteriscoides*	Respiratory complaints	Tincture
A. afra, E. globulus and *Leonotis microphylla*	Fever, chest infections and digestive disturbances	Infusion
A. afra, Z. capense and *Allium sativum*	Respiratory complaints	Decoction
A. afra and *Lippia javanica*	Fevers, respiratory complaints, measles and as a prophylactic against lung inflammations	Infusion, taken with milk
A. afra, O. asteriscoides and *E. globulus*	Respiratory complaints	Infusion, tincture
A. afra and *Tetradenia riparia* and salt	Coughs	Decoctions
A. afra and *Alepidea amatymbica*	Colds and flu	Leaves and root/rhizome
A. afra and *Warburgia salutaris*	Acute bronchitis, coughs from colds or flu, fever	Leaves and bark
A. afra, A. amatymbica and *Leonotic leonurns.*	Asthma	Leaves and root
A. afra, W. salutaris and *Acorns calamus*	Chronic bronchitis and emphysema	Leaves, bark and rhizome

The Whittle and Skett patent [45] relates to administration of pharmaceutical compounds and compositions for use in the treatment of diabetes or other hyperglycaemic defects of carbohydrate metabolism which includes extracts from plant *Artemisia* spp, (A. *herba-alba, A. pallens* or *A. afra, A. judaica),* so prepared that it contains effective ingredients viz., insulinomimetic and substance having glucagon antagonist properties with acceptable excipient which can be given orally or by parentral route. The patent also relates how the manufacture method of successive fractionation of the plant extract improves

its utility by reducing its toxicity and yielding insulin-like and glucagons antagonist activities thereby increasing therapeutic efficacy. To achieve this, the alcoholic extract obtained by (i) extracting the plant with water, (ii) concentrating the extract

to dryness, and (iii) treating the dry residue with alcohol with successive chromatographic separation with different mobile phases (i.e., gradient of eluents) and lastly (iv) the eluate containing at least one portion of the effective ingredient is selected from the different portions related to different mobile phases.

Traditional Uses

A. afra belonging to genus Artemisia is exceptionally and widely used in many parts of the world either alone or in combination with other plants as herbal remedies for a varietyof ailments like simple headache to neurological disorder like epilepsy. There are more than 1 lakh traditional healers practicing in South Africa [13]. In this section, the various conditions in which *A. afra* is being traditionally used, as cited in the literature is given.

Respiratory tract related problems

It is primarily used in common cold, cough, sore throat, influenza, asthma as it is said to clear the respiratory and bronchial passages [5053]. The leaves are heated and the vapors inhaled to alleviate symptoms of colds and flu [52,54]. It is also used to clear the blocked nasal passage by inserting fresh leaves in the nostrils or by using as snuff; to relieve pain in the throat in scarlet fever, either the hot infusion is used as gargle or the throat is exposed to vapors [52,55]. The leaves are commonly smoked by some tribes to help release phlegm, to ease and soothe a sore throat, coughing at night [56]. For cold and chest problems in infants, fresh leaves are placed in flannel bag and hung around baby's neck [57]. The use of *A. afra* in combination with other medicinal plants has been widely documented in the ethnobotanical literature is given [58] in Table 2.

Gastro intestinal disorders

It is used in the digestive complaints like indigestion, colic, constipation, flatulence, gastritis, dry dyspepsia and to get rid of intestinal worms [51,59-61]. It is consumed to overcome general debility and as an appetizer [62-64]. The leaves are prepared as an infusion or decoction and taken orally.

Topical use for skin afflictions

Watt and Breyer-Brandwijk [52] report that the (i) extract is applied

topically to ease the pain and hasten bursting of boils, carbuncles, large acne pimples; (ii) hot bath in the decoction is used to bring out the rash in measles, mumps, chicken pox; (iii) infusion or decoction is used to bathe hemorrhoids, herpes, venereal sores; (iv) poultice (of the leaf) is applied as a dressing to relieve neuralgia, to the swelling of mumps and other glandular or skin inflammations and (v) lotion is used to wash the body to rejuvenate the skin.

Gynecological problems

It is used for dysmenorrhea [9], amenorrhea and menstrual cramps [4]. The genitalia are steamed with vapors for menstrual chills and also after childbirth, while decoctions of leaves have been administered for extended labor [65].

Fever

The decoction of garlic leaves and bulbs is mixed with *A. afra* and *Xanthoxylum capensis* and used as febrifuge [52], a decoction of the plant is drunk as a remedy for fever [66]. An infusion of *A. afra* is widely used in Malaria [66] along with *Lippia javanica* [52]. Bally [67] reports that a poultice is applied on inflamed throat and for fever in children.

Miscellaneous uses

An infusion of a double handful of leaves with a quart of hot water is administered either as enema or emetic for febrile complaints [52]. It is also used in the inflammatory disease like rheumatism [29], gout [51]; neurological disorder like epilepsy [68], in haematuria and to alleviate stabbing pain [69] and as anti-fertility agent [70]. According to Watt and Beyer-Brandwijk [52], *A. afra* has been used to keep urine free from sugar in the case of diabetes mellitus, reports Deutschlander et al. [71], while it is used in tinea captitis reports Abebe and Ayehu [69].

Scope of *A. afra* in Modern Diseases

In the present mechanized life of less physical activity and more mental work, it is pertinent to discuss the afflictions of modern mankind that would also be carried over to new generations, in the context of ongoing global research on the herb *A. afra*.

WHO [72] states that aging of populations in low- and middle- income countries will result in significant increase in the total deaths mostly from non-communicable diseases (NCDs) over the next 25 years, which would be mainly from cardiovascular diseases (CVD), cancers, diabetes and chronic respiratory diseases, causing an estimated 35 million deaths each year. It reports that in year 2004, ~58.8 million deaths occurred globally, of which ~27.7 million were of females and —31.1 millions of males. More than half of all deaths involved people 60 years and older, of whom 22 million were people aged 70 years and older and 10.7 million were people aged 80 years and older; that almost one in five deaths in the world was of a child under the age of five year. Figure 3 shows the distribution of deaths at all ages for 12 major causes, illustrating the relative importance of the respective causes of death and of male-female différences, in year 2004. WHO projections of Global Burden of Disease (GBD) by cause for 2008, 2015 and 2030 are given in Table 3, based on 2004 GBD estimates as a starting-point [72].

Diabetes

Diabetes is a life threatening condition. The number of people getting affected by diabetes is increasing due to population growth, aging, urbanization, increasing prevalence of obesity and mechanized life style. The studies undertaken by Roglic et al. [73] reveals that diabetes is the fifth leading cause of death, killing —2.9 million people in the year 2000, which is equivalent to 5.2% of all deaths. The prevalence of diabetes and the number of people of all ages with diabetes in the year 2000 and projections for 2030 was estimated by Wild et al. [74]. The paper reports that the prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. The prevalence of diabetes is higher in men than in women, but there are more women with diabetes than men

Table 3: Projected deaths by cause, globally [72].

Year	2008		2015		2030	
Population (in billion)	6700628		7186888		8110599	
Disease	(In	% Total	(In	%	(In	%
Total Deaths	58766	100.0	60856	100.0	67790	100
I. Communicable diseases, maternal and perinatal	15980	27.2	13705	22.5	9370	13.8
Infectious and parasitic diseases (like Tuberculosis, STDs, HIV/AIDS, diarrhea, Meningitis	8427	14.3	7044	11.6	4216	6.2
Respiratory infections	3816	6.5	3427	5.6	2871	4.2
Maternal conditions	424	0.7	316	0.5	180	0.3
Perinatal conditions (e)	2913	5.0	2606	4.3	1898	2.8
Nutritional deficiencies	401	0.7	313	0.5	205	0.3
II. Noncommunicable conditions	37124	63.2	41193	67.7	51619	76.1
Malignant neoplasms (like cancer of mouth & orophyrynx, oesophagus, stomach,	8097	13.8	9259	15.2	11928	17.6
Other neoplasms	178	0.3	201	0.3	253	0.4
Diabetes mellitus	1294	2.2	1656	2.7	2229	3.3
Nutritional/endocrine disorders	310	0.5	331	0.5	395	0.6
Neuropsychiatric disorders (like schizophrenia, epilepsy, alcohol use disorders	1320	2.2	1429	2.3	1757	2.6
Sense organ disorders	5	0.0	5	0.0	6	0.0
Cardiovascular diseases	17890	30.4	19388	31.9	23578	34.8
Respiratory diseases	4426	7.5	5220	8.6	7373	10.9
Digestive diseases	2010	3.4	2015	3.3	2164	3.2
Diseases of the genitourinary system	980	1.7	1089	1.8	1376	2.0
Skin diseases	71	0.1	80	0.1	103	0.2
Musculoskeletal diseases	131	0.2	142	0.2	175	0.3
Congenital abnormalities	408	0.7	373	0.6	294	0.4
Oral diseases	3	0.0	4	0.0	5	0.0
III. Injuries	5663	9.6	5957	9.8	6801	10.0
Unintentional injuries	3977	6.8	4181	6.9	4786	7.1
Intentional injuries	1685	2.9	1777	2.9	2015	3.0

The urban population in developing countries is projected to double between 2000 and 2030. The most important demographic change to diabetes prevalence across the world appears to be the increase in the proportions of people >65 years of age. The three nations which top the list in prevalence of diabetes are India, China and U.S. with estimated 31.7, 20.8 and 17.7 million people affected by diabetes in the year 2000; is projected to reach 79.4, 42.3 and 30.3 million people in the year 2030, respectively.

Cardio-vascular diseases

As the average human life expectancy has increased, so has the impact of ageing and age-related diseases like CVDs. CVDs are a group of disorders [75] of the heart and blood vessels and include (a) coronary heart disease - disease of the blood vessels supplying the heart muscle,

(b) cerebrovascular disease - disease of the blood vessels supplying the brain, (c) peripheral arterial disease - disease of blood vessels supplying the arms and legs, (d) rheumatic heart disease - damage to the heart muscle and heart valves from rheumatic fever, caused by streptococcal bacteria, (e) congenital heart disease - malformations of heart structure existing at birth and (f) deep vein thrombosis and pulmonary embolism - blood clots in the leg veins, which can dislodge and move to the heart and lungs.

One of the major causes of CVDs [76] is essential hypertension, known as the silent killer, which does not cause symptoms for many years until a vital organ is damaged [77]. Essential hypertension is multi-factorial in origin [78], cannot be cured but can be controlled [7980] effectively by use of medicine [81]. The other non-pharmacological approach [82] could be through (a) weight control [83-85], (b) sodium restriction [86-90], (c) fat content [90], (d) alcohol restriction [9192], (e) physical exercise [93-94], (f) relaxation therapies for stress reduction [95-97] and (g) potassium therapy [98-99].

CVDs are the number one cause of death globally [100]. An estimated 17.1 million people died from CVDs (29% of all global deaths) in 2004. Of these deaths, ~7.2 million and ~5.7 million deaths were due to coronary heart disease and stroke, respectively. 82% of CVD deaths take place in low- and middle-income countries and occur almost equally in men and women. It is projected that by 2030, almost 23.6 million people will die from CVDs, mainly from heart disease and stroke, with largest increase in number of deaths would be in the South-East Asia Region, WHO [101]. There are currently about 800 million people with high BP worldwide. The current prevalence in many developing countries, particularly in urban societies, is already as high as those seen in developed countries [102-103]. Studies indicate that (i) by lowering of each 10 mmHg of systolic BP, there is 1/3rd decrease in risk of stroke

in people of age between 60-79 years; (ii) by lowering diastolic blood pressure (DBP) by *2-7%* below 95 mmHg, million deaths per year from coronary heart disease and stroke can averted by 2020.

Cancer

Cancer [104] is a generic term for a large group of diseases that can affect any part of the body. Other terms used are malignant tumours and neoplasms. One defining feature of cancer is the rapid creation of abnormal cells that grow beyond their usual boundaries, and which can then invade adjoining parts of the body and spread to other organs. It arises from one single cell. The transformation from a normal cell into a tumour cell is a multistage process, typically a progression from a pre-cancerous lesion to malignant tumours. These changes are the result of the interaction between a person's genetic factors and three categories of external agents, including (i) physical carcinogens, such as ultraviolet and ionizing radiation, (ii) chemical carcinogens, such as asbestos, components of tobacco smoke, aflatoxin (a food contaminant) and arsenic (a drinking water contaminant) and (iii) biological carcinogens, such as infections from certain viruses, bacteria or parasites. The relative importance of the most common cancers [72] in terms of number of deaths at all ages is summarized in Table 4.

Globally lung cancer (including trachea and bronchus cancers) are the most common cause of death from cancer among men, and stomach cancer mortality is second. Colon and rectum cancers are the 4^{th} leading cause & oesophagus cancer the 5^{th} leading cause globally. Prostate cancer is the 6^{th} globally. For woman, 15 cancers are ranked, of which the most common is the breast cancer, followed by cancers of trachea, bronchus, lung and stomach cancer. Other cancers of female reproductive system are Cervix uteri (5^{th}), ovary (8^{th}) and Corpus uteri (13^{th}) the leading cause of death in woman.

In 2005, 7.6 million people died of cancer [105]. WHO [106] projects that with steadily increasing proportion of elderly people in the world will result in approximately 50% increase in new cancer

S.	Type of Cancer	Ranking	Ranking in
1.	Trachea, brochus,	1	2
2.	Stomach cancer	2	3
3.	Liver cancer	3	6
4.	Colon and rectum	4	4
5.	Oesophagus cancer	5	7
6.	Prostrate cancer	6	-
7.	Mouth and	7	12
8.	Lymphomas &	8	9
9.	Leukaemia	9	11
10.	Bladder cancer	10	14
11.	Pancreas cancer	11	10
12.	Melanoma & other	12	15
13.	Breast cancer	-	1
14.	Cervix uteri cancer	-	5
15.	Ovary cancer	-	8
16.	Corpus uteri cancer	-	13

Table 4: Ranking of most common cancer among men and women according to number of deaths, by cancer site, WHO worldwide data, 2004 [72].

cases over next 20 years. From the studies based on 5-year prevalence between 1998-2002, WHO projects that the number of people affecting from cancer would rise from ~10.9 million in 2002 to ~16 million in 2020, almost nearly a 50% increase; 2/3rd of them would be from newly industrialized and developing countries. It is estimated that almost 7 million people would die each year of cancer and 10.3 million by 2020 unless proper measures are not taken. Dr. John R. Seffrin, President, UICC states, "Cancer is potentially the most preventable and most curable of the major life-threatening disease facing human kind. We can save 2 million lives by 2020 and 6.5 million by 2040."

Chronic respiratory disease

As per WHO [107] "chronic respiratory diseases" are chronic diseases of the airways and other structures of the lung. Some of the most common are asthma, chronic obstructive pulmonary disease (COPD), respiratory allergies, occupational lung diseases and pulmonary hypertension.

Asthma [108] is a chronic disease characterized by recurrent attacks of breathlessness and wheezing, which vary in severity and frequency from person to person. Symptoms may occur several times in a day or week in affected individuals, and for some people become worse during physical activity or at night. Asthma is the most common chronic disease amongst children. According to WHO estimates, 300 million people suffer from asthma and 0.25 million people died of asthma in 2005. COPD [109] is a lung ailment that is characterized by a persistent blockage of airflow from the lungs. It is an under-diagnosed, life-threatening lung disease that interferes with normal breathing and is not fully reversible. An estimated 210

million people have COPD worldwide. More than 3 million people died of COPD in 2005, which is equal to 5% of all deaths globally that year. The primary cause of COPD is tobacco smoke (through tobacco use or second-hand smoke). Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke. Allergic rhinitis or hay fever [110] happens when one breathes in something to which he/she is allergic, and the inside of the nose becomes inflamed and swollen. Sinusitis [110] is an inflammation of the lining inside the sinuses which can be acute or chronic. When the sinuses become blocked and fill with fluid, germs can grow and cause symptoms such as headache and nasal yellowish secretions. Blocked sinuses can be caused by the common cold, hay fever or nasal polyps (small lumps inside the nose). Allergic rhinitis and sinusitis are linked to each other. Acute sinusitis usually subsides without any need for specific treatment. Chronic sinusitis may require antibiotics, decongestants or steroid nasal sprays. Pulmonary hypertension [111] is a condition in which there is high blood pressure in the lung arteries as the arteries become narrow affecting the blood flow. Over time, some of the arteries may stiffen and become completely blocked, causing the right side of heart to work harder to pump blood through the lungs. Over time, the heart muscle weakens and loses its ability to pump enough blood for the body's needs. The extra stress causes the heart to enlarge and become less flexible. Heart failure is one of the most common causes of death in people who have pulmonary hypertension. In some cases, pulmonary hypertension is caused by *schistosomiasis,* a worm infection common in Africa and Latin America; and sickle cell disease, a genetic abnormality of blood which is common in persons of African origin. Difficulty in breathing or shortness of breath is the main symptom of pulmonary hypertension. Other symptoms are fatigue, dizziness, swelling in the ankles or legs (edema), bluish lips and

skin (cyanosis), chest pain, racing pulse and palpitations. There are no mortality details on the allergic rhinitis or hay fever and pulmonary hypertension on WHO website.

Pharmacognostic Aspects Common name

Artemisia afra is known by many names like "African wormwood" in English "Umhlonyane" in Xhosa, "Mhlonyane" in Zulu, "Lanyana" in Sotho, "Lengana" in Tswana, "Wilde als" in Africaans, "Koddoo-adi"

& "Chugughee" in Ethiopia [29,34,112,113]. It is also known by other names viz., Als, Wild wormwood, Fivi, Lusanje, Luyanga, Iliongana [114].

The genus name *Artemisia* is derived in honor of the Greek goddess of hunting Artemis [115]. Another story [116] goes that the name is kept after Artemisia, the famous botanical and medical researcher and the wife of the Greek/Persian King Mausolus, who built a magnificent Mausoleum tomb known as seven Wonders of the Ancient World, after his death in 353 BC.

Taxonomy

Artemisia afra belongs to Domain: *Eukaryota,* Kingdom: *Plantae,* Subkingdom: *Viridaeplantae,* Phylum: *Tracheophyta,* Subphylum: *Euphyllphytina,* Infraphylum: *Radiatopses,* Class: *Magnoiopsida,* Subclass: *Asteridae,* Superorder: *Asteranae,* Order: *Asterales,* Family: *Asteraceae,* Subfamily: *Asteroideae,* Tribe: *Anthemideae,* Genus: *Artemisia,* Specific ephithet: *afra*- Jacq., Botanical name: *Artemisia afra* [117]. The *Asteraceae* is one of the most important family of plants in the world. More than 23000 species from about 1300 genera have been identified [118]. Many species have been used as sources of rubber, medicines, edible oils, vegetables, pesticides and so on. Some are popular ornamental plants. The genus *Artemisia* contains more than 400 species [119,120].

Phylogeny

The review paper by Hayat et al. [121] discusses the development in the classification and phylogeny of genus *Artemisia* L. They report that this plant group could have been originated in temperate Asia (mesothermic subarctic or semihumid environments prevailing near Ural Mountains); in the mid-tertiary period of Cenozoic era, and the centers of diversity of this

Figure 4: Distribution of *A. afra* in South Africa [Scott, G. and Springfield, E. P. (2004). Artemisia Afra Herba. In: Pharmaceutical Monographs on CDROM for 60 South African plant species used as traditional medicines. South African National Biodiversity Institute, Pretoria [125]. Reproduced with copyright permission from authors.

genus could be in the temperate and cold temperate regions of Eurasia, North America and Asia. The paper discusses the basis of disagreements amongst the Scientists with respect to

Figure 6: The flowering stem containing yellow florets and buds from Fabian & Germishuizen, 1997 [130].

taxonomic treatment of *Artemisia* in the last half decade for maintaining a single large genus of over 500 species to the recognition of six to eight genera within its taxonomic boundaries. The conclusion of (i) palynological, (ii) karyological, (iii) floral & capitular morphological and (iv) molecular phylogenetic studies for pollen evaluation, chromosomal counts & polyploidy, evolution of floral characters and molecular phylogeny respectively undertaken by various researchers are reported.

Geographical distribution

A. afra is a herb growing in the high land areas of Eastern and Southern Africa altitudes ranging between 1500 and 3000m where the soils range from volcanic ash, loamy sands, to sandy or calcareous clay loams of volcanic or granitic origin [114,122]. The plant grows in the South and Eastern regions of the continent and has been located in Ethiopia, Kenya, Tanzania, Zaire, Zambia, Zimbabwe, Angola and the Republic of South Africa [52,122]. In South Africa, it usually grows in rocky mountainous areas along forest margins and stream sides and its natural distribution extends from the Northern and Eastern Transvaal to the Western Cape, except the Northern Cape [123]. It is also predominantly found in Asia, Europe and North America [119,120]. The geographical distribution of *A. afra* in South Africa [124] with the copyright permission from Scott & Springfield [125] is given in Figure 4. It's one of the domesticated plant in these regions [126].

Plant description

Artemisia afra is a medium sized multi-stemmed, clump-forming woody perennial shrub, which grows up to 2 meters in height with a leafy, hairy ridged stem [6,112].

Its soft leaves are finely-divided (like a fern), are silver-grey due to the presence of fine hairs reaching in length up to 80 mm and

width up to 40 mm arranged alternately, oval in shape [11,53,127]. An image from BBC Magazines Ltd. [128] is given in Figure 5a. The adaxial surface of the leaf is darker compared to its abaxial surface [6]. Figure 5b is the picture of fully grown plant from the South African Biodiversity Institute's Plant Information [112]. The plant has an easily identifiable aromatic odour and smells pungent and sweet after bruising [129]. It produces pale yellow tubular florets, with few outer female and inner bisexual florets occurring in an elongated racemose panicle, an image from the book, Wild flowers of Northen South Africa [130] is given, Figure 6.

The capitula are small, receptacle flat and naked. The African wormwood produces small, inconspicuous wild fertilized flowers between March and July, and the seeds are produced from August to November. The fruits are about 1 mm long, somewhat 3-angled and slightly curved with a silvery-white coating [11,53,56,131].

Histology

The salient microscopic properties presented here are obtained from the Monograph of *"Artemisia afra* Herba" given by South African Medical Council Research, South Africa Health Information [124] and copyright permission [125], Figure 7 (i -ix). (i) Fibrous layer of anther, (ii) corolla showing papillate inner epidermis, (iii) tricolporate yellow- brown pollen grains, ± 20 |i in diameter, (iv) polygonal epidermal cells of upper leaf lamina, (v) small block-like cells of stamen filament, (vi) epidermal cells of lower leaf lamina with sinuous slightly thickened walls, (vii) fragment of corolla (tubular floret) with microcrystals of calcium oxalate, (viii) vessels of stamen filament and (ix) fragments of corolla with striated outer epidermis.

Cultivation and collection

The intensive harvesting of medicinal plants for use and commercial trade in South Africa poses a threat to many species. Hence, cultivation has been considered as an alternative to collection in the wild. Keirungi and Fabricius [118] assessed the feasibility of cultivating 17 selected medicinal plants based on its medicinal importance in Nqabara Administrative Area on South Africa's Wild Coast and reported that *A. afra* holds 8th rank in the list of important medicinal plant with a market value.



Figure 7: Salient identifying microscopic characters of *A. afra.* Scott, G. and Springfield, E. P. (2004). Artemisia Afra Herba. In: Pharmaceutical Monographs on CD-ROM for 60 South African plant species used as traditional medicines. South African National Biodiversity Institute, Pretoria [125]. Reproduced with copyright permission from authors.

Factors affecting cultivation of medicinal plants: The main factors which generally affect the cultivation of medicinal plants can be stated as (i) proximity to plant source, (ii) time spent in collecting the plant, (iii) number of ailments perceived to be healed i.e., frequency of usage, (iv) retention of activity, (v) acceptance to use plants which are cultivated, (vi) ease to cultivate - availability of seeds or grafts, soil quality, venerability to pests, modest water requirements, maintenance etc., (vii) impact on other plants, (viii) market value and economic potential and (ix) awareness amongst people that they have been causing adverse effect on large trees due to plucking shrubs around its vicinity and willingness to conserve indigenous forests.

Habitat: *A. afra* is very drought resistant and hardy [53], common to arid soils [131], open to sunny situation with light, well drained soil [131] , needing water occasionally [53]. The optimal temperature and annual rain fall as described in FAO *Artemisia afra* Data Sheet are 22- 33°C and 550-750 mm respectively [114].

Cultivation: The Plant Biology Guide to Growing Artemisia Wormwood [132] mentions that the seeds can be sown either in spring or autumn, in well drained soil at a pH of 5.5 to 7. The soil should be kept moist until germination takes places, which is normally 2-8 weeks.

The seedlings should be put out after the last frost and planted from 30 cm (small species) to 60 cm (larger species). Fertilizer should be applied in the early spring, and mulch applied in the late autumn. The leaves can be harvested any time. A very quick and easy way to propagate is from cuttings [53] in summer and by division in spring, prune in spring to stimulate growth. These would grow in any soil and needs just occasional watering and cutting back.

The South Africa Department of Agriculture, Directorate of Plant Production, Division of Industrial Crops [133] has compiled in collaboration with members of South African Essential Oils Producer

Association (SAEOPA) and KARWIL consultancy all the vital aspects involved in the production of *Artemisia afra.* It is made freely available on the official website of Directorate of Agriculture Information Services viz., http://www.nda.agric.za/publications. It is a 26 page document comprising 5 parts along with references for further reading. It details general aspects (like classification, origin & distribution, production levels, major production areas in South Africa, plant description, climatic & soil requirements); cultivation practices (like propagation, soil preparation & planting, fertilization & irrigation; pest, disease & weed control, mulching & harvesting); post-harvest handling (like sorting & distillation, grading; packaging, storage & marketing); production schedule and finally its utilization.

Choice of genotypes: Graven et al. [134] demonstrated that by selecting superior genotypes from the wild and cultivating it, provides major opportunities for the economic advancement of the new crop as the chemical composition in a plant is genetically determined and should not affect when cultivated. The thujone content in wild *A. afra* plants varies from 10% to 93% between individual plants. When the mother plant containing 91% thujone was selected and propagated by root cuttings, the results showed that the thujone content of the vegetatively propagated cuttings did not vary by more than 2% over 5 generations of vegetative propagation. The author suggests that the identification of mother plants having the desired chemical composition, coupled with vegetative propagation will retain the desired genetic characteristics, and facilitate the development of superior clones for cultivation. In this manner, clones can be developed which exceed the minimum standards for the active ingredients as required by the phyto-medicinal and essential oil industries.

Socio-economic impact: A study by team of Wiersum et al. [135] was carried out in the Amatola region of Eastern Cape, South Africa,

to assess whether cultivation of medicinal plants can serve as a tool for combined biodiversity conservation and poverty alleviation. The natives were found to use more than 100 plants, of which over 50 species were found to be cultivated in the home gardens. *A. afra* topped in the cultivation frequency list standing at 40%. The authors conclude that cultivation of medicinal plants play a significant role in the maintenance of cultural identity, increased human capital and dignity by alleviating poverty. However, one should not be too optimistic about the scope of medicinal plant cultivation by poor people as a practical strategy for *in domo* conservation of threatened species as (i) the preferred species for cultivation may not necessarily be the most threatened species and (ii) it was still not clear whether such cultivation substitutes the collection of wild species or supplements it.

Chemical Constituents

There are extensive data showing that the flavonoid synthesis is influenced by different abiotic (geographical variation, UV light radiation, drought, ozone), biotic (phytopathogens, insect detterents) factors [136]. Also, there are human factors like method of cultivation, processing parameters (collection, drying etc.) and extraction techniques that influence the plant constituents both qualitatively and quantitatively. These are discussed in this section.

Method of extraction on yield and chemical composition

Asfaw et al. [137] studied the four different methods of extraction viz., (i)

Table 5: A. afra components determined by GC-FID analysis.

k[a]	Compound	Relative peak areas (%)				
		$scCO_2$[b]	$l\text{-}CO_2$[c]	Sonic[d]	^-wave[e]	HD[f]
903	Santonlina triene	0.6	0.6	1.7	2.3	2.1
917	A-Pinene	-	-	-	0.4	0.8
956	Camphene	0.6	0.6	0.5	0.9	0.6
999	Yogomi alcohol	0.4	0.4	0.1	3.6	8.1
1027	Limonene	2.6	4.1	2.5	4.8	3.6
1033	1,8-Cineole	2.2	1.4	1.6	3.0	2.9
1061	Artemisia ketone	6.8	9.9	7.1	13.3	12.4
1080	Linalool	0.3	0.3	0.2	0.8	1.7
1116	p-Menthatriene	2.4	2.5	1.8	1.4	1.0
1172	Artemisia acetate	22.4	17.4	12.7	25.6	26.8
1174	Aretmisia alcohol	11.3	14.5	11.4	14.7	9.9
1255	Geraniol	4.5	5.5	2.9	6.2	6.2
1305	Bornyl acetate	3.6	2.2	2.5	4.1	8.2
	8 Sesquiterpenes	13	16	29	-	-

[a]Experimentally determined Kovats indices on the DB-5 column.

[b]$scCO_2$: Extraction carried out for 20 min, at 50 ^{O}C, 100 bar, liquid CO_2 (at -10 ^{O}C) was delivered to the extractor vessel at a constant flow rate of 5 mL min^{-1}. [c]$l\text{-}CO_2$: Extraction carried out for 20 min, at 30 ^{O}C, 100 bar, liquid CO_2 (at -10 ^{O}C) was delivered to the extractor vessel at a constant flow rate of 5 mL min^{-1}. [d]Ultrasonic irradiation for 30 min, in diethyl ether at ambient temperature and pressure. [e]Microwave irradiation for 10 min, at ambient pressure.

'Hydrodistilation for 180 min.

Green Chemistry, Z. N. Asfaw, P. Licence, A. A. Novitskii, M. Poliakoff, Green chemistry in Ethiopia: The cleaner extraction of essential oils from Artemisia afra: a comparison of clean technology with conventional methodology, 352-356,2005]. Reproduced by permission of The Royal Society of Chemistry [137].

hydrodistillation (HD), (ii) microwave assisted extraction (MAE), (iii) ultrasound assisted extraction (UAE), and (iv) liquid/ supercritical CO_2 extraction (l-CO_2 and sc-CO_2) to determine its extractive property both in terms of yield and chemical composition from *A. afra* plant. In general, the essential oil obtained from each method of extraction were similar in appearance - pale colored and fragranced. The details of the components with Kovats indices determined by Gas Chromatography - Flame Ionization Detector (GC-FID) from 900 to 1350 are given in Table 5. The yields were highest with I-CO_2 and sc-CO_2 (3.2% v/w), followed by traditional HD (1.5% v/w). The lowest yield was obtained with UAE (0.7% v/w). When a comparison of different fractions obtained was made for yogomi alcohol content in the extracts obtained from I-CO_2 and sc-CO_2, UAE, MAE and HD, it was found to be 0.4%, 0.4%, 0.1%, 3.6% and 8.1% respectively. Eight sesquiterpenes could only be detected in the sc-CO_2, I-CO_2 and UAE, with relative percentage peak areas of 13%, 16% and 29%, respectively. The différences could be ascribed to the solubility differences or instability of compounds during the different methods of extraction.

Method of analysis

To identify the major components in the oil, the only reported analytical equipment used was gas chromatography coupled with either a flame ionization detector or mass spectroscopy detector [137]. Liu et al. [129] classified and compiled 131 volatile secondary metabolites and 44 non-volatile secondary metabolites from *A. afra* oil in 4 and 10 categories from 16 and 8 published papers respectively to date and is summarized in the Table 6.

Geographical variation

The main components of the volatile secondary metabolites in *A. afra* varied enormously in plants from different geographical regions. The major constituent in Ethiopian oil [138] was artemisyl acetate (24.4-32.1%) while it was 1,8-cineole (67.4%) in Kenyan oil [139]. In Zimbabwean oil, a- and p-thujone (52%) was the major constituent [140] while a-thujone (54.2%) was in South African oil [141].

Viljoen et al. [142] analyzed the hydro-distilled essential oil by GC- MS obtained from aerial parts of 16 individual *A. afra* plants collected from four natural population [viz., 3 plants each from Setibeng (Lesotho), Giant's Castle (KwaZulu-Natal), Qwa-qwa (Free State) and

7 plants from Klipriversberg (Gauteng)] and found that quantitative and qualitative variation within and between natural populations with no correlation to the geographical distribution.

Oyedeji et al. [43] studied the a-thujone content isolated from

S.	Component Type	No. of
	A. Volatile Secondary	
1.	Monoterpenoids	83
2.	Sesquiterpenes	30
3.	Others	15
4.	Probably contained compounds	3
	Total	131
	B. Non-volatile Secondary	
5.	Sesquiterpenes	1
6.	Glaucolides	7
7.	Guaianolides	6
8.	Others	1
9.	Triterpenes	4
10.	Long chain alkanes	6
11.	Coumarins	5
12.	Organic acids	1
13.	Glycosides	1
14.	Flavonoids	11
	Total	43

Table 6: Volatile and non-volatile secondary metabolites in *A. afra.*

essential oil obtained by hydrodistillation of twigs of *A. afra* plants obtained from different locations in the Eastern Cape, Free State and KwaZulu-Natal by GC and GCMS. Their analysis revealed compositional variations in the levels of a- and p-thujone, 1,8-cineole and camphor. a-thujone was the major component of the essential oils of *A. afra* from Philippolis (Free State) and Keiskammahoek (Eastern Cape) (62-74%), while the camphor content was very low (<0.10.6%). The samples from Gqumahshe, Hogsback (Eastern Cape) and Empangeni (KwaZulu Natal) had low a-thujone contents (3.7-20.0%) while 1,8-cineole (13.0-49.5%) and camphor (13.9-21.2%) were the main components of the essential oils.

Avula et al. [44] estimated five flavonoids viz., (i) apigenin, (ii) chrysoeriol, (iii) tamarixetin, (iv) acacetin and (v) and genkwanin (Figure 8) by HPLC-UV and HPLC-MS technique to determine flavonoids in the aerial parts of the 11 samples of *Artemisia afra* Jacq. ex Willd plant obtained from widely separated populations in the provinces of Kwa-Zulu Natal and the Western Cape in South Africa. Figure 9 was plotted from the data published by them, which shows that the geographical variation does effect the total % content of flavonoids and the proportions of which varies in almost all samples accordingly for each ingredient, seen by uncrossed curves in the graph. Other details are given in under the heading “Analysis and Quality Control”.

Effect of cultivation

Chagonda et al. [143] reports the difference in volatile oils obtained from wild and organically cultivated plants of *A. afra* (Jacq.) (Compositae) from two pilot sites in Zimbabwe. The oil yield from the cultivated plant was between 0.33 and 0.60% (v/w), greenish- to brownish-yellow in color. Oils from the two cultivated sites had pleasant but different and distinct odours. The constituents of volatile secondary metabolites obtained by steam distillation were analyzed by GC-MS and are given in Table 7. Analysis of oils from fresh cultivated *A. afra* showed the presence of two chemotypes: one dominated by artemisia ketones (32.1-34.8%), a-copaene/camphor (21.8-24.4%) and 1,8-cineole (10.9-16.9%) and cultivated in Harare, and the other by 1,8 cineole (23.5-28.7%), a-copaene/camphor (20.2-21.3%) and borneol (14.2-17.0%) cultivated in Murehwa. The cineole chemotype had, as other notable minor components, bornyl acetate (1.6-3.3%), p-caryophylene (2.0-5.0%), sabinene (0.6-7.9%) and camphene (3.0-



Figure 8: Structure of flavonoids from [44].



Figure 9: % Content of flavonoids of Apigenin (□), Chrysoeriol (O), Tamarixetin (A) Acacetin ( ) and Genkwanin (0) by by HPLC-UV method and Apigenin (■), Chrysoeriol (•), Tamarixetin (▲) Acacetin (▼) and Genkwanin () by HPLC-MS method.

5.6%). The oil from the semi-dried plant material with the cineole chemotype had a similar pattern in its oil composition to that from the fresh plant and contained 1,8-cineole (22.5-29.3%), borneol (17.9-19.1%) and a-copaene/camphor (6.2-19.9%) as the major components.

No.	Component'	A = wild	B = cultivated UZ Farm				C = cultivated Murehwa			
		A (%) 1996 *n* = (3)	Bo (%) 9/1996 (1)	B_{fl} (%) 5/97 (3)	b. (%) 8/97 (1)	B_3 (%) 4/98 (2)	C (%) 5/97 (1)	C. (%) 3/98 (1)	C_3 (%) 4/98 (1)	S/dry herb C_4 (%) (2)
1	Tricylene	0.1-0.2	tr	0.1-0.2	0.1	0.0-0.1	0.1	0.3	---	tr-0.2
2 + 3	a-Pinene + a-thujone	0.4-1.1	0.3	0.5	0.8	0.5-1.1	0.7	1.3	1.75	0.9-1.1
4	a-Fenchene	0.2-1.0	1.4	0.6-1.1	0.7	0.4-0.9	---	0.6	---	tr
5	Camphene	0.3-3.9	8.0	3.9-4.0	0.6	3.0-3.8	3.0	5.2	5.6	3.4-4.5
6	p-Pinene	0.1-0.7	0.4	0.3-0.4	3.7	0.2-0.3	0.3	1.5	0.5	0.3-0.5
7	Sabinene	0.1-2.6	0.2	0.3-0.4	0.3	0.2-0.5	7.9	0.6	7.3	1.5-6.3
8	Myrcene	0.1-1.0	1.6	0.5	0.3		0.6	1.0	1.1	tr-0.6
9	a-Terpinene	0.1-1.1	0.3	0.3	---	0.2-1.8	0.5	0.3	1.1	0.6-1.3
10	Dehydro-1,8-cineole	0.1-0.2	0.1	0.1	0.7	tr-0.3	0.2	0.7	0.2	tr-0.2
11	Limonene	0.1-0.5	0.9	0.2	0.1	0.1	0.5			tr-0.4
12	1,8-Cineole	0.1-27.9	10.7	16.5-16-9	15.7	10.9-15.3	23.5	25.1	28.7	22.5-29.3
13	(E)-p-Ocimene	0.1-0.3	tr	0.2	---	tr-1.0	---	---	---	tr-0.4
14	y-Terpinolene	0.3-1.9	0.7	0.6	---	tr-0.2	1.3	0.2	2.6	1.3-2.4
15	p-Cymene	0.3-2.0	0.8	1.0-1.1	1.6	0.6-1.5	1.2	1.3	1.2	2.2-2.7
16	Terpinolene	0.1-0.5	0.3	0.2	---	tr-0.2	0.3	0.5	0.5	0.3-0.6
17	Artemisia ketone	6.3-41.9	0.1	32.1-32.5	34-8	32.1-33.1	0.1	0.3	0.1	tr-0.4
18	Santolina alcohol	3.1-10.1	---	2.5-4.5	8.0	2.7-4.3	0.1	0.1	0.1	tr-0.1
19	a-Thujone	1.0-2.9	0.7	0.5	0.5	0.2-4.9	0.1	0.1	0.1	tr
20	Artemisyl acetate	tr-0.1	---	---	0.5	1.0-0.9	0.1	---	0.2	tr-0.1
21	p-Thujone	tr	---	---	---	tr-0.2	---	tr	tr	tr-0.3
22	cis-Sabinene hydrate	0.2-0.5	0.4	0.1	---	tr-0.2	1.3	0.8	1.3	1.0
23	Artemisia alcohol	tr-0.3	---	0.1	---	tr-0.1	---	0.1	---	tr-0.2
24/25	a-Copaene/Camphor	8.5-27.1	50.3	23.0-23.1	21.8	24.3-24.4	20.6	21.3	20.2	6.2-19.9
26	frans-Sabinene hydrate	1.8-4.4	3.5	0.1-3.5	3.5	3.0-3.7	---	---	---	tr-0.1
27	cis-p-Menth-2-en-1-ol	0.2-0.4	0.8	0.1-0.2	---	0.1-0.5	1.0	0.9	1.5	1.0
28	Bornyl acetate	0.3-1.5	0.5	0.2-0.3	0.7	0.6-0.7	3.3	1.6	1.8	2.7-4.2
29	p-Caryophyllene	0.5-2.3	1.2	0.7	0.7	0.4-0.8	5.0	2.0	2.4	2.0-2.8
30	Terpinene-4-ol	tr-0.1	---	0.1	---	tr-0.1	0.5	0.3	0.7	tr-0.8
31	Myrtenal	---	---	0.1	---	---	0.6	0.4	0.3	tr
32	frans-p-Meth-2-en-1-ol	0.2-0.3	---	0.1	---	0.1-0.2	0.4	0.3	0.2	tr-0.3
33	Not identified	tr-0.1	---	0.1	---	0.2	0.1	0.2	0.1	tr-1.3

Bornyl acetate (2.7-4.2%), p-caryophyllene (2.0-2.8%) and camphene (3.4-3.5%) were notable minor constituents. Différences in oil composition were observed between fresh and semi-dried plant material and dry plant material (winter post-harvested collected dry plant B_o with the later yielding a-copaene/camphor (50.6%) as the major component.

Method of drying

The impact of drying methods on the quantity and quality of the essential oil of *A. afra* was studied by Asekun et al. [144]. The yields of oil from the plant differed according to the drying methods; viz: 0.18%, 0.88%, 1.54% and 1.88% for fresh, oven-dried, air-dried and sun-dried oils, respectively. They also found that the oil extracted from fresh plants contained artemisia ketone (6.9%) which was absent in the oil extracts obtained from air- and sun dried plants. Extracts from sun- dried plants had 14 components and the lowest number. Oyedeji et al [43], studied the a-thujone content isolated from essential oil obtained by hydrodistillation of fresh and dried twigs of *A. afra* plants by GC and GC-MS and found that the concentration of a-thujone increased significantly in the dry leaves when compared with the fresh leaves.

Variation between plants

It is already dealt under the heading “Geographical variation”, that

Substance	C (Mgm/ml)		Selectivity Index (SI)
	T. b. brucei	HL-60	
MeOH Extract	77.54	132.97	1.71
CH_2Cl_2 Extract	25.27	123.21	4.87
Diminazene aceturate drug	0.088	>128.88	>1464.00

Table 8: Trypanocidal and cytotoxic activities of artemisinin and crude extract from *A. afra.*

34	5-Terpineol	0.1-2.5	0.7	0.3	---	tr-0.5	1.0	0.9	0.9	tr-0.1
35	Borneol	0.6-3.4	2.8	0.8-0.9	0.8	1.4-	17.0	15.3	14.2	17.9-19.1
36	a-Terpineol	0.1-0.7	0.4	0.2-0.3	0.4	2.4	1.9	0.9	0.2	0.2-8.1
37	Bicyclogermacrene	0.2-0.5	---	0.3	---	0.5-0.8	0.2	---	0.2	–
38	Piperitol*	0.1-0.7	1.8	0.4	---	tr-0.6	0.1	0.1	---	tr-0.1
39	5-Cadinene	0.5-0.8	0.2	0.6	0.6	1.0-1.2	1.9	1.7	1.6	0.9-1.0
40	Cuminaldehyde	tr-0.5	0.2	0.1	---	0.1-0.7	0.2	tr	0.2	tr-0.3
41	Myrtenol	tr-0.1	0.3	0.1	---	0.1-0.1	0.2	0.2	0.2	tr-0.1
42	Calamenene*	0.1-0.9	0.1	0.1	---	0.1	0.4	0.1	0.2	tr-0.2
43	cis-Carveol	–	0.1	---	---	0.1	0.1	tr	0.1	tr
44	Not identified	–	0.1	tr	---	---	0.1	tr	0.1	tr-0.1
45	Not identified	---	0.3	tr	---	---	0.1	0.1	0.1	tr
46	trans-Caryophyllene oxide	tr-0.1	0.1	0.1	---	0.1	0.1	0.1	0.2	tr-0.1
47	Methyl linolenate	tr-0.1	---	---	---	---	0.1	---	0.1	tr-0.1
48	Germacrene-D-4-ol	---	0.1	---	---	---	0.1	---	---	tr
49	Methyl linolenate**	---	0.1	---	---	---	0.1	---	0.2	tr
50	p-Cymen-8-ol	---	0.1	tr	---	---	0.1	0.1	---	tr-0.1
51	Spathulenol	---	---	---	---	0.3-0.6	0.1	0.2	---	---
52	T-muurolol	tr-0.5	0.4	0.1	---	tr-0.6	0.2	---	0.1	0.4-0.6
53	Intermedeol	tr-0.4	0.1	---	0.3	0.1-0.2	0.2	0.1	0.1	tr
54	Not identified	—	---	---	---	—	0.4	---	---	tr-1.7

t Identified by GC-MS; * Isomer not identified; ** Tentative. *n* = no. of batches.

Flavor and Fragrance Journal, 14 (2), Chagonda L. S. Chalchat J Claude. The essential oil of cultivated Artemisia afra (Jacq.) from Zimbabwe. 140-142, 1999. Reproduced by permission of John

the constituent do vary between two plants.

Variation within plants

The oil obtained from different parts of the same plant showed variation in the constituents [142]. Goodson [24] found camphor, a wax ester, triacontane, scopoletin and quebrachitol in the flowering tops of *A. afra*. Bohlmann and Zdero [25] revealed that the roots of *A. afra* contained isomeric courmarins and five acetylenes, while the aerial parts contained thujone and umbelliferone-derivatives and no acetylenes. Similar variations were reported in the volatile secondary metabolite composition between the leaves [139] and the whole plant [138] of *A. afra*. The results showed that the oil obtained from the leaves mainly consisted 1,8-cineole (67.4%); while yogomi alcohol (21.6-26.8%) and artemisyl acetate (24.4-32.1%) predominated in the oil extracted from the whole plant.

Activity Reported in the Literature

The scientific research in determining the activity of *A. afra* for its medicinal properties and the publications thereof are given in this section.

Anti-fungal and anti-bacterial

Recent studies have demonstrated that steam distilled *A. afra* oil possess antimicrobial [140] properties. The author report that out of 25 bacterial species and three filamentous fungi

used to assess the anti-microbial properties, 15 test bacteria and one fungus showed high degree of inhibition of growth caused by volatile oil. The most susceptible organisms were *Acinetobacter calcoaceticu, Beneckea natrienges, Brevibacterium linens, Brochothrix thermosphacta, Citrobacter freundii, Klebsiella pneumonia* and *Serratia marcescens.*

Trypanocidal and cytotoxic

Nibert and Wink [34] studied *in vitro* effects on antitrypanosomal and cytotoxic activities using *T. b. brucei* and human leukaemia cell, HL-60 against standard drug diminazene aceturate. The IC_{50} (concentration at which 50% of the growth of cells is inhibited) and SI (Selectivity Index, which is the ratio of cytotoxicity of drug against HL-60 to its activity against *T. b. brucei)* for *A. afra* are given in Table 8.

The biological activity was attributed to the major compounds of the extract viz., epolylinalol (29.10%) and dihydrocostunolide (22.14%). However, davonone, bornyl acetate, 4-terpineol and chamazulene were reported to be the major essential oil compounds of the plants [29]. Besides this, the author's do not rule out the possibility of trypanocidal activity due to the presence of other non-volatile compounds. The authors propose that the weak selectivity indices of 4.87 and 1.71 for dichloromethane (DCM) and methanol (MeOH) extracts of the plant against HL-60 warrant its toxicity to human cells.

Anti-diabeteic

The studies reported in literature are either survey or animal studies. Erasto et al. [145] adopting the method of general conversation and questionnaires with the traditional healers and herbalists, obtained

ethno-medical information in the various locations in the Eastern Cape Province in South Africa consisting of many villages classified as rural and poor in the treatment of diabetes. Their studies revealed that 14 species belonging to six families were frequently used. Plants from the family *Asteraceae* were most commonly used in the treatment of diabetes constituting 50% of the plant. Infusion of leaves or roots of *A. afra* was mixed with sugar to mask the bitterness and consumed for a long period on daily basis.

Anti-cancer

The potential of using natural products as anti-cancer agents was recognized by the U.S. National Cancer Institute (NCI) in 1950s and since then been contributing to the discovery of naturally occurring anticancer agents [146]. With the discovery of vinca alkaloids, vinblastine and vincristine and isolation of the cytotoxic podophyllottoxins from plant sources in 1950s, more plants were screened for anti-cancer agents. As a result, the US NCI initiated an extensive plant collection program to potentially lead them to the discovery of novel chemotypes showing a range of cytotoxic activities [147] in 1960s. Over 60% of currently used anti-cancer agents are derived in one way or another from natural sources, including plants, marine organisms and micro-organisms [148,149]. However, Cragg & Newman [148] report that there is no plant derived clinical anti-cancer agents as yet reached the stage of general use, but a number of agents are in pre-clinical development. A collaborative research programme between US NCI and South Africa Council for Scientific & Industrial Research (CSIR) initially screened 7500 randomly selected plant extracts representing 700 taxa for anticancer activity against three human cell lines namely breast MCF7, renal TK10 and melanoma UACC62 and *A. afra* was one of the 32nd plant extracts to have exhibited potent anti-cancer activity [150]. Further, it was screened against 60 human cancer cell lines organized into sub-panels representing leukemia, melanoma and cancer of the lung, colon, kidney, ovary and central nervous system [31]. The anticancer activity for plant extract was labeled moderate when the Total Growth Inhibition (TGI - drug concentration that is indicative of the cytostatic effect of the test agent) was observed in the range of 6.25-15 |igm/mL for atleast two cell lines. The DCM-MeOH (1:1 ratio) *A. afra* leaf extract had 26.62 |igm/mL, 15.00 |igm/mL and 9.73 |igm/mL for Renal TK10, Breast MCF7 and Melanoma UACC62 cancer cell lines against standard Etoposide as a positive control (Renal TK10: 27.00 |igm/mL; breast MCF7: >100 |igm/mL and melanoma UACC62: 36.20 |igm/mL). *A. afra* leaf extract was further tested for selective cyto- toxicity over a defined range of concentrations to determine the relative degree of Growth Inhibition (GI_{50}) against each cell lines namely leukemia (L) lines [CCRF-CEM, HL-60(TB), K-562, MOLT-4, RPMI- 8226],

non-small cell lung cancer(NSCLC) lines [A549/ATCC, EKVX, HOP-62, NCI-H226, NCI-H23, NCI-H322M, NCI-H460, NCI-H522], colon cancer (CL) lines [COLO205, HCT-116, HCT-15, HT29, KM12, SW-620], central nervous system cancer (CNSC) lines [SF-268, SF-295, SF-539, SNB-19, U251], melanoma (M) lines [LOX IMVI, M14, SK-MEL-2, SK-MEL-28, SKMEL-5, UACC-257, UACC-62], ovarian cancer (OC) lines [IGROV1,OVCAR-3, OVCAR-5, OVCAR-8, SK- OV-3], renal cancer (RC) lines[786-0, A498, ACHN, CAKI-1, SN12C, TK-10, UO-31], prostate cancer (PC) lines [PC-3, DU-145] and breast cancer (BC) lines [MCF7,NCI/ADR-RES, MDA-MB-231/ATCC, HS 578T, MDA-MB-435, MDAN, BT-549]. The log GI_{50} value for *A. afra* extract was 1.02 M and the TGI (|igm/mL) for three most active cell lines were 13.49 (NSCLC NCI-H522); 13.49 (melanoma SK-MEL-5); 14.13 (colon HT29). Fouche et al. [31] research group conclude from their study that the leaf extract of *A. afra* plant to exhibit moderate anticancer activity. However, it can provide leads for the development of novel anti-cancer agents.

It is reported that the flavonoids present in the *A. afra* to have chemo-preventive activity against skin cancer (e.g. apigenin); inhibitory effects on chemically induced mammary gland, urinary bladder and colon carcinogenesis in laboratory animals (e.g. hesperetin); and anti-carcinogenic and platelets anti-aggregatory effects (e.g. quercetin) [151,152]. Furthermore, the flavonoid luteolin has been shown to exhibit anti-mutagenic and anti-tumorigenic activities [153].

Cardiovascular

The effect of *A. afra* Jacq. ex. Willd herb on isoproterenol (ISO)- induced myocardial injury in male albino rats of Wister strain was investigated by Sunmonu and Afolayan [35]. Pretreatment with the aqueous leaf extract of the plant at 100 and 200 mg/kg body weight for 30 days prevented the elevation of serum marker enzymes namely lactate dehydrogenase (LDH), aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) in myocardial injured rats. ISO-induced animals exhibited decreased levels of glutathione reductase (GR), glutathione peroxides (GPx), superoxide dismutase (SOD) and glutathione (GSH) in the heart, which were restored to near normal levels following treatment with the herb. The extract also attenuated lipid peroxidation (LPO) in the heart and restored the lipid profile to near normalcy, an improved the atherogenic index. The effect was more prominent at 200 mg/ kg body weight. Authors suggest that the aqueous extract of *A. afra* exerts cardio protective antihyperlipidemic and antioxidant activities by synthesizing endogenous antioxidants in ISO-induced myocardial injury.

Guantai & Addae-Mensah [154] investigated the cardiovascular effects of a mixture of long chain fatty esters ($C_{44}H_{88}O_2$) and scopoletin isolated from *A. afra* and an aqueous extract of the plant in rabbits. They found that the long chain fatty esters induced hypotensive effects at doses of 0.5, 1.0, 1.5 and 3 mg/kg. The diastolic pressure was affected more than the systolic. Aqueous *A. afra* extract (10-45 mg/kg) had a hypotensive effect *in vivo* and a dose-dependent biphasic effect on the heart *in vitro.* Lower doses induced an initial cardio-stimulation followed by cardio-depression, whereas higher doses were mainly cardio-depressant. Scopoletin, a coumarin derivative, at a dose of 1.02.5 mg, induced a dose-dependent decrease in inotropic activity plus an appreciable decrease in chronotropic effects, especially at higher dose levels. These results suggest that *A. afra* and its constituents are potentially useful for the management of hypertensive conditions.

Respiratory infections

The synergistic antimicrobial effects of *A. afra* essential oil when combined with other essential oils obtained from *Agathosma betulina, Eucalyptus globulus,* and *Osmitopsis asteriscoides* were investigated by Suliman et al. [58] against *M. catarrhalis* ATCC 23246, *K. pneumoniae* NCTC 9633, *E. faecalis* ATCC 29212, *C. neoformans* ATCC 90112 test organisms by estimating Fractional Inhibitory Concentration using MIC data [155]. The modified version of FIC Index ($FIC._{ndei}$) was adopted from Odds [156] that included an additive interpretation [157,158] were determined using following equations:

$$FlCne = FIC, + FIC_n$$

where FIC_I and FIC_{II} are calculated as follows

$$\_\_ MICiA+Bl = x$$

$$I \quad MIC(A)$$

$$F \_\_ MICiA+B) = r$$

$$I \quad MIC(B)$$

where "A" represented *A. afra* and "B" represented either *A. betulina, E. globules* or *O. asteriscoides*.

The data were further evaluated by plotting isobolograms that considered different ratios at which the two plant samples were combined [155] by taking $FIC_:$ and FIC_n values as X and Y- axes values respectively. The effect of combination of essential oils were considered synergistic (<0.5), additive (>0.5-1.0), non-interactive (>1.0-<4.0) or antagonistic (>4.0). The authors report that the individual oils exhibited moderate antimicrobial activity. The MIC values for *A. afra*, *A. betulina*, *E. globulus*, and *O. asteriscoides* ranged (2.6-9.3), (6.016.0), (1.3-8.0) and (0.6-8.0) mg/mL respectively against the selective pathogens used in the study.

The combination proportions of essential oils between *A. afra* and other oil was varied from 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8 and 1:9. They also report that their studies did not show any antagonistic interactions but predominantly found additive (>0.5-1.0) activity. However, combination of *A. afra* oil with *O. asteriscoides* in 8:2 ratio yielded synergistic interaction with FIC value of 0.5. The authors suggest that additive/synergistic effect of combination of essential oils needs to be substantiated to establish efficacy through clinical studies.

Viljoen et al. [142] studied the effects of geographical variation on *A. afra* essential oil content (details discussed under the heading "Geographical variation" of this review) and antimicrobial activity. The antimicrobial activity studies by time-kill methodology using the respiratory pathogens *C. neoformans* and *K. pneumoniae* showed prominent antimicrobial effect within 10 min at 0.75% concentration for *K. pneumoniae* and within 60 min at 1% concentration for *C. neoformans.* Investigations of the four major compounds most abundant in the *A. afra* oil (Artemisia ketone, 1,8-cineole, a- and p- thujone) indicated minimal antimicrobial activity when investigated independently and in various combinations against *K. pneumonia.*

To elucidate the rationale behind burning and then inhaling the liberated smoke for its antimicrobial activity, Braithwiate et al. [41] designed an apparatus to simulate the burning process that occurs in a traditional setting and captured the smoke fractions for analysis and bioassay. Parallelly, extracts of MeOH and acetone as well as the essential oil (for the aromatic species) were also prepared and assayed. The anti-microbial studies revealed that the 'smoke-extract' obtained after burning had lower minimum inhibitory concentration (MIC) values than the corresponding solvent extracts and essential oils. The combustion, acetone and MeOH extracts produced different chromatographic profiles, wherein several compounds noted in the smoke fraction were not present in the extracts, suggesting that the combustion process produced an 'extract' with superior antimicrobial activity and provided *in vitro* evidence for inhalation of medicinal

smoke as an efficient mode of administration in traditional healing. Anti-tuberculotic

To verify the traditional phytotherapeutic usefulness of *A. afra* extracts in tuberculosis, Ntutela et al. [159] investigated if *M. aurum* and *M. tuberculosis* replication could be controlled. The authors used aqueous-, MeOH- and DCM extracts of *A. afra* and found that the bacterial replication was inhibited in the *M. aurum* cultures by DCM extract only. Activity of the DCM extract was confirmed in dose- dependent studies against both *M. aurum* and *M. tuberculosis* with an IC_{50} = 270 |igm/ml and IC_{50} = 290 |igm/ml, respectively. Fractionation of the DCM extract and evaluation of its in vitro antimycobacterial activity was

found to be mostly associated with isolate fraction C8 that contained several sesquiterpene lactones, the most prominent of which were Artemin and Arsubin. Evaluation of the bactericidal efficacy *in vitro* showed that isolate fraction C8 reduced replication of *M. aurum* and *M. tuberculosis* in a dose-dependent manner with IC_{50} = 1.9 |igm/ ml and IC_{50} = 2.0 |igm/ml, respectively, and an MIC = 10 |igm/ml. Further, isolate fraction C8 and the DCM extract were administered to *M. tuberculosis-infected* mice at a tolerated dose of 1000 |igm/kg for up to 26 weeks and mycobacterial burdens compared to untreated-, INH/RIF treated- and aqueous-extract-treated animals to assess its *in vivo* bactericidal activity. Bacterial replication remained unaffected during treatment with either isolate fraction C8 or the DCM extract resulting in pulmonary and splenic bacilli burdens comparable to that of untreated mice. In contrast, INH/RIF (Isonicotinic Hydrazide / Rifampin) treatment cleared *M. tuberculosis* infection after only 8 weeks to undetectable levels. Interestingly, treatment of *M. tuberculosis- infected* mice with aqueous extract of *A. afra* regulated pulmonary inflammation during early infection notwithstanding its inability to inhibit mycobacterial growth. Their study clearly demonstrated that *A. afra* contains *in vitro* anti-mycobacterial activity, modulated pulmonary inflammation in early mycobacterial infection, and that the mouse experimental tuberculosis model could serve as a useful assay for evaluating the utility of phytotherapy. Studies carried out by Mativandelela et al. [32] also supported the traditional use of *A. afra* in TB-related symptoms. The MIC against *M. smegmatis* were in the range of 0.781 to 6.25 mg/mL.

Anti-malarial

A. afra has been used as an infusion to treat malaria in the southern parts of Africa. Clarkson et al. [160] studied 134 species of plants native to South Africa representing 54 families for *in vitro* anti-plasmodial activity against *P. falciparum* strain D10 using the parasite lactate dehydrogenase (pLDH) assay to identify the potential sources of new antimicrobial. Of the species assayed, 49% showed promising anti- plasmodial activity (IC_{50} < 10 |igm/mL) while 17% were found to be highly active (IC_{50} < 5 |igm/mL). The IC_{50} value for *A. afra* leaf extract in (i) DCM, (ii) DCM/MeOH (1:1), (iii) MeOH and (iv) Water were 5, 7.3, 8 and >100 indicating non-polar solvent DCM extract to have highest activity against the *P. falciparum,* substantiating the activity reported earlier by Kraft et al. [161]. Liu et al. [162] investigated the antiplasmodial activity of various extracts of *A. afra* and *A. annua* including an ethnopharmacological prepared sample by using multivariate data analysis. The extracts were tested for activity against *P. falciparum* 3D7 (chloroquine-sensitive strain) with chloroquine, quinine and artemisinin as positive controls. The apolar fractions of both *A. afra*

and *A. annua* showed activity against *P. falciparum* while activity were only found in the tea infusion of *A. annua.* The authors concluded that there aren't any *in vitro* activity in the tea infusion (polar extract) of *A. afra.* Similar conclusions were drawn by Kraft et al. [160] with lipophilic extracts (apolar) of the aerial parts of *A. afra* in the *in vitro* studies. The *A. afra* extract were found to be most active against the chloroquin-sensitive strain PoW and against the chloroquine-resistant clone Dd2 of *P. falciparum* when evaluated with *Cussonia spicata* (Araliaceae), *Vernonia colorata, V. natalensis* (Asteraceae), *Parinari curatellifolia* (Chrysobalanaceae), *Clutia hirsuta, Flueggea virosa,* (Euphorbiaceae), *Adenia gummifera* (Passifloraceae) and *Hymenodictyon floribundum,* (Rubiaceae). Bioassay-guided fractionation of the extract of *A. afra* yielded seven flavonoids, of which acacetin, genkwanin and 7-methoxyacacetin showed *in vitro* activity; the IC_{50} values ranged from 4.3-12.6 |igm/mL. In addition, several sesquiterpene lactones could be obtained from the most active fractions. Whereas eudesmaafraglaucolide proved to be inactive, the guaianolides 1-desoxy-1alpha-peroxy-rupicolin A-8-O-acetate, 1alpha, 4alpha-dihydroxybishopsolicepolide and rupicolin A-8-O- acetate revealed *in vitro* anti-plasmodial activity.

Anti-spasmolytic

Mulatu and Mekonnen [163] tested the ethanol and aqueous extracts of *A. afra* and leaf of *A. rehan* (from powdered dried leaf and root) on isolated mouse duodenum (MD) and guinea pig ileum (GPI). They tested different concentrations of each extract ofthe plants ranging from 20-200 |igm/ml in the presence of agonist control, acetylcholine (in MD) and histamine (in GPI) as contraction stimulators. They conclude that *A. afra* leaf ethanol (ALE) and *A. rehan* leaf ethanol (RLE) significantly reduced both spontaneous rhythmic and agonist-induced contractions of MD and GPI. ALE and RLE caused mean contractile response of 44.3 (±0.9% at a dose of 160 |igm/ml) and 35 (± 1.8% at a dose of 120 |igm/ml) respectively in isolated MD and a mean contractile response of 60.9 (±2.7%) and 43.5 (±2.7%) respectively at maximal doses of 200 |igm/ml in isolated GPI; thus justifying the traditional use of these plants in stomach pains and intestinal cramps.

Anti-histaminic and narcotic analgesic

A. afra has been reported to contain anti-histaminic and narcotic analgesic effects [53,124].

Anti-oxidant

The volatile oil from *A. afra* is shown to have exerted considerable anti-oxidative effect [140]. The antioxidant activity of the oil in preventing the discoloration of p-carotene and linoleic acid is given in the Monograph [124]. The free radical 'OH scavenging of the

essential oils from *A. afra* was studied by Burits et al. [29] using an assay for non-enzymatic lipid peroxidation in liposome. The IC_{50} value for *A. afra* essential oil were 0.09 |iL/mL against pure chamazulene, which were 0.0021 |iL/mL, could be ascribed to chamazulene content present in the oil.

In a novel veterinary application, Naidoo et al. [42] investigated the anti-oxidant property of *A. afra* extract in poultry. They attempted to control *Eimera* parasite infections associated with coccidal infection with lipid peroxidation of the intestinal mucosa for economic reasons and to avoid potential dangers of anti-microbials in producing animal protein. *A. afra* extract at 150 mg/kg resulted in feed conversion ratios similar to totrazuril (standard drug) and hence recommended its use as prophylactic and in the management of coccidiosis in poultry industry.

Preservative

Preservation of any product is an important integral part ofproduct development. Generally, a combination of preservatives is used for wide spectrum antimicrobial activity. Use of natural plant products is generally considered to be safe in comparison to synthetic preservatives. The preservative use of aromatic essential oils in part or full in cosmetic preparations not only prevents the product from microbial spoilage but also enhances dermato-cosmetic properties [164]. Muyima et al. [165] evaluated the preservative capabilities of the essential oils obtained from *A. afra* and others viz., *P. incana, L. officinalis* and *R. officinalis* in aqueous cream by Challenge Test against seven micro-organisms namely *E. coli* ATCC 35218; *S. aureus* ATCC 2592; *P. aeruginosa* ATCC 27853; *C. albicans* ATCC 10231; *A. niger* ATCC 16404; and two environmental isolates identified as *P. aeruginosa* and *R. pickettii* by Challenge Test. The concentration of essential oils in aqueous cream was 0.5, 1.0 and 1.5% v/w of individual oil as sole preservative and the control cream contained commercial preservative. Their studies show that the antimicrobial property of essential oils in the test creams in all the three concentrations were better than the control cream except *P. incana* which were almost similar to that of control cream. The Challenge Test in almost all test creams showed $\log_{10}$ reductions within 24 hrs, two to three $\log_{10}$ reductions in 2 days and four $\log_{10}$ within 2-7 days, suggesting their use as natural cosmetic preservatives.

Ashebir and Ashenafi [166] assessed the *in vitro* antibacterial activity of *A. afra* leaves traditionally used in the food borne diseases. The growth or inhibition of micro-organisms like *B. cereus, S. aureus,*

S.boydii, S. flexineri, S. typhimurium and *E. coli* were determined in culture media using 5% weight by volume crude extract of *A. afra* leaves in distilled water. Their results showed that

B. cereus and *S. aureus* had markedly lower final counts in the media containing crude preparation when compared to Control (without the crude extract). Retarding effect were noted on *S. Flexineri* and *S. Boydii* in the initial stages. The counts of *S. typhimurium* were as low as one log unit against the Control until eight hours while it had no effect on *E. coli.* Hence, the authors suggested of taking extract at four hours intervals to enhance the anti-microbial effect.

Insecticide

The volatile oil obtained from the ground parts of the crop showed antimicrobial activity against various bacteria and fungi of public health or agricultural significance [124].

A. afra is also known to have good insecticidal properties and can be used as a companion plant to reduce pest pressure on crops. It is planted as a border plant surrounding other medicinal or vegetable plants. It is used in formulations for animal shampoos and insect repellents [124].

Analysis and Quality Control

Avula et al. [44] developed a simple and specific High Performance Liquid Chromatography (HPLC) technique to determine flavonoids viz., (i) apigenin, (ii) chrysoeriol, (iii) tamarixetin, (iv) acacetin and (v) and genkwanin (Figure 8) in the aerial parts of the 11 samples of *Artemisia afra* Jacq. ex Willd plant obtained from widely separated populations in the provinces of Kwa-Zulu Natal and the Western Cape in South Africa. They also validated the technique for accuracy and precision before undertaking quantitative analysis. The limits of detection (LOD) by HPLC-MS were found to be 7.5, 7.5, 10, 2.0, and 2.0 ng/mL; and by HPLC-UV were 500, 500, 500, 300, and 300 ng/ mL for apigenin, chrysoeriol, tamarixetin, acacetin and genkwanin, respectively. The limits of quantification (LOQ) by HPLC-MS were found to be 25, 25, 25, 10 and 10 ng/mL; and by HPLC-UV were 1000, 1000, 1000, 500 and 500 ng/mL for apigenin, chrysoeriol, tamarixetin, acacetin and genkwanin, respectively. They reported HPLC-MS method 50-150 times more sensitive compared to HPLC-UV method. The flavonoid contents estimated by HPLC-UV and HPLC-MS are presented in Figure 9 from the calculated average values (11 samples of the plant) along with the standard deviations thereof for each component expressed in percentage. It was seen that irrespective of the method (which differs in sensitivity by many hundred folds), the average values and the standard deviation values were almost same and the compound Tamarixetin was absent in *A. afra* when determined by both methods. The same trend were seen when individual HPLC-UV analytical values were compared with HPLC-MS in each plant sample (Figure 9). Also, that the standard deviation values quoted by the authors for

each triplicate samples analyzed for all the 11 plant samples by either method were shown to be higher than the average values, the reasons of which are not being given or well understood.

Pharmaceutical Dosage Form

Research achievements has not yet reached to an extent that a successful dosage form of *A. afra* is produced at industrial scale and made available for mass consumptions. The plant is still being screened for its various potential pharmacological properties and some positive results have been achieved. Besides, the available literature does not report separation and isolation of various chemical constituents & screened individually for the activity. However, there could be every possibility to hope that some parallel ongoing synthetic work is in full progress that would be made public with filing of the patent for product and process.

Some work has been done at the University of the Western Cape, South Africa in an attempt to develop a pharmaceutically acceptable dosage form. Komperlla [167] attempted to formulate and evaluate tablets from *A. afra* plant. From the studies, the author concluded that the dried aqueous extract of *A. afra* leaves were problematically very hygroscopic. However, tablets of suitable pharmaceutical quality could be manufactured from the dried extract of *A. afra* leaves under controlled humidity conditions. Dube [39] aimed at preparing a standard tea bag dosage form from standardized *A. afra* leaves and from the freeze-dried aqueous extract to minimize dose variation and evaluated the dosage form criteria. He concluded from his studies that the (i) tea bag were a suitable dosage form for *A. afra* standardized dried leaves but not the freeze-dried aqueous extract powder due to stability problem and (ii) tea-bag preparations did not have similar infusion profiles to that of loose leaves, but could be still used if adjustment in the dose preparation and administration methods are made.

Toxicity

The herb, *A. afra* is not patented for its being used traditionally for number of ailments. This could be one of the reasons why this herb could not attract so much of attention from the industry and validated scientifically through clinical trials [168,169].

Safety of *A. afra* has been a controversial issue due to its high thujone content. In 1970s, WHO declared the plant being unsafe for consumption but however its use in folklore medication, is gaining significance in use of modern diseases. Oyedeji et al. [43] studied the a-thujone content isolated from essential oil obtained by hydrodistillation of fresh and dried twigs of *A. afra* plants obtained from different locations in the Eastern Cape, Free State and KwaZulu- Natal. Analysis of the oil by GC and GCMS revealed compositional variations in the levels of a- and p-thujone, 1,8-cineole and camphor in the extracts. They also found that

the concentration of a-thujone increased significantly in the dry leaves when compared with the fresh leaves. Based on these results, they suggested the use of fresh leaves for infusion.

Mukinda and Syce [170] investigated the safety of *A. afra* aqueous extract (mimicking the traditional decoction dosage form) by determining its pharmaco-toxicological effects after acute and chronic administration in mice and rats, respectively. In mice, single intraperitoneal injections of the extract (1.5-5.5 gm/kg) induced a regular dose-dependent increase in the death rate and incidence of general behaviour adverse effects, while with single oral doses (2-24 gm/kg) increase in the incidence of general behavioral adverse effects and mortality rate were dose-independent. The LD_{50} after acute intraperitoneal and oral doses were 2.45 and 8.96 gm/kg, respectively. Rats given oral doses of the extract (0.1 or 1 gm/kg/day) survived the 3 months of dosing (i.e. LD_{50} much higher than 1mgm/kg), experienced no significant changes in general behaviour and haematological and biochemical parameters, except for transient decrease in AST activity. No significant changes were observed in organ weights, and histopathological results showed normal profile suggesting no morphological alterations. They concluded that the *A. afra* extract is non-toxic when given acutely and has low chronic toxicity potential; in high doses it may have a hepatoprotective effect.

The Directorate Agricultural Information Services [133] instructs the users that *A. afra* should not be taken longer than a period of 7 to 10 days as it can cause headaches and shaking, owing to high content of thujone. Also, this oil must not be used internally, and should be used with caution during pregnancy and in epilepsy.

Clinical Studies

An effort was made by van Wyk [171] team of researchers from the University of Western Cape in South Africa in 2003-04. A protocol entitled "A Pilot study on Mild to Moderate Asthmatic subjects to test the bronchodilatory effect of the herbal plant *Artemisia afra* was prepared to undertake clinical study to evaluate the efficacy and safety of *A. afra*" herbal preparation for asthma. The protocol was designed after incorporating various aspects given in the Guidelines of different Countries including WHO by thoroughly going through the Guidelines available on the web between Feb. to Aug. 2003. They submitted the Protocol to the Medical Control Council and Ethics Committees which was rejected on account of lack of safety data, toxicological studies and pharmacokinetics of the drug. The researchers however feel that permission to undertake clinical study should be considered on the basis of historical use of herb to circumvent the issue of lack of safety data.

In this context, it is pertinent to mention the recent efforts made at global level in the direction of conduct of Clinical Trials so as to prevent the patients from self-medication with

unregulated products raising number of safety concerns that exists for lack of specific Guidelines to conduct Clinical Trials in herbal/traditional medicines. As per the Innovations Report [172], world's first clinical study on

African traditional medicine will be undertaken by The International Center for Indigenous Phytotherapy Studies (TICIPS) in collaboration with the University of Missouri-Columbia and the University of the Western Cape, South Africa. The center will be funded by a $4.4 million, 4-year grant from the National Center for Complementary and Alternative Medicines (NCCAM), a division of the National Institutes of Health. On the 7th International Clinical Trials Day 2011, a Multi-disciplinary University Traditional Health Initiative (MUTHI) which is new international consortium with the aim of increasing the capacity of African clinical and public health researchers to conduct trials of traditional medicines was launched by Prof. Quinton Johnson, Director of the South African Herbal Science and Medicine Institute at the University of the Western Cape outlining its plans to facilitate the assessment of the medicinal properties of plants [173]. With an intension of "one-world medicine" for the sake of all patients in industrialized and developing countries, Efferth [174] discussed strategies for (i) preservation of traditional knowledge on natural medicines, (ii) sustainability of medicinal herbs and natural products, and (iii) standardization and quality control.

Conclusion

From the available literature, it can be stated that *A. afra* is a potential herb showing activity for many ailments. The capabilities Mother Nature has imbibed in this plant has been only attempted and explored in past few years, needs to be accelerated in all the areas so that successful products are available for mass consumption to alleviate diseases afflicting mankind. This review is a humble effort to compile the existing literature in one paper, covering maximum aspects of *A. afra* with a hope to benefit the researchers.

Acknowledgements

Gayathri V. Patil acknowledges Prof. J. K. Lalla for the constant motivation, moral support and guidance. Authors express their thanks to Dr. S. C. Jindal, Librarian, Central Science Library, University of Delhi, Delhi 110007 for the co- operation.

References

1. Traditional medicine, Fact sheet N^{O}134 Revised (2008) WHO.
2. **Hutchings A (1989) Observations in plant usage in Xhosa and Zulu medicine. Bothalia 19: 225-235.**
3. **Brandt HD, Muller GJ (1995) Traditional medicines and acute poisoning. CME 13: 1053-1060.**

4. Steenkamp V (2003) Traditional herbal remedies used by South African women for gynaecological complaints. J Ethnopharmacol 86: 97-108**.**
5. Coetzee C, Jefthas E, Reinten E (1999) Indigenous Plant Genetic Resources of South Africa. In Janick J (eds) Perspectives on new crops and new uses, ASHS Press, Alexandria, VA, 160-163.
6. **van Wyk BE, van Oudtshoorn B, Gericke N (1997) Medicinal Plants of South Africa. 1st Ed. Briza, South Africa, Briza Publications, Pretoria, South Africa, ISBN:978-1-875093-37-3.**
7. van Wyk BE (2008) A broad review of commercially important southern African medicinal plants. J Ethnopharmacol 119: 342-355**.**
8. Klopper RR, Chatelain C, Banninger V, Habashi C, Steyn HM, et al. (2006) Checklist of the flowering plants of Sub-Saharan Africa: An index of accepted names and synonyms. South African Botanical Diversity Network Report No 42.
9. van Wyk BE, Gericke N (2000) People's Plants: A Guide to Useful Plants of Southern Africa. Briza Publications, Pretoria, South Africa.
10. Mulholland DA, Drewes SE (2004) Global phytochemistry: Indigenous medicinal chemistry on track in southern. Phytochemistry 65: 769-782.
11. **Van Wyk BE, Van OB, Gericke N (2000) Medicinal plants of South Africa. 2nd Ed. Briza Publications, Pretoria, South Africa, ISBN: 1875093095.**
12. **Cunningham AB, (1988) An investigation of the herbal medicine trade in Natal/KwaZulu. Investigational Report No. 29. Institute for Natural Resources, University of KwaZulu-Natal, Pietermaritzburg, South Africa.**
13. Mander M (1998) Marketing of Indigenous Medicinal Plants in South Africa: A Case Study in KwaZulu-Natal. Food and Agricultural Organization of the United Nations, Rome.
14. Williams VL, Balkwill K, Witkowski ETF (2000) Unraveling the commercial market for medicinal plants and plant parts on the Witwatersrand, South Africa. Economic Bot 54: 310-327.
15. **Diederichs N (2006) Commercializing Medicinal Plants A Southern African Guide. Sun Press, Stellenbosch, South Africa, ISBN:1-919980-83-0.**
16. **Geldenhuys CJ, van Wyk B-E (2002) Indigenous biological resources of Africa. In Baijnath H, Singh Y (eds) Rebirth of Science in Africa, Umdaus Press, South Africa, ISBN:1-919766-23-5.**
17. **Williams VL (1996) The Witwatersrand multi trade. Veld and Flora 82: 12-14.**

18. Keirungi J, Fabricius C (2005) Selecting medicinal plants for cultivation at Nqabara on the Eastern Cape Wild Coast, South Africa. S Afr J Sci 101: 497501.
19. **Cunningham AB (1989) Herbal medicine trade: A hidden economy. Indicator South Africa 6: 51-54.**
20. Dauskardt RPA (1990) The changing geography of traditional medicine: urban herbalism on the Witwatersrand, South Africa. Geo J 22: 275-283.
21. **Dauskardt R (1991) Urban herbalism: The restructuring of informal survival in Johannesburg. In Preston-Whyte E, Rogerson C (eds) South Africa's Informal Economy Oxford Univ. Press, Cape Town, 87-100. ISBN:0195706331.**
22. Cocks ML, Dold AP, Grundy IM (2004) The trade in medicinal plants from forests in the Eastern Cape province. In Lawes MJ et al (eds) Indigenous forests and woodlands in South Africa: policy, people and practice. University of KwaZulu-Natal Press, Scottsville, South Africa, 473-492.
23. Scirus (2011)**.**
24. Goodson JA (1922) The constituents of the flowering tops of Artemisia afra, Jacq. Biochem J 16: 489-493.
25. **Bohlmann F, Zdero C (1972) Constituents of Artemisia afra, Phytochem. 11: 2329-2330.**
26. Jakupovic J, Klemeyer H, Bohlmann F, Graven EH (1988) Glucolides and Guaianolides from Artemisza afra. Phytochemistry 27: 1129-1133**.**
27. Gundidza M (1993) Antifungal activity of essential oil from Artemisia afra Jacq. Cent Afr J Med 39: 140-142.
28. Rabe T, van Staden J (1997) Antibacterial activity of South African plants used for medicinal purposes. J Ethnopharmacol 56: 81-87.
29. Burits M, Asres K, Bucar F (2001) The Antioxidant Activity of the Essential Oils of Artemisia afra, Artemisia abyssinica and Juniperus procera. Phytother Res 15: 103-108.
30. Elgorashi EE, Taylor JLS, Vershaeve L, Maes A, van Staden J, et al. (2003) Screening of medicinal plants used in South African traditional medicine for genotoxic effects. Toxicol Lett 143: 195-207.
31. Fouche G, Cragg GM, Pillay P, Kolesnikova NI, Haharaj VJ, et al. (2008) In vitro anti-cancer screening of South African plants. J Ethnopharmacol 119: 455-461.
32. Mativandlela SP, Meyer JJ, Hussein AA, Houghton PJ, Hamilton CJ, et al. (2008) Activity against Mycobacterium smegmatics and M. tuberculosis by extract of South African medicinal plants. Phytother Res 22: 841-845**.**

33. van der Kooy F, Verpoorte R, Meyer JJM (2008) Metabolomic quality control of claimed anti-malarial Artemisia afra herbal remedy and A. afra and A. annua plant extracts. S Afr J Bot 74: 186-189.
34. Nibert E, Wink M (2010) Volatile components of four Ethiopia Artemisa species extracts and their in vitro antitrypanosomal and cytotoxic activities. Phytomedicine 17: 369-374.
35. Sunmonu TO, Afolayan AJ (2010) Protective effect of Artemisia afra Jacq. on isoproterenol-induced myocardial injury in Wistar rats. Food Chem Toxicol 48: 1969-1972.
36. Mukinda JT, Syce JA, Fisher D, Meyer M (2010) Effect of the plant matrix on the uptake of luteolin derivatives-containing Artemisia afra aqueous extract in Caco-2 cells. J Ethanopharmacol 130: 439-449.
37. Yoon KD, Chin Y-W, Yang MH, Kim JS, Kim E (2011) Separation of anti- ulcer flavonois from Artemisia extracts by high speed counter current chromatography. Food Chemistry 129: 679-683.
38. Nielsen ND, Sandager M, Stafford GI, van Staden J, Jager AK (2004) Screening of indigenous plants from South Africa for affinity to the serotonin reuptake transport protein. J Ethanopharmacol 94: 159-163.
39. Dube A (2006) The design, preparation and evaluation of Artemisia afra and placebos in tea bag dosage form suitable for use in clinical trials, University of the Western Cape, Bellville, South Africa.
40. van Vuuren SF, du Toit LC, Parry A, Pillay V, Choonara YE (2010) Encapsulation of essential oils within a polymeric liposomal formulation for enhancement of antimicrobial efficacy. Nat Prod Commun 5: 1401-1408.
41. Braithwaite M, van Vuuren SF, Viljoen AM (2008) Validation of smoke inhalation therapy to treat microbial infections. J Ethnopharmacol 119: 501-506.
42. NaidooV, McGaw LJ, Bisschop SPR, Duncan N, Eloff JN (2008) The value of plant extracts with antioxidant activity in attenuating coccidiosis in broiler chickens. Veterinary Parasitology 153: 214-219.
43. Oyedeji AO, Afolayan AJ, Hutchings A (2009) Compositional variation of the essential oils of Artemisia afra Jacq. from three provinces in South Africa-- a case study of its safety. Nat Prod Commun 4: 849-852.
44. Avula B, Wang Y-W, Smillie TJ, Mabusela W, Vincent L, et al. (2009) Quantitative Determination of Flavonoids by Column High-Performance Liquid Chromatography with Mass Spectrometry and Ultraviolet Absorption Detection in Artemisia afra and Comparative Studies with Various Species of Artemisia Plants. J AOAC Int 92: 633-644.

45. Whittle BA, Skett PG (1997) Pharmaceutical compositions and methods for the manufacture thereof. Assigned to Phytotech Limited, The University Court of the University of Glasgow, Patent Cooperation Treaty Application, European Patent No. WÜ97035598.

46. Omer HA (2008) Preparation of Artemisia to treat human cancer, autoimmune disease, IgA-Nephropathy, and to counteract weight loss in cancer patients, Assigned to Omer Harun A., Rheinfelden, 79618, DE, US, United patent and Trademark Office Pre-grant Publication, Patent No. US20080311230.

47. Bobotas G, Rongen Roelof, ML, Fawzy A, Kling D (2008) CB1 Antanogist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same, Assigned to Reliant Pharmaceuticals, Inc., Patent Cooperation Treaty Application. European Patent No. WÜ08115574.

48. Jager R, Wenk H-H, Dieck HT, Hoope HU, Rabeler R (2009) Physiological active composition. Assigned to Fullbright & Jaworkski, LLP, New York 101033198, US, United States Patent and Trademark Office Pre-grant Publication, Patent No. US20090142425.

49. PubMed, US National Library of Medicine National Institutes of Health.

50. Graven EH, Webber M, Gardner JB (1990) The development of Artemisia afra (Jacq.) as a new essential oil crop. JEOR 2: 215-220.

51. van Wyk B-E, Wink M (2004) Medicinal Plants of the World. Briza Publications. South Africa 54-56.

52. Watt JM, Breyer-Brandwijk MG (1962) The medicinal and poisonous plants of Southern and Eastern Africa, 2nd Ed. London, Livingstone, 199-202.

53. Hutchings A, Scott AH, Lewis G, Cunningham A (1996) Zulu Medicinal plants: An inventory. South Africa, University of Natal press, Scottsville: 327: 195-196.

54. Bhat RB, Jacob TV (1995) Traditional herbal medicine in Transkei. J Ethnopharmacol 48: 7-12.

55. Taylor JLS, Rabe T, McGaw LJ, Jager AK, van Staden J (2001) Towards the scientific validation of traditional medicinal plants. Plant Growth Regulation 34: 23-37.

56. Roberts M (1992) In Indigenous healing plants. Southern Book Publishers, Halfway House, South Africa.

57. van Wyk B-E, de Wef H, van Heerden FR (2008) An ethnobotanical survey of medicinal plants in the southern eastern Karoo, South Africa. S Afr J Bot 47: 696-704.

58. Suliman S, van Vuuren SF, Viljoen AM (2010) Validating the in vitro antimicrobial activity of Artemisia afra in polyherbal combinations to treat respiratory infections. S Afr J

Bot 76: 655-661.

59. **Buchbauer G, Silbernagel E (1989) Artemisia afra, der Südafrikanische Wermut. Dtsch Apoth Ztg 129: 2173-2177.**
60. **Jansen PCM (1981) In Spices, Condiments and Medicinal Plants in Ethiopia, their taxonomy and agriculture significance, Agricultural Research Reports, Pudoc, Wageningen, Netherlands 205-215.**
61. McGaw LJ, Jager AK, van Staden J (2000) Antibacterial, anthelmintic and antiamoebic activity in South African medicinal plants. J Ethnopharmacol 72: 247-263.
62. **Dykman EJ, De Suid Afrikaanse Kook-, Koek- en Resepte Boek(1908)14th Improved impression. Paarl Printers Ltd., Paarl (Cape Colony), South Africa.**
63. **Rood B (1994) Uit die veldapteek. Tafelberg Publishers, Cape Town, ISBN:0- 624-03318-X.**
64. Thring TSA, Weitz, FM (2006) Medicinal plant use in the Bredasdorp/Elim region of the Southern Overberg in the Western Cape Province of South Africa. J Ethnopharmacol 103: 261-275.
65. Gelfand M, Mavi S, Drummond RB, Ndermera B (1985) In: The Traditional Medicinal Practioner in Zimbabwe: his principles of practice and pharmacopoeia (Zambeziana), Mambo, Zimbabwe.
66. Fowler DG (2006) Traditional Fever Remedies: A list of Zambian plants 1-61.
67. **Bally PRO (1937) Native Medicinal and Poisonous Plants of East Africa, Bulletin Miscellany Information.** http://www/jstor.org/pss/4107637
68. Yineger H, Kelbessa E, Bekele T, Lulekal E (2008) Plants used in traditional management of human ailments at Bale Mountains National Park, Southeastern Ethiopia. J Med Plants Res 2: 132-153.
69. Abebe D (1993) In Medicinal Plants and Enigmatic Health Practices of Northern Ethiopia, BSPE, Addis Ababa**.**
70. Desta B (1994) Ethiopian traditional herbal drugs. Part III: Anti-fertility activity of 70 medicinal plants. J Ethnopharmacol 44: 199-209.
71. Deutschlander MS, N Lall, M van der, Venter M (2009) Plant species used in the treatment of diabetes by South African traditional healers: An inventory Pharmaceutical Biology 47: 348-365.
72. The Global Burden of Diseases: 2004 Update (2008) World Health Organization**.**
73. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, et al. (2005) The burden of mortality attributable to diabetes: Realistic estimates for the year 2000. Diabetes Care 28:

2130-2135.

74. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
75. Cardiovascular diseases, Definition of cardiovascular diseases, WHO**.**
76. (1993) The fifth report on the Joint Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNCV). Arch Intern Med 153: 154-183.
77. Berkow R, Beers MH, Fletcher AJ (1997) High blood pressure. In The Merck Manual of Medical Information Home Ed. Merck Res. Laboratories, Merck & Co., Inc., Whitehouse Station, New Jersey 112-118.
78. Ward R (1990) Familial aggregation and genetic epidemiology of blood. In Laragh JH, Brenner BM (eds) Hypertension: Pathophysiology, Diagnosis and Mangement, Raven Press, New York 81-100.
79. Lonn E, McKelvie R (2000) Drug treatment in heart failure. BMJ 320: 11881192.
80. Dustan HP, Roccella EJ, Garrison HH (1996) Controlling Hypertension - a research success story. Arch Intern Med 156: 1926-1935.
81. Lyons D, Petrie JC, Reid JL (1994) Drug treatment: present and future. Br Med Bull 50: 472-493.
82. **Oates JA (1996) Antihypertensive Agents and the Drug Therapy of Hypertension; In Goodman and Gillman's The Pharmacological Basis of Therapeutics 9th Int Ed McGraw-Hill Health Professions Division, New York, 780-808. ISBN:0-07-026266-7.**
83. Havlik RJ, Hubert HB, Fabsitz RR, Feinleib M (1983) Weight and Hypertension. Ann Intern Med 98: 855-859.
84. Andrews G, MacMahon SW, Austin A, Byrne DG (1982) Hypertension: Comparison of drug and non-drug treatments. Br Med J (Clin Res Ed) 284: 1523-1526**.**
85. Maxwell MH, Kushiro T, Dornfeld LP, Tuck ML, Waks AU (1984) BP changes in obese hypertensive subjects during rapid weight loss; comparison of restricted verses unchanged salt intake. Arch Intern Med 144: 1581-1584**.**
86. Fall in blood pressure with modest reduction in dietary salt intake in mild hypertension, Australian National Health and Medical Research Council Dietary Salt Study Management Committee (1989) Lancet 1: 399-402.
87. Law MR, Frost CD, Wald NJ (1991) By how much does dietary salt restriction lower blood pressure? I: Analysis of observational data among populations. BMJ 302: 811-815**.**
88. Law MR, Frost CD, Wald NJ (1991) By how much does dietary salt restriction lower blood pressure? III: Analysis of data from trials of salt reduction. BMJ 302: 819-824.

89. Frost CD, Law MR, Wald NJ (1991) By how much does dietary salt restriction lower blood pressure, II: Analysis of observational data within populations. BMJ 302: 815-818.

90. Puska P, Lacono JM, Nissinen A, Korhonen HJ, Vartianinen E, et al. (1983) Controlled, randomized trial of the effect of dietary fat on blood pressure. Lancet 1: 1-5.

91. Walsh CR, Larson MJ, Evans JC, Djoussee L, Ellison RD, et al. (2002) Alcohol consumption and risk for congestive heart failure in the Framingham heart study. Ann Intern Med 136: 181-191.

92. Nicolas JM, Fernandez-Sola J, Estruch R, Paré JC, Scanella E, et al. (2002) The effect of controlled drinking in alcoholic cardiomayopathy. Ann Intern Med 136: 192-200.

93. Paffenbarger R, Hyde RT, Wing, AL, Hsieh CC (1986) Physical activity, all cause mortality and longevity of college alumni. N Engl J Med 314: 605-613.

94. Blair SN, Goodyear NN, Gibbons IW, Cooper KH (1984) Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA 252: 487-490.

95. Stein F (2001) Occupational stress, relaxation therapies, exercise and biofeedback. Work 17: 235-345.

96. Schneider RH, Alexander CN, Salerno JW, Robinson DK, Fields JZ, et al. (2002) Disease prevention and health promotion in aging with a traditional system of natural medicine: Maharishi Vedic Medicine. J Aging Health 14: 57
78.

97. Patel C, Marmot MG, Terry DG, Carruther M, Hunt B, et al. (1985) Trial of relaxation in reducing coronary risk: four year follow up. Br Med J (Clin Res Ed) 290: 1103-1106.

98. Lever AF, Beretta-Piccoli C, Brown JJ, Davies DL, Fraser R, et al. (1981) Sodium and potassium in essential hypertension. BMJ (Clin Res) 283: 463-468.

99. Siana A, Strazzullo P, Russo L, Guglielmi S, Lacoviello L, et al. (1987) Controlled trial of long term oral potassium supplements in patients with mild hypertension. Br Med J (Clin Res Ed) 294: 1453-1456.

100. Cardiovascular Diseases (CDVs), Fact Sheet N^{O}317, Updated on Sept. 2011, WHO.

101. The Future of CVD, WHO.

102. Khor GL (2001) Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr 10: 76-80.

103. Vorster HH (2002) The emergence of cardiovascular disease during urbanization of Africans. Public Health Nutr 5: 239-243.

104. Cancer (2009) Fact Sheet N^{O}297, WHO.

105. Cancer control: Knowledge into action, WHO.

106. Global Action Against Cancer Now, Updated Ed. (2005) World Health Organization & International Union Against Cancer, WHO Press, Switzerland.

107. Programes and Projects, Chronic Respiratory diseases, WHO.

108. Asthma, Chronic Respiratory diseases, Programmes and Projects, WHO.

109. Chronic obstructive pulmonary disease (COPD) Fact Sheet N^{O}315 (2009) Media Center, Programmes and Projects, WHO.

110. Allergic rhinitis and sinusitis, Other Chronic respiratory diseases, Chronic respiratory diseases, Programmes and Projects, WHO.

111. Pulmonary hypertension, Other Chronic respiratory diseases, Chronic respiratory diseases, Programmes and Projects, WHO.

112. **van der Walt L (2004) Artemisia afra, page downloaded from the South African Biodiverisity Institute's Plant Information, accessed from plantzafrica.com**

113. Mesfin F, Demissew S, Teklehaymanot T (2009) An ethnobotanical study of medicinal plants in Wonago Woreda, SNNPR, Ethiopia. J Ethnobiology Ethnomedicine 5: 5-28.

114. FAO - Food and Agriculture Organization, (1993) Ecocrop, Data Sheet, Artemisia afra.

115. **Jackson WPU (1990), Origins and meanings of names of South African plant genera, Univ. of Cape Town, ISBN:0799212849.**

116. Bremness L (1988) The complete book of herbs, Dorling Kindersley, London.

117. **Artemisia afra,** http://zipcodezoo.com/Plants/A/Artemisia_afra/

118. Bremer K (1994) In Asteraceae: Cladistics and Classification. Timber Press, Oregon 752.

119. Tan RX, Zheng WF, Tang HQ (1998) Biological active substances from the genus Artemisia. Planta Med 64: 295-302.

120. **Mucciarelli M, Maffei M (2002) Ch. Introduction to the genus Artemisia. In Wright CW (ed) Medicinal and Aromatic Plants - Industrial Profiles, Taylor & Francis, London, ISBN:04152721212 1-50.**

121. Hayat MQ, Ashraf M, Khan MA, Mushtaq TM, Ahmad M, et al. (2009) Phylogeny of Artemisia L.: Recent developments. Afr J Biotechnol 8: 24232428.

122. Iwu MM (1993) Handbook of African Medicinal plants. USA, Florida, CRC Press, 121-122.

123. Mukinda JT (2005) Acute and chronic toxicity of the flavonoid- containing plant, Artemisia afra in rodents, Thesis, University of the Western Cape.

124. **Artemisia afra Herba Monograph (1999) Traditional Medicine, South African Medical Council Research, SAHealth Info.**

125.Scott G, Springfield EP (2004) Artemisia afra Herba. In: Pharmaceutical Monographs on CD-ROM for 60 South African plant species used as traditional medicines. South African National Biodiversity Institute, Pretoria.

126. Msuya TS, Kideghesho JR (2009) The role of traditional management practices in enhancing sustainable use and conservation of medicinal plants in West Usambara Mountains, Tanzania, Tropical Conservation Sci. 2: 88-105.

127. Dyson A (1998) In Ashwell A (ed) Discovering indigenous healing plants of the herb and fragrance gardens at Kirstenbosch National Botanical Garden. Cape Town, National Botanical Institute, The Printing Press 9-10.

128. BBC Magazines Ltd., African wormwood, Artemisia afra, picture by bbc.co.uk/ gardening.

129. Liu NQ, van der Kooy F, Verpoorte R (2009) Artemisia afra: A potential flagship for African medicinal plants? S Afr J Bot 75: 185-195.

130. Fabian A, Germishuizen G (1997) In: Wild Flowers of Northern South Africa, Fernwwod Press Ltd., South Africa.

131. Greenham J (2000) Medicinal Plants, Draft Final Report, The ARD Consortium, USAID Agribusiness Linkages Project, USAID South Africa Grant No. 674-G- 00-00-00072-00 1-38.

132. Guide to growing Artemisia Wormwood (2005) Plant Biology.

133. Directorate Agricultural Information Services, South Africa (2009) African wormwood production, Essential oil crops, Production guidelines for African wormwood.

134. Graven E, Hansford G, Turner P, Collins N (2001) Sustainable cultivation of wild medicinal and essential oil plants: lessons from southern Africa, IUCN SSC Commercial captive propagation and Wild Species Conservation, White Oak Foundation, Jacksonville, Florida USA.

135. Wiersum KF, Dold AP, Husselman M, Cocks M (2006) Ch. Cultivation of medicinal plants as tools for biodiversity conservation and poverty alleviation in the Amatola region, South Africa. Bogers RJ, Craker LE, Lange D (ed) Medicinal & Aromatic Plants - agricultural, commercial, ecological, legal, pharmacological and social aspects, Wagneningen UR, 43-57.

136. Nikolova MT, Ivancheva SV (2005) Acta. Quantitative flavonoid variation of Artemisia vulgaris L. and Veronica chamaedrys L. in relation to altitude and polluted environment, Biol Szeged 49: 29-32.

137. Asfaw N, Licence P, Novitskii AA, Poliakoff M (2005) Green chemistry in Ethiopia:

The cleaner extraction of essential oils from Artemisia afra: a comparison of clean technology with conventional methodology. Green Chem 7: 352-356.

138. Worku T, Rubiolo P (1996) Major constituents of Artemisia afra oil. JEOR 8: 55-357.
139. **Mwangi JW, Achola JK, Sinei KA, Lwande W, Laurent R (1995) Essential oil constituents of Artemisia afra Willd JEOR 7: 97-99. ISSN:1041-2905**
140. Graven EH, Deans SG, Svoboda KP, Mavi S, Gundidiza MG (1992) Antimicrobial and antioxidative properties of the volatile (essential) oil of Artemisia afra Jacq. Flavour and Frangrance J 7: 121-123.
141. **Libbey LM, Sturtz G (1989) Unusual essential oils grown in Oregon. I. Artemisia afra Jacq. JEOR 1: 29-31.**
142. Viljoen AM, van Vuuren SF, Gwebu T, Demirci B, Hüsnü K, et al. (2006) The geographical variation and antimicrobial activity of African wormwood (Artemisia afra Jacq.) JEOR 18: 19-25.
143. **Chagonda LS, Makanda C, Chalchat J-C (1999) The essential oil of cultivated Artemisia afra (Jacq.) from Zimbabwe. Flavor and Fragrance J 14: 140-142.**
144. **Asekun OT, Grierson DS, Afolayan AJ (2007) Variations in the quality and yield of the essential oil from Artemisia afra using different drying methods. JEOBP 10: 5-9. ISSN: 0972-060X.** http://www.jeobp.com/
145. Erasto P, Adebola PO, Grierson DS, Afolayan AJ (2005) An ethnobotanical study of plants used for the treatment of diabetes in the Eastern Cape Province, South Africa. Afr J Biotechnol 4: 1458-1460.
146. Cragg GM, Newman DJ, Yang SS (2005) Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. J Nat Prod 69: 488-498.
147. Cassady JM, Douros JD (1980) Anticancer Agents Based on Natural Product Models. Academic Press, New York.
148. Cragg GM, Newman DJ (2005) Plants as a source of anti-cancer agents. J Ethnopharmacol 100: 72-79.
149. Newman DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66: 1022-1037.
150. Fouche G, Khorombi E, Kolesnikova N, Maharaj VJ, Nthambeleni R, et al. (2006) Investigation of south african plants For anticancer properties. Pharmacologyonline 3: 494-500.
151. Erlund I (2002) Chemical analysis and pharmacokinetics of the flavonoids quercetin, hesperetin and naringenin in humans. Dissertation. Dept. of Applied chemistry and

Microbiology, University of Helsinki, Helsinki, Finland.

152. **Waithaka J (2004) The evaluation of markers for quality control studies of flavonoid-containing medicinal preparations. M. Pharm. Thesis, University of the Western Cape. Bellville, South Africa.**

153. Shimoi K, Okada H, Furugori M, Goda T, Takase S, et al. (1998) Intestinal absorption of luteolin and luteolin 7-O-beta glucoside in rats and humans. FEBS Lett 438: 220-224.

154. Guantai AN, Addae-Mensah I (1999) Cardiovascular effect of Artemisa Afra and its Constituents. Pharmaceutical Biology 37: 351-356.

155. van Vuuren SF (2007) The antimicrobial activity and essential oil composition of medicinal aromatic plants used in African traditional healing, Ph.D. Thesis, The University of the Witwatersrand, Gauten, South Africa.

156. Odds FC (2003) Synergy, antagonism and what the chequerboard puts between them. J Antimicrob Chemother 52: 1-3**.**

157. Shelz Z, Molnar J, Hohmann J (2006) Antimicrobial and antiplasmid activities of essential oils. Fitoterapia 77: 279-285.

158. Iten F, Saller R, Abel G, Reichling, J (2009) Additive antimicrobial effects of the active components of the essential oil of Thymus vulgaris - chemotype carvacrol. Planta Med 75: 1231-1236.

159. Ntutela S, Smith P, Matika L, Mukinda J, Arendse H, et al. (2009) Efficacy of Artemisia afra phytotherapy in experimental tuberculosis. Tuberculosis (Edinb) 1: 33-40.

160. Clarkson C, Maharaj VJ, Crouch NR, Grace OM, Pillay P, et al. (2004) In vitro antiplasmodial activity of medicinal plants native to or naturalised in South Africa. J Ethnopharmacol 92: 177-191.

161. Kraft C, Jenett-Siems K, Siems K, Jakupovic J, Mavi S, et al. (2003) In vitro antiplasmodial evaluation of medicinal plants from Zimbabwe. Phytother Res 17: 123-128.

162. Liu NQ, Cao M, Frédérich M, Choi YH, Verpoorte R, et al. (2010) Metabolomic investigation of the ethnopharmacological use of Artemisia afra with NMR spectroscopy and multivariate data analysis. J Ethnopharmacol 128: 230-235.

163. Mulatu A, Mekonnen Y (2007) Spasmolytic effects of Artemisia afra and Artemisia rehan in tissue preparation. Ethiop Med J 45: 371-376.

164. Manou I, Bouillard L, Devleeschouwer MJ, Barel AO (1988) Evaluation of the preservative properties of Thymus vulgaris essential oil in topically applied formulations under a challenge test. J Applied Microbiol 84: 368-376.

165. Muyima NYO, Zulu G, Bhengu T, Popplewell D (2002) The potential application of

some novel essential oils as natural cosmetic preservatives in aqueous cream formulation. Flavour Fragr J 17: 258-266.

166. Ashebir M, Ashenafi M (1999) Assessment of the antibacterial activity of some traditional medicinal plants on some food-borne pathogens. Ethiopian J Health Develop 13: 211-216.
167. Komperlla MK (2004) The formulation and evaluation of rapid release tablets manufactured from Artemisia afra plant material, M. Pharm. Thesis, University of the Western Cape, Bellville, South Africa.
168. Calixto, JB (2000) Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents) Braz J Med Biol Res 33: 179-189.
169. Gilani AH, Attar-ur-Rahman (2005) Trends in Ethnopharmacology. J Ethnopharmacol 100: 43-49.
170. Mukinda JT, Syce JA (2007) Acute and chronic toxicity of the aqueous extract of Artemisia afra in rodents. J Ethnopharmacol 112: 138-144.
171. van Wyk A (2005) Evaluation of Guideline for Clinical Trials of Traditional Plant Medicines, M. Pharm. Thesis, University of the Western Cape.

172. Study of African traditional medicine will begin world-first clinical trial (2007).

173. Trials of traditional medicines and plants (2011)**.**
174. Efferth T (2011) Perspectives for Globalized Natural Medicines. Chinese Journal of Natural Medicines 9: 1-6.

Fiche signalétique

NOM : SANOGO.

PRENOM : DIAKALIA KOULOU.

NATIONALITE : Malienne.

TITRE DE LA THESE : ETATS DE LIEUX DES UTILISATIONS DE *ARTEMISIA AFRA* JACQ EX. WILLD. (ASTERACEAE)

ANNEE : 2020 – 2021.

VILLE DE SOUTENANCE : Bamako.

PAYS D'ORIGINE : Mali.

LIEU DE DEPOT : Bibliothèque de la Faculté de Médecine, d'Odonto-Stomatologie et de la Faculté Pharmacie (FMOS et FAPH).

SECTEUR D'INTERET : Pharmacognosie, Médecine traditionnelle.

RESUME

Artemisia afra Jacq. Ex. Willd. (Asteraceae) est l'une des plantes les plus populaires et les plus couramment utilisées en Afrique du Sud. Face au succès de *Artemisia annua*, de nombreuses investigations ont été menées sur cette espèce africaine. La présente étude avait pour objectif de collecter les données de sécurité, d'efficacité clinique et de qualité de *Artemisia afra.*

Une revue de la littérature a été faite de janvier 2020 à janvier 2021 pour collecter des informations sur les données d'utilisations traditionnelles, données de qualités, d'efficacité clinique et de sécurité de *Artemisia afra*

Selon les données de la littérature, *Artemisia afra* est utilisée fréquemment dans le traitement des infections microbiennes (13 citations) suivies du paludisme (10) et du diabète (5). Les feuilles constituent la partie la plus utilisée. Des études ont démontré les propriétés antimicrobiennes, antiplasmodiales et antidiabétiques pouvant justifier ces principales indications.

Des études ont démontré l'efficacité clinique de la tisane de *Artemisia afra* en cas de paludisme et de schistosomiases. Un bon échantillon des feuilles de *Artemisia afra* doit avoir une teneur en eau ≤ 10%, une teneur en cendres ≥ 8,9%, une teneur en cendres insolubles dans l'acide chlorhydrique **≤ 1**%.

Les données de sécurité, d'efficacité clinique et de qualité disponibles sur les feuilles de *Artemisia afra* peuvent permettre de proposer un phytomédicament catégorie 2 pouvant être utilisé dans la prise en charge des infections microbiennes et du paludisme.

Mots clés : *Artemisia afra* ; Infections microbiennes ; Paludisme.

Abstract :

Artemisia afra Jacq. Ex. Willd. (Asteraceae) is one of the most popular and commonly used plants in South Africa. Faced with the success of *Artemisia annua*, many investigations have been carried out on this African species. The objective of the present study was to collect security, clinical efficacy and quality data on *Artemisia afra*.

A review of the literature was carried out from January 2020 to January 2021 to collect information on traditional uses, qualities, clinical efficacy and security data on *Artemisia afra.*

According to literature data, *Artemisia afra* is used frequently in the treatment of microbial infections (13 citations) followed by malaria (10) and diabetes (5). The leaves are the most used part. Studies have demonstrated the antimicrobial, antiplasmodial and antidiabetic properties that can justify these main indications.

Studies have shown the clinical efficacy of *Artemisia afra* tea in malaria and schistosomiasis. A good sample of *Artemisia afra* leaves should have a moisture content of ≤ 10 %, an ash content of ≥ 8.9%, an ash content insoluble in hydrochloric acid ≤ 1%.

The safety, clinical efficacy and quality data available on the leaves of *Artemisia afra* may make it possible to propose phytomedicine category 2 that can be used in the management of microbial infections and malaria.

Keywords : *Artemisia afra* ; Microbial infections ; Malaria.

Serment de Galien

Je jure, en présence des maîtres de la Faculté, des conseillers de l'ordre des pharmaciens et de mes condisciples :

D'honorer ceux qui m'ont instruit dans les préceptes de mon art et de leur témoigner ma reconnaissance en restant fidèle à leur enseignement ;

D'exercer, dans l'intérêt de la santé publique, ma profession avec conscience et de respecter non seulement la législation en vigueur, mais aussi les règles de l'honneur, de la probité et du désintéressement ;

De ne jamais oublier ma responsabilité et mes devoirs envers le malade et sa dignité humaine ; en aucun cas, je ne consentirai à utiliser mes connaissances et mon état pour corrompre les mœurs et favoriser des actes criminels ;

Que les hommes m'accordent leur estime si je suis fidèle à mes promesses ;

Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque ;

Je le jure!